Document_and_Entity_Informatio
Document and Entity Information (USD $) | 12 Months Ended | ||
In Billions, except Share data, unless otherwise specified | Dec. 31, 2013 | Feb. 18, 2014 | Jun. 28, 2013 |
Document And Entity Information [Abstract] | ' | ' | ' |
Document Type | '10-K | ' | ' |
Amendment Flag | 'false | ' | ' |
Document Period End Date | 31-Dec-13 | ' | ' |
Document Fiscal Year Focus | '2013 | ' | ' |
Document Fiscal Period Focus | 'FY | ' | ' |
Trading Symbol | 'CPHD | ' | ' |
Entity Registrant Name | 'CEPHEID | ' | ' |
Entity Central Index Key | '0001037760 | ' | ' |
Current Fiscal Year End Date | '--12-31 | ' | ' |
Entity Well-known Seasoned Issuer | 'Yes | ' | ' |
Entity Current Reporting Status | 'Yes | ' | ' |
Entity Voluntary Filers | 'No | ' | ' |
Entity Filer Category | 'Large Accelerated Filer | ' | ' |
Entity Common Stock, Shares Outstanding | ' | 69,414,543 | ' |
Entity Public Float | ' | ' | $2.30 |
Consolidated_Balance_Sheets
Consolidated Balance Sheets (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Current assets: | ' | ' |
Cash and cash equivalents | $66,072 | $95,779 |
Short-term investments | 8,837 | ' |
Accounts receivable, less allowance for doubtful accounts of $198 thousand and $176 thousand as of December 31, 2013 and 2012, respectively | 52,202 | 43,999 |
Inventory | 103,866 | 70,114 |
Prepaid expenses and other current assets | 13,037 | 9,448 |
Total current assets | 244,014 | 219,340 |
Property and equipment, net | 84,886 | 54,830 |
Investments | 9,820 | ' |
Other non-current assets | 958 | 913 |
Intangible assets, net | 15,245 | 18,767 |
Goodwill | 39,681 | 37,694 |
Total assets | 394,604 | 331,544 |
Current liabilities: | ' | ' |
Accounts payable | 52,609 | 33,701 |
Accrued compensation | 22,009 | 16,540 |
Accrued royalties | 5,245 | 7,992 |
Accrued and other liabilities | 7,246 | 4,235 |
Current portion of deferred revenue | 8,183 | 9,599 |
Current portion of notes payable | 194 | 183 |
Total current liabilities | 95,486 | 72,250 |
Long-term portion of deferred revenue | 3,424 | 1,156 |
Long-term portion of notes payable | 1,479 | 1,685 |
Other liabilities | 8,975 | 8,911 |
Total liabilities | 109,364 | 84,002 |
Commitments and contingencies (Note 8) | ' | ' |
Shareholders' equity: | ' | ' |
Preferred stock, no par value; 5,000,000 shares authorized, none issued or outstanding | ' | ' |
Common stock, no par value; 100,000,000 shares authorized, 68,556,392 and 66,603,884 shares issued and outstanding at December 31, 2013 and 2012, respectively | 383,379 | 355,867 |
Additional paid-in capital | 145,900 | 117,217 |
Accumulated other comprehensive income (loss) | -476 | 56 |
Accumulated deficit | -243,563 | -225,598 |
Total shareholders' equity | 285,240 | 247,542 |
Total liabilities and shareholders' equity | $394,604 | $331,544 |
Consolidated_Balance_Sheets_Pa
Consolidated Balance Sheets (Parenthetical) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, except Share data, unless otherwise specified | ||
Statement Of Financial Position [Abstract] | ' | ' |
Accounts receivable, allowance for doubtful accounts | $198 | $176 |
Preferred stock, par value | $0 | $0 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $0 | $0 |
Common stock, shares authorized | 100,000,000 | 100,000,000 |
Common stock, shares issued | 68,556,392 | 66,603,884 |
Common stock, shares outstanding | 68,556,392 | 66,603,884 |
Consolidated_Statements_of_Ope
Consolidated Statements of Operations (USD $) | 12 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Income Statement [Abstract] | ' | ' | ' |
Sales | $401,292 | $331,212 | $277,575 |
Costs and operating expenses: | ' | ' | ' |
Cost of sales | 207,933 | 153,365 | 122,840 |
Collaboration profit sharing | 7,512 | 7,183 | 4,863 |
Research and development | 80,197 | 71,673 | 59,362 |
Sales and marketing | 79,941 | 61,907 | 50,691 |
General and administrative | 41,719 | 43,298 | 36,004 |
Litigation settlement | ' | 15,110 | ' |
Total costs and operating expenses | 417,302 | 352,536 | 273,760 |
Income (loss) from operations | -16,010 | -21,324 | 3,815 |
Interest and other income, net | 45 | 26 | 23 |
Interest expense | -137 | -147 | -511 |
Foreign currency exchange gain (loss) and other, net | -715 | 117 | -655 |
Other expense, net | -807 | -4 | -1,143 |
Income (loss) before income taxes | -16,817 | -21,328 | 2,672 |
Benefit from (provision for) income taxes | -1,148 | 1,285 | -45 |
Net income (loss) | ($17,965) | ($20,043) | $2,627 |
Basic net income (loss) per share | ($0.27) | ($0.30) | $0.04 |
Diluted net income (loss) per share | ($0.27) | ($0.30) | $0.04 |
Shares used in computing basic net income (loss) per share | 67,485 | 65,812 | 62,735 |
Shares used in computing diluted net income (loss) per share | 67,485 | 65,812 | 66,750 |
Consolidated_Statements_of_Com
Consolidated Statements of Comprehensive Income (Loss) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Statement Of Income And Comprehensive Income [Abstract] | ' | ' | ' |
Net income (loss) | ($17,965) | ($20,043) | $2,627 |
Other comprehensive income (loss), net of taxes of $0: | ' | ' | ' |
Foreign currency translation adjustments | ' | 140 | -693 |
Unrealized gains and losses related to cash flow hedges: | ' | ' | ' |
Loss recognized in other comprehensive income | -118 | -401 | ' |
(Gain)/Loss reclassified from accumulated comprehensive income to the statement of operations | -427 | 285 | ' |
Unrealized gains and losses related to available-for-sale investments, net: | ' | ' | ' |
Gain recognized in other comprehensive income | 15 | ' | ' |
(Gain) reclassified from accumulated comprehensive income to the statement of operations | -2 | ' | ' |
Comprehensive income (loss) | ($18,497) | ($20,019) | $1,934 |
Consolidated_Statements_of_Com1
Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Statement Of Income And Comprehensive Income [Abstract] | ' | ' | ' |
Other comprehensive income (loss), tax | $0 | $0 | $0 |
Consolidated_Statements_of_Sha
Consolidated Statements of Shareholders' Equity (USD $) | Total | Common Stock [Member] | Additional Paid-In Capital [Member] | Accumulated Other Comprehensive Income (Loss) [Member] | Accumulated Deficit [Member] |
In Thousands, except Share data | |||||
Beginning Balance at Dec. 31, 2010 | $153,662 | $288,387 | $72,731 | $726 | ($208,182) |
Beginning Balance, Shares at Dec. 31, 2010 | ' | 60,569,000 | ' | ' | ' |
Net income (loss) | 2,627 | ' | ' | ' | 2,627 |
Foreign currency translation adjustment | -693 | ' | ' | -693 | ' |
Issuance of shares of common stock under employee and director option plans | 32,128 | 32,128 | ' | ' | ' |
Issuance of shares of common stock under employee and director option plans, Shares | ' | 3,213,000 | ' | ' | ' |
Stock-based compensation related to stock options and awards and employee stock purchase plans | 20,413 | ' | 20,413 | ' | ' |
Issuance of shares of common stock under employee stock purchase plans | 3,696 | 3,696 | ' | ' | ' |
Issuance of shares of common stock under employee stock purchase plans, Shares | ' | 375,000 | ' | ' | ' |
Ending Balance at Dec. 31, 2011 | 211,833 | 324,211 | 93,144 | 33 | -205,555 |
Ending Balance, Shares at Dec. 31, 2011 | ' | 64,157,000 | ' | ' | ' |
Net income (loss) | -20,043 | ' | ' | ' | -20,043 |
Unrealized loss related to cash flow hedging | -117 | ' | ' | -117 | ' |
Foreign currency translation adjustment | 140 | ' | ' | 140 | ' |
Issuance of shares of common stock under employee and director option plans | 22,373 | 22,373 | ' | ' | ' |
Issuance of shares of common stock under employee and director option plans, Shares | ' | 2,060,000 | ' | ' | ' |
Shares issued for purchase of a business | 4,577 | 4,577 | ' | ' | ' |
Shares issued for purchase of a business, Shares | ' | 157,000 | ' | ' | ' |
Stock-based compensation related to stock options and awards and employee stock purchase plans | 24,073 | ' | 24,073 | ' | ' |
Issuance of shares of common stock under employee stock purchase plans | 4,706 | 4,706 | ' | ' | ' |
Issuance of shares of common stock under employee stock purchase plans, Shares | ' | 230,000 | ' | ' | ' |
Ending Balance at Dec. 31, 2012 | 247,542 | 355,867 | 117,217 | 56 | -225,598 |
Ending Balance, Shares at Dec. 31, 2012 | 66,603,884 | 66,604,000 | ' | ' | ' |
Net income (loss) | -17,965 | ' | ' | ' | -17,965 |
Unrealized loss related to cash flow hedging | -545 | ' | ' | -545 | ' |
Unrealized gain related to available-for-sale investments, net | 13 | ' | ' | 13 | ' |
Issuance of shares of common stock under employee and director option plans | 22,159 | 22,159 | ' | ' | ' |
Issuance of shares of common stock under employee and director option plans, Shares | ' | 1,740,000 | ' | ' | ' |
Stock-based compensation related to stock options and awards and employee stock purchase plans | 28,683 | ' | 28,683 | ' | ' |
Issuance of shares of common stock under employee stock purchase plans | 5,353 | 5,353 | ' | ' | ' |
Issuance of shares of common stock under employee stock purchase plans, Shares | ' | 212,000 | ' | ' | ' |
Ending Balance at Dec. 31, 2013 | $285,240 | $383,379 | $145,900 | ($476) | ($243,563) |
Ending Balance, Shares at Dec. 31, 2013 | 68,556,392 | 68,556,000 | ' | ' | ' |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Cash flows from operating activities: | ' | ' | ' |
Net income (loss) | ($17,965) | ($20,043) | $2,627 |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ' | ' | ' |
Depreciation and amortization of property and equipment | 17,769 | 13,446 | 10,298 |
Amortization of intangible assets | 5,418 | 4,965 | 6,523 |
Unrealized foreign exchange differences | 419 | ' | ' |
Impairment of acquired intangible assets, licenses, property and equipment | 2,855 | 1,399 | 5,372 |
Stock-based compensation related to employees and consulting services rendered | 27,635 | 24,496 | 19,768 |
Changes in operating assets and liabilities: | ' | ' | ' |
Accounts receivable | -6,960 | -6,443 | -7,830 |
Inventory | -32,638 | -5,105 | -23,982 |
Prepaid expenses and other current assets | -5,263 | -2,714 | -237 |
Other non-current assets | 150 | -172 | -122 |
Accounts payable and other current liabilities | 17,334 | -5,740 | 11,365 |
Accrued compensation | 5,421 | -1,736 | 5,334 |
Deferred revenue | 837 | 575 | -2,084 |
Net cash provided by operating activities | 15,012 | 2,928 | 27,032 |
Cash flows from investing activities: | ' | ' | ' |
Capital expenditures | -47,526 | -23,150 | -18,922 |
Payments for technology licenses | -1,125 | -2,140 | -1,655 |
Cost of acquisitions, net of cash acquired | -3,669 | -24,021 | -296 |
Proceeds from maturities and sales of marketable securities and investments | 3,850 | ' | ' |
Purchases of marketable securities and investments | -22,511 | ' | ' |
Net cash used in investing activities | -70,981 | -49,311 | -20,873 |
Cash flows from financing activities: | ' | ' | ' |
Net proceeds from the issuance of common shares and exercise of stock options | 27,512 | 27,079 | 35,857 |
Proceeds from bank borrowing | ' | 156 | ' |
Principal payments of notes payable | -874 | -72 | -6,669 |
Net cash provided by financing activities | 26,638 | 27,163 | 29,188 |
Effect of foreign exchange rate change on cash and cash equivalents | -376 | -9 | 123 |
Net increase (decrease) in cash and cash equivalents | -29,707 | -19,229 | 35,470 |
Cash and cash equivalents at beginning of period | 95,779 | 115,008 | 79,538 |
Cash and cash equivalents at end of period | 66,072 | 95,779 | 115,008 |
Supplemental Cash Flow Information | ' | ' | ' |
Cash paid for interest | 109 | 124 | 207 |
Cash paid for taxes | $632 | $1,051 | $50 |
Organization_and_Summary_of_Si
Organization and Summary of Significant Accounting Policies | 12 Months Ended | ||||||||||||
Dec. 31, 2013 | |||||||||||||
Text Block [Abstract] | ' | ||||||||||||
Organization and Summary of Significant Accounting Policies | ' | ||||||||||||
1. Organization and Summary of Significant Accounting Policies | |||||||||||||
Organization and Business | |||||||||||||
Cepheid (the “Company”) was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for testing in the Clinical market, as well as for application in the Company’s legacy Non-Clinical market. The Company’s systems enable rapid, sophisticated molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. | |||||||||||||
Principles of Consolidation | |||||||||||||
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances. On July 1, 2012, the Company changed the functional currency for certain foreign subsidiaries from the local currency to the U.S. dollar due to changes in the way these businesses and their operations are structured and managed. As a result, all foreign subsidiaries are using the U.S. dollar as the functional currency effective July 1, 2012. Prior to this change, adjustments resulting from translating the foreign currency financial statements of these subsidiaries into the U.S. dollar had been included as a separate component of accumulated other comprehensive income (loss). Upon the change of the functional currency, these subsidiaries no longer generate further translation adjustments, and the accumulated translation adjustments from prior periods will continue to remain a component of accumulated other comprehensive income (loss). | |||||||||||||
Net income (loss) includes the gains and losses arising from transactions denominated in a currency other than the functional currency of a location, the remeasurement of assets and liabilities of foreign subsidiaries using U.S. dollars as their functional currency, and the realized results of the Company’s foreign currency hedging activities. | |||||||||||||
Within the consolidated statements of cash flows from operating and investing activities, certain amounts were reclassified to conform to the current period presentation. | |||||||||||||
Use of Estimates | |||||||||||||
The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. | |||||||||||||
Fair Value of Financial Instruments | |||||||||||||
The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company’s valuation techniques used to measure fair value maximized the use of observable inputs and minimized the use of unobservable inputs. The fair value hierarchy is based on the following three levels of inputs: | |||||||||||||
• | Level 1—Quoted prices in active markets for identical assets or liabilities. | ||||||||||||
• | Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. | ||||||||||||
• | Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. | ||||||||||||
See Note 2, “Fair Value”, for information and related disclosures regarding the Company’s fair value measurements. | |||||||||||||
Cash, Cash Equivalents, Short-Term Investments and Investments | |||||||||||||
Cash and cash equivalents consist of cash on deposit with banks and money market instruments. Interest income includes interest, dividends, amortization of purchase premiums and discounts and realized gains and losses on sales of securities. | |||||||||||||
All highly liquid investments with maturities of three months or less at the date of purchase are classified as cash equivalents. The Company’s marketable debt securities have been classified and accounted for as available-for-sale. The Company determines the appropriate classification of its investments at the time of purchase and re-evaluates the designations at each balance sheet date. The Company classifies its marketable debt securities as either short-term or long-term based on each instrument’s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. The Company’s marketable debt securities are carried at fair value, with the unrealized gains and losses reported as a component of shareholders’ equity. The cost of securities sold is based upon the specific identification method. | |||||||||||||
The Company assesses whether an other-than-temporary impairment loss on its investments has occurred due to declines in fair value or other market conditions. With respect to the Company’s debt securities, this assessment takes into account the severity and duration of the decline in value, the Company’s intent to sell the security, whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis, and whether or not the Company expects to recover the entire amortized cost basis of the security (that is, a credit loss exists). | |||||||||||||
See Note 3, “Investments”, for information and related disclosures regarding the Company’s investments. | |||||||||||||
Concentration of Credit Risks and Other Uncertainties | |||||||||||||
The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments and investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s derivative instruments consist of large financial institutions of high credit standing. | |||||||||||||
The Company’s main financial institution for banking operations held 55% and 71% of the Company’s cash and cash equivalents as of December 31, 2013 and 2012, respectively. | |||||||||||||
The Company’s accounts receivable are derived from net revenue to customers and distributors located in the United States and other countries. The Company performs credit evaluations of its customers’ financial condition. The Company provides reserves for potential credit losses but has not experienced significant losses to date. There was one direct customer whose accounts receivable balance represented 14% and 7% of total accounts receivable as of December 31, 2013 and 2012, respectively. | |||||||||||||
The Company currently sells products through its direct sales force and distributors. There were no direct customers that accounted for 10% or more of total sales for the years ended December 31, 2013, 2012 and 2011. No single country outside of the United States or South Africa represented more than 10% of the Company’s total revenues or total assets in any period presented. | |||||||||||||
Inventory | |||||||||||||
Inventory is stated at the lower of standard cost (which approximates actual cost) or market, with cost determined on the first-in-first-out method. Accordingly, allocation of fixed production overheads to conversion costs is based on normal capacity of production. Abnormal amounts of idle facility expense, freight, handling costs and spoilage are expensed as incurred and not included in overhead. In addition, stock-based compensation expenses of approximately $2.1 million and $1.1 million were included in inventory as of December 31, 2013 and 2012, respectively. | |||||||||||||
The components of inventories were as follows (in thousands): | |||||||||||||
December 31 | |||||||||||||
2013 | 2012 | ||||||||||||
Raw Materials | $ | 35,760 | $ | 26,041 | |||||||||
Work in Process | 36,580 | 30,113 | |||||||||||
Finished Goods | 31,526 | 13,960 | |||||||||||
$ | 103,866 | $ | 70,114 | ||||||||||
Property and Equipment | |||||||||||||
Property and equipment are stated at cost. Depreciation is calculated using the straight-line method, and the cost is depreciated over the respective estimated useful lives of the assets, which range from 3 to 7 years. Leasehold improvements are amortized using the straight-line method over the estimated useful lives of the assets or the term of the lease, whichever is shorter. During the fourth quarter of 2013, the Company concluded that certain manufacturing capital assets will not be utilized and therefore have no future realizable value and thus an impairment was recorded of approximately $1.3 million as cost of sales. | |||||||||||||
Property and equipment consisted of the following (in thousands): | |||||||||||||
December 31 | |||||||||||||
2013 | 2012 | ||||||||||||
Land | $ | 21 | $ | 21 | |||||||||
Building | 3,970 | 3,044 | |||||||||||
Scientific equipment | 42,845 | 35,248 | |||||||||||
Manufacturing equipment | 45,339 | 26,226 | |||||||||||
Office furniture, computers and equipment | 21,810 | 17,994 | |||||||||||
Leasehold improvements | 48,879 | 31,166 | |||||||||||
$ | 162,864 | $ | 113,699 | ||||||||||
Less accumulated depreciation and amortization | (77,978 | ) | (58,869 | ) | |||||||||
$ | 84,886 | $ | 54,830 | ||||||||||
Total depreciation and amortization expense on our property and equipment in the years ended December 31, 2013, 2012 and 2011 totaled $17.8 million, $13.4 million and $10.3 million, respectively. | |||||||||||||
Intangible Assets and Goodwill | |||||||||||||
Intangible assets related to licenses are recorded at cost, less accumulated amortization. Intangible assets related to technology and other intangible assets acquired in acquisitions are recorded at fair value at the date of acquisition, less accumulated amortization. Intangible assets are amortized over their estimated useful lives, ranging from 3 to 15 years, primarily on a straight-line basis. Amortization of intangible assets is included in cost of sales, research and development and sales and marketing in the Consolidated Statements of Operations. | |||||||||||||
The Company reviews its intangible assets for impairment and conducts the impairment review when events or circumstances indicate the carrying value of a long-lived asset may be impaired by estimating the future undiscounted cash flows to be derived from an asset to assess whether or not a potential impairment exists. If the carrying value exceeds the Company’s estimate of future undiscounted cash flows, an impairment value is calculated as the excess of the carrying value of the asset over the Company’s estimate of its fair market value. Events or circumstances which could trigger an impairment review include a significant adverse change in the business climate, an adverse action or assessment by a regulator, unanticipated competition, significant changes in the Company’s use of acquired assets, the Company’s overall business strategy, or significant negative industry or economic trends. In 2013 and 2012, the Company recorded an impairment charge of $1.3 million and $1.4 million, respectively to cost of sales primarily related to acquired technology for one of its legacy products. In 2011, the Company terminated a license agreement with Roche which resulted in accelerating the amortization of the remaining up-front license fee of $5.4 million to cost of sales. | |||||||||||||
Goodwill is tested for impairment at a minimum on an annual basis and at the reporting unit level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the reporting unit does not pass the qualitative assessment, then the reporting unit’s carrying value is compared to its fair value. The fair values of the reporting units are estimated using market and discounted cash flow approaches. Goodwill is considered impaired if the carrying value of the reporting unit exceeds its fair value. The discounted cash flow approach uses expected future operating results. Failure to achieve these expected results may cause a future impairment of goodwill at the reporting unit. We conducted our annual impairment tests of goodwill in the fourth quarters of 2013 and 2012. As a result of these tests, we determined that no adjustment to the carrying value of goodwill for any reporting units was required. | |||||||||||||
Warranty Reserve | |||||||||||||
The Company warrants its systems to be free from defects for a period of generally 12 to 24 months from the date of sale and its disposable products to be free from defects, when handled according to product specifications, for the stated life of such products. Accordingly, a provision for the estimated cost of warranty repair or replacement is recorded at the time revenue is recognized. The Company’s warranty provision is established using management’s estimate of future failure rates and future costs of repairing any failures during the warranty period or replacing any disposable products with defects. The activities in the warranty provision consisted of the following (in thousands): | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Balance at beginning of year | $ | 1,953 | $ | 1,981 | $ | 969 | |||||||
Costs incurred and charged against reserve | (783 | ) | (690 | ) | (571 | ) | |||||||
Accrual related to current year product sales | 2,156 | 662 | 1,583 | ||||||||||
Balance at end of year | $ | 3,326 | $ | 1,953 | $ | 1,981 | |||||||
Revenue Recognition | |||||||||||||
The Company recognizes revenue from sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. No right of return exists for the Company’s products except in the case of damaged goods. The Company has not experienced any significant returns of its products. Shipping and handling costs are expensed as incurred and included in cost of sales. In those cases where the Company bills shipping and handling costs to customers, the amounts billed are classified as revenue. | |||||||||||||
The Company enters into revenue arrangements that may consist of multiple deliverables of its products and services. In situations with multiple deliverables, revenue is recognized upon the delivery of the separate elements. The Company sells service contracts for which revenue is deferred and recognized ratably over the contract period. | |||||||||||||
For multiple element arrangements entered into or materially modified on or subsequent to January 1, 2011, the total consideration for an arrangement is allocated among the separate elements in the arrangement based on a selling price hierarchy. The selling price hierarchy for a deliverable is based on: 1) vendor specific objective evidence (VSOE), if available; 2) third party evidence of selling price if VSOE is not available; or 3) an estimated selling price, if neither VSOE nor third party evidence is available. Estimated selling price is the Company’s best estimate of the selling price of an element in a transaction. The Company limits the amount of revenue recognized for delivered elements to the amount that is not contingent on the future delivery of products or services or other future performance obligations. The Company recognizes revenue for delivered elements only when the Company determines there are no uncertainties regarding customer acceptance. | |||||||||||||
Revenue includes fees for technology licenses and research and development services, including research and development under grants and government sponsored research, royalties under license and collaboration agreements. Fees for technology licenses are generally fully recognized only after the license period has commenced, the technology has been delivered and no further involvement of the Company is required. When the Company has continuing involvement related to a technology license, revenue is recognized over the license term. Revenue related to research and development services is recognized as the related service is performed based on the performance requirements of the relevant contract. Under such agreements, the Company is required to perform specific research and development activities and is compensated either based on the costs or costs plus a mark-up associated with each specific contract over the term of the agreement or based on the Company’s progress to completion and recoverability is reasonably assured. Royalties are typically based on licensees’ net sales of products that utilize the Company’s technology and royalty revenues are recognized as earned in accordance with the contract terms when the royalties can be reliably measured and their collectability is reasonably assured, such as upon the receipt of a royalty statement from the customer. Advance payments received in excess of amounts earned, such as funds received in advance of products to be delivered or services to be performed, are classified as deferred revenue until earned. | |||||||||||||
During 2012, the Company entered into agreements with The Bill and Melinda Gates Foundation (“BMGF”), The United States Agency for International Development (“USAID”) and UNITAID to reduce the price of the Company’s Multi-Drug Resistant Tuberculosis test to $9.98 for customers in the HBDC program. The Company received one-time payments of $3.5 million each from BMGF and USAID in 2012 and $3.2 million from UNITAID during 2013. Based on the terms of the agreements, the Company recognized revenue related to the BMGF and USAID agreements on a per-unit basis. Under the UNITAID agreement, the Company will recognize the $3.2 million of revenue on a straight line basis over a period of ten years. For the years ended December 31, 2013 and 2012, the Company recognized revenue of $2.7 million and $4.8 million, respectively, related to the BMGF, USAID and UNITAID agreements. | |||||||||||||
Research and Development | |||||||||||||
Research and development expenses consist of costs incurred for company-sponsored and collaborative research and development activities. These costs include direct and research-related overhead expenses and amortization of certain intangible assets. The Company expenses research and development costs, including the expenses for research under collaborative agreements, as such costs are incurred. | |||||||||||||
Stock-Based Compensation | |||||||||||||
Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s condensed consolidated statements of operations. The Company recognizes the fair value of the Company’s stock option awards as compensation expense over the requisite service period of each award, which is generally four years. | |||||||||||||
In determining fair value of the stock-based compensation payments, the Company uses the Black–Scholes model and a single option award approach, which requires the input of subjective assumptions. These assumptions include: estimating the length of time employees will retain their vested stock options before exercising them (expected term), the estimated volatility of the Company’s common stock price over the expected term (expected volatility), the risk-free interest rate (interest rate), expected dividends and the number of shares subject to options that will ultimately not complete their vesting requirements (forfeitures). Changes in the following assumptions can materially affect the estimate of the fair value of stock–based compensation. | |||||||||||||
• | Expected term is determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior as influenced by changes to the terms of its stock-based awards. | ||||||||||||
• | Expected volatility is based on the blend of historical volatility of the past period equal to the Company’s expected term and the current implied volatility. | ||||||||||||
• | Risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award. | ||||||||||||
• | Expected dividend is based on the Company’s expectation of issuing a dividend over the expected term. The Company has never issued dividends. | ||||||||||||
• | Estimated forfeitures are based on voluntary termination behavior as well as analysis of actual option forfeitures. | ||||||||||||
Foreign Currency Hedging | |||||||||||||
The Company uses forward contracts designated as cash flow hedges to protect against the foreign currency exchange rate risks inherent in its forecasted net revenue, cost of sales and operating expenses denominated in currencies other than the U.S. dollar. The Company also enters into non-qualifying foreign currency forward contracts to partially offset the foreign currency exchange gains and losses generated by the re-measurement of certain assets and liabilities. The Company’s foreign currency cash flow hedges mature generally within twelve months. For derivative instruments that are designated and qualify as cash flow hedges, the Company initially records the effective portion of the gain or loss on the derivative instrument in accumulated other comprehensive income or loss as a separate component of stockholders’ equity and subsequently reclassifies these amounts into earnings in the period during which the hedged transaction is recognized in earnings. The effective portion of cash flow hedges is reported in the same financial statement line item as the changes in value of the hedged item. For non-qualifying derivative instruments, the Company records the gain or loss for each period in earnings. During fiscal year 2013, there was no significant impact to the results of operations as a result of ineffective cash flow hedges. | |||||||||||||
Net Income (Loss) Per Share | |||||||||||||
Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. Stock options, employee stock purchases, restricted stock awards and restricted stock units that could potentially dilute basic earnings per share in the future were not included in the computation of diluted earnings per share because to do so would have been antidilutive for the periods presented. These anti-dilutive common stock equivalent shares totaled 5,267,000, 4,145,000 and 1,011,000 for the years ended December 31, 2013, 2012 and 2011, respectively. | |||||||||||||
The following summarizes the computation of basic and diluted income (loss) per share (in thousands, except for per share amounts): | |||||||||||||
Years ended December 31, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Basic: | |||||||||||||
Net income (loss) | $ | (17,965 | ) | $ | (20,043 | ) | $ | 2,627 | |||||
Basic weighted shares outstanding | 67,485 | 65,812 | 62,735 | ||||||||||
Net income (loss) per share | $ | (0.27 | ) | $ | (0.30 | ) | $ | 0.04 | |||||
Diluted: | |||||||||||||
Net income (loss) | $ | (17,965 | ) | $ | (20,043 | ) | $ | 2,627 | |||||
Basic weighted shares outstanding | 67,485 | 65,812 | 62,735 | ||||||||||
Effect of dilutive securities: | |||||||||||||
Stock options, ESPP, restricted stock units and restricted stock awards | — | — | 4,015 | ||||||||||
Diluted weighted shares outstanding | 67,485 | 65,812 | 66,750 | ||||||||||
Net income (loss) per share | $ | (0.27 | ) | $ | (0.30 | ) | $ | 0.04 | |||||
Income Taxes | |||||||||||||
The Company accounts for income taxes using an asset and liability approach, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s consolidated financial statements, but have not been reflected in the its taxable income. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. Therefore, the Company provides a valuation allowance to the extent that the Company does not believe it is more likely than not that it will generate sufficient taxable income in future periods to realize the benefit of its deferred tax assets. |
Fair_Value
Fair Value | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Fair Value Disclosures [Abstract] | ' | ||||||||||||||||
Fair Value | ' | ||||||||||||||||
2. Fair Value | |||||||||||||||||
The following table summarizes the fair value hierarchy for the Company’s financial assets (cash, cash equivalents, short-term investments and long-term investments) and financial liabilities (foreign currency derivatives and contingent consideration) measured at fair value on a recurring basis as of December 31, 2013 and December 31, 2012 (in thousands): | |||||||||||||||||
Balance as of December 31, 2013: | |||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | ||||||||||||||
Assets: | |||||||||||||||||
Cash and cash equivalents | $ | 64,772 | $ | 1,300 | $ | — | $ | 66,072 | |||||||||
Short-term investments: | |||||||||||||||||
Corporate debt securities | — | 1,881 | — | 1,881 | |||||||||||||
Commercial paper | — | 5,448 | — | 5,448 | |||||||||||||
Government agency securities | — | 1,508 | — | 1,508 | |||||||||||||
Total short-term investments | — | 8,837 | — | 8,837 | |||||||||||||
Foreign currency derivatives | — | 873 | — | 873 | |||||||||||||
Investments: | |||||||||||||||||
United States government securities | — | 2,149 | — | 2,149 | |||||||||||||
Government agency securities | — | 3,405 | — | 3,405 | |||||||||||||
Corporate debt securities | — | 1,975 | — | 1,975 | |||||||||||||
Other | — | 2,291 | — | 2,291 | |||||||||||||
Total investments | — | 9,820 | — | 9,820 | |||||||||||||
Total | $ | 64,772 | $ | 20,830 | $ | — | $ | 85,602 | |||||||||
Liabilities: | |||||||||||||||||
Foreign currency derivatives | $ | — | $ | 1,555 | $ | — | $ | 1,555 | |||||||||
Contingent consideration | — | — | 310 | 310 | |||||||||||||
Total | $ | — | $ | 1,555 | $ | 310 | $ | 1,865 | |||||||||
Balance as of December 31, 2012: | |||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | ||||||||||||||
Assets: | |||||||||||||||||
Cash | $ | 84,906 | $ | — | $ | — | $ | 84,906 | |||||||||
Cash equivalents - money market funds | 10,873 | — | — | 10,873 | |||||||||||||
Foreign currency derivatives | — | 1,458 | — | 1,458 | |||||||||||||
Total | $ | 95,779 | $ | 1,458 | $ | — | $ | 97,237 | |||||||||
Liabilities: | |||||||||||||||||
Foreign currency derivatives | $ | — | $ | 1,572 | $ | — | $ | 1,572 | |||||||||
Contingent consideration | — | — | 550 | 550 | |||||||||||||
Total | $ | — | $ | 1,572 | $ | 550 | $ | 2,122 | |||||||||
The Company utilized levels 1 and 2 to value its financial assets on a recurring basis. Level 1 instruments use quoted prices in active markets for identical assets or liabilities, which include the Company’s cash accounts, short-term deposits and money market funds as these specific assets are liquid. Level 2 instruments are valued using the market approach which uses quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 instruments include commercial paper, corporate obligations, United States government securities, government agency securities and asset-backed securities as similar or identical instruments can be found in active markets. | |||||||||||||||||
The Company recorded derivative assets and liabilities at fair value. The Company’s derivatives consist of foreign exchange forward contracts. The Company has elected to use the income approach to value the derivatives, using observable Level 2 market expectations at the measurement date and standard valuation techniques to convert future amounts to a single present amount assuming that participants are motivated, but not compelled to transact. | |||||||||||||||||
Level 2 inputs for the valuations are limited to quoted prices for similar assets or liabilities in active markets (specifically foreign currency spot rate and forward points) and inputs other than quoted prices that are observable for the asset or liability (specifically LIBOR rates, credit default spot rates, and company specific LIBOR spread). Mid-market pricing is used as a practical expedient for fair value measurements. The fair value measurement of an asset or liability must reflect the nonperformance risk of the entity and the counterparty. Therefore, the impact of the counterparty’s creditworthiness when in an asset position and the Company’s creditworthiness when in a liability position has also been factored into the fair value measurement of the derivative instruments and did not have a material impact on the fair value of these derivative instruments. Both the counterparty and the Company are expected to continue to perform under the contractual terms of the instruments. | |||||||||||||||||
Level 3 liabilities, consisting of contingent consideration to be made in connection with the acquisition of a company in 2012 and an acquisition of certain assets in 2013, are valued by applying the income approach and are based on significant unobservable inputs that are supported by little or no market activity. |
Investments
Investments | 12 Months Ended | ||||||||||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||||||||||
Investments Schedule [Abstract] | ' | ||||||||||||||||||||||||
Investments | ' | ||||||||||||||||||||||||
3. Investments | |||||||||||||||||||||||||
During the year ended December 31, 2013, the Company initiated a program to purchase marketable securities. The Company’s marketable securities as of December 31, 2013 were classified as available-for-sale securities, with changes in fair value recognized in stockholders’ equity as a component of accumulated other comprehensive income (loss). Classification of marketable securities as a current asset is based on the intended holding period and realizability of the investment. As of December 31, 2012 the Company did not have any available for sale marketable securities. | |||||||||||||||||||||||||
The following tables summarize available-for-sale marketable securities at December 31, 2013 (in thousands): | |||||||||||||||||||||||||
Balance as of December 31, 2013: | |||||||||||||||||||||||||
Cost | Gross Unrealized | Gross Unrealized | Estimated Fair | ||||||||||||||||||||||
Gain | Loss | Value | |||||||||||||||||||||||
Short-term investments: | |||||||||||||||||||||||||
Commercial paper | $ | 6,747 | $ | 1 | $ | — | $ | 6,748 | |||||||||||||||||
Corporate debt securities | 1,881 | — | — | 1,881 | |||||||||||||||||||||
Government agency securities | 1,506 | 2 | — | 1,508 | |||||||||||||||||||||
Amounts classified as cash equivalents | (1,300 | ) | — | — | (1,300 | ) | |||||||||||||||||||
Total short-term investments | $ | 8,834 | $ | 3 | $ | — | $ | 8,837 | |||||||||||||||||
Investments: | |||||||||||||||||||||||||
United States government securities | $ | 2,145 | $ | 4 | $ | — | $ | 2,149 | |||||||||||||||||
Government agency securities | 3,405 | 1 | (1 | ) | 3,405 | ||||||||||||||||||||
Corporate debt securities | 1,970 | 5 | — | 1,975 | |||||||||||||||||||||
Other | 2,290 | 1 | — | 2,291 | |||||||||||||||||||||
Total investments | $ | 9,810 | $ | 11 | $ | (1 | ) | $ | 9,820 | ||||||||||||||||
For the year ended December 31, 2013, $2.5 million of proceeds from sales of marketable securities were collected while no proceeds were received for the year ended December 31, 2012. The Company determines gains and losses from sales of marketable securities based on specific identification of the securities sold. Gross realized gains and losses from sales of marketable securities, all of which are reported as a component of “Foreign currency exchange gain (loss) and other, net” in the consolidated statements of operations, were for the years ended December 31, 2013 and 2012 (in thousands): | |||||||||||||||||||||||||
Years Ended December 31, | |||||||||||||||||||||||||
2013 | 2012 | ||||||||||||||||||||||||
Gross realized gains | $ | 2 | $ | — | |||||||||||||||||||||
Gross realized losses | — | — | |||||||||||||||||||||||
Realized gains, net | $ | 2 | $ | — | |||||||||||||||||||||
The fair value of the Company’s marketable securities with unrealized losses at December 31, 2013 and December 31, 2012, and the duration of time that such losses had been unrealized (in thousands) were: | |||||||||||||||||||||||||
Balance at December 31, 2013: | |||||||||||||||||||||||||
Less Than 12 months | More than 12 months | Total | |||||||||||||||||||||||
Fair Value | Unrealized Loss | Fair Value | Unrealized Loss | Fair Value | Unrealized Loss | ||||||||||||||||||||
Corporate debt securities | $ | 1,180 | $ | — | $ | — | $ | — | $ | 1,180 | $ | — | |||||||||||||
Government agency securities | 1,104 | 1 | — | — | 1,104 | 1 | |||||||||||||||||||
Other | 800 | — | — | — | 800 | — | |||||||||||||||||||
Total | $ | 3,084 | $ | 1 | $ | — | $ | — | $ | 3,084 | $ | 1 | |||||||||||||
Balance at December 31, 2012: | |||||||||||||||||||||||||
Less Than 12 months | More than 12 months | Total | |||||||||||||||||||||||
Fair Value | Unrealized Loss | Fair Value | Unrealized Loss | Fair Value | Unrealized Loss | ||||||||||||||||||||
Corporate debt securities | $ | — | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||||||
Government agency securities | — | — | — | — | — | — | |||||||||||||||||||
Other | — | — | — | — | — | — | |||||||||||||||||||
Total | $ | — | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||||||
The Company has evaluated such securities, which consist of investments in Corporate debt, Government agency and other securities as of December 31, 2013 and has determined that there was no indication of other-than-temporary impairments. This determination was based on several factors, including the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the debt issuer, and the Company’s intent and ability to hold the corporate securities for a period of time sufficient to allow for any anticipated recovery in market value. | |||||||||||||||||||||||||
The following table summarizes the amortized cost and estimated fair value of available-for-sale debt securities at December 31, 2013 and December 31, 2012, by contractual maturity (in thousands): | |||||||||||||||||||||||||
December 31, 2013 | December 31, 2012 | ||||||||||||||||||||||||
Amortized Cost | Estimated Fair Value | Amortized Cost | Estimated Fair Value | ||||||||||||||||||||||
Debt securities: | |||||||||||||||||||||||||
Mature in one year or less | $ | 10,134 | $ | 10,137 | $ | — | $ | — | |||||||||||||||||
Mature after one year through three years | 9,810 | 9,820 | — | — | |||||||||||||||||||||
Mature in more than three years | — | — | — | — | |||||||||||||||||||||
Total debt securities | 19,944 | 19,957 | — | — | |||||||||||||||||||||
Securities with no contractual maturity | 55 | 55 | — | — | |||||||||||||||||||||
Total | $ | 19,999 | $ | 20,012 | $ | — | $ | — | |||||||||||||||||
Derivative_Financial_Instrumen
Derivative Financial Instruments | 12 Months Ended | ||||||||||||||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||||||||||||||
Derivative Instruments And Hedging Activities Disclosure [Abstract] | ' | ||||||||||||||||||||||||||||
Derivative Financial Instruments | ' | ||||||||||||||||||||||||||||
4. Derivative Financial Instruments | |||||||||||||||||||||||||||||
The Company uses derivatives to partially offset its business exposure to foreign currency exchange risk. The Company may enter into foreign currency forward contracts to offset some of the foreign exchange risk on expected future cash flows on certain forecasted revenue and cost of sales and on certain existing assets and liabilities. | |||||||||||||||||||||||||||||
To help protect gross margins from fluctuations in foreign currency exchange rates, a portion of forecasted foreign currency revenue and expenses of certain of the Company’s subsidiaries are hedged. The Company typically hedges portions of its forecasted foreign currency exposure associated with revenue, cost of sales and operating expenses generally up to twelve months. | |||||||||||||||||||||||||||||
The Company may also enter into foreign currency forward contracts to partially offset the foreign currency exchange gains and losses generated by the re-measurement of certain assets and liabilities. However, the Company may choose not to hedge certain foreign currency exchange exposures for a variety of reasons including, but not limited to, accounting considerations and the prohibitive economic cost of hedging particular exposures. | |||||||||||||||||||||||||||||
The Company records all derivatives in the Condensed Consolidated Balance Sheets at fair value. The Company’s accounting treatment of these instruments is based on whether the instruments are designated as hedge or non-hedge instruments. The effective portions of cash flow hedges are recorded in accumulated other comprehensive income (loss) (“AOCI”) until the hedged item is recognized in earnings on the respective line item in the Statement of Operations. The ineffective portions of cash flow hedges are recorded in other income and expense. | |||||||||||||||||||||||||||||
The Company had a net deferred loss associated with cash flow hedges of $0.6 million and $0.1 million recorded in AOCI as of December 31, 2013 and December 31, 2012, respectively. Deferred gains and losses associated with cash flow hedges of forecasted foreign currency revenue are recognized as a component of revenues in the same period as the related revenue is recognized, and deferred gains and losses related to cash flow hedges of forecasted expenses are recognized as a component of cost of sales, research and development expense, sales and marketing expense and general and administrative expense in the same period as the related expenses are recognized. The Company’s hedged transactions as of December 31, 2013 are expected to occur within twelve months. | |||||||||||||||||||||||||||||
Derivative instruments designated as cash flow hedges must be de-designated as hedges when it is probable the forecasted hedged transaction will not occur in the initially identified time period or within a subsequent two-month time period. Deferred gains and losses in AOCI associated with such derivative instruments are reclassified immediately into other income and expense. Any subsequent changes in fair value of such derivative instruments are reflected in other income and expense unless they are re-designated as hedges of other transactions. The Company did not recognize any significant net gains or losses related to the loss of hedge designation on discontinued cash flow hedges during the years ended December 31, 2013, 2012 and 2011. | |||||||||||||||||||||||||||||
During the years ended December 31, 2013, 2012 and 2011, the Company recognized a gain of $0.1 million, $0.4 million and $0.3 million respectively, as a component of Foreign currency exchange gain (loss) and other. Gains or losses on derivatives not designated as hedging instruments are recorded in other income (expense). These amounts represent the net gain or loss on the derivative contracts and do not include changes in the related exposures or ineffective portion, which generally offset a portion of the gain or loss on the derivative contracts. | |||||||||||||||||||||||||||||
The notional principle amounts of the Company’s outstanding derivative instruments designated as cash flow hedges are $96.6 million and $79.3 million as of December 31, 2013 and 2012, respectively. The notional principle amounts of the Company’s outstanding derivative instruments not designated as cash flow hedges is $24.2 million and $9.2 million as of December 31, 2013 and 2012, respectively. | |||||||||||||||||||||||||||||
The following tables show the Company’s derivative instruments at gross fair value as reflected in the Consolidated Balance Sheets as of December 31, 2013 and 2012 (in thousands): | |||||||||||||||||||||||||||||
December 31, 2013 | |||||||||||||||||||||||||||||
Fair Value of Derivatives | Fair Value of Derivatives | Total Fair Value | |||||||||||||||||||||||||||
Designated as Hedge | Not Designated as Hedge | ||||||||||||||||||||||||||||
Instruments | Instruments | ||||||||||||||||||||||||||||
Derivative Assets (a): | |||||||||||||||||||||||||||||
Foreign exchange contracts | $ | 782 | $ | 91 | $ | 873 | |||||||||||||||||||||||
Derivative Liabilities (b): | |||||||||||||||||||||||||||||
Foreign exchange contracts | (1,446 | ) | (109 | ) | (1,555 | ) | |||||||||||||||||||||||
December 31, 2012 | |||||||||||||||||||||||||||||
Fair Value of Derivatives | Fair Value of Derivatives | Total Fair Value | |||||||||||||||||||||||||||
Designated as Hedge | Not Designated as Hedge | ||||||||||||||||||||||||||||
Instruments | Instruments | ||||||||||||||||||||||||||||
Derivative Assets (a): | |||||||||||||||||||||||||||||
Foreign exchange contracts | $ | 1,457 | $ | 1 | $ | 1,458 | |||||||||||||||||||||||
Derivative Liabilities (b): | |||||||||||||||||||||||||||||
Foreign exchange contracts | (1,561 | ) | (11 | ) | (1,572 | ) | |||||||||||||||||||||||
a) | The fair value of derivative assets is measured using Level 2 fair value inputs and is recorded as other current assets in the Condensed Consolidated Balance Sheets. | ||||||||||||||||||||||||||||
b) | The fair value of derivative liabilities is measured using Level 2 fair value inputs and is recorded as accrued other liabilities in the Condensed Consolidated Balance Sheets. | ||||||||||||||||||||||||||||
The following tables show the pre-tax effect of the Company’s derivative instruments designated as cash flow hedges in the Condensed Consolidated Statements of Operations for the years ended December 31, 2013 and 2012 (in thousands): | |||||||||||||||||||||||||||||
Years Ended | |||||||||||||||||||||||||||||
Gains/(Losses) Recognized in | Gains/(Losses) Reclassified | Gains/(Losses) Recognized - Ineffective Portion | |||||||||||||||||||||||||||
OCI - Effective Portion | from AOCI into Income - | and Amount Excluded from Effectiveness | |||||||||||||||||||||||||||
Effective Portion | Testing | ||||||||||||||||||||||||||||
December 31, | December 31, | December 31, | December 31, | Location | December 31, | December 31, | |||||||||||||||||||||||
2013 | 2012 | 2013 (a) | 2012 (b) | 2013 | 2012 | ||||||||||||||||||||||||
Cash flow hedges | |||||||||||||||||||||||||||||
Foreign exchange contracts | $ | (118 | ) | $ | (401 | ) | $ | 427 | $ | (285 | ) | Other income | $ | (10 | ) | $ | 38 | ||||||||||||
and expense | |||||||||||||||||||||||||||||
$ | (118 | ) | $ | (401 | ) | $ | 427 | $ | (285 | ) | $ | (10 | ) | $ | 38 | ||||||||||||||
a) | Includes gains (losses) reclassified from AOCI into net income for the effective portion of cash flow hedges, of which a gain of $1.3 million within cost of sales and operating expenses and a loss of $0.9 million within net sales, respectively, were recognized within the Condensed Consolidated Statement of Operations for the year ended December 31, 2013. | ||||||||||||||||||||||||||||
b) | Includes gains (losses) reclassified from AOCI into net income for the effective portion of cash flow hedges, of which a gain of $0.6 million within cost of sales and operating expenses and a loss of $0.9 million within net sales, respectively, were recognized within the Condensed Consolidated Statement of Operations for the year ended December 31, 2012. |
Intangible_Assets
Intangible Assets | 12 Months Ended | ||||||||||||
Dec. 31, 2013 | |||||||||||||
Goodwill And Intangible Assets Disclosure [Abstract] | ' | ||||||||||||
Intangible Assets | ' | ||||||||||||
5. Intangible Assets | |||||||||||||
Intangible assets related to licenses are recorded at cost, less accumulated amortization. Intangible assets related to technology and other intangible assets acquired in acquisitions are recorded at fair value at the date of acquisition, less accumulated amortization. Intangible assets are amortized over their estimated useful lives, ranging from 3 to 15 years, on a straight-line basis, except for intangible assets acquired in acquisitions, which are amortized on the basis of economic useful life. Amortization of intangible assets is primarily included in cost of sales in the accompanying consolidated statements of operations. | |||||||||||||
The recorded value and accumulated amortization of major classes of intangible assets were as follows (in thousands): | |||||||||||||
Gross Carrying | Accumulated | Net Carrying | |||||||||||
Amount | Amortization | Amount | |||||||||||
Balance, December 31, 2013 | |||||||||||||
Licenses | $ | 28,577 | $ | (21,597 | ) | $ | 6,980 | ||||||
Technology acquired in acquisitions | 8,613 | (8,613 | ) | — | |||||||||
Customer relationships and other intangible assets acquired in acquisitions | 15,748 | (7,483 | ) | 8,265 | |||||||||
$ | 52,938 | $ | (37,693 | ) | $ | 15,245 | |||||||
Balance, December 31, 2012 | |||||||||||||
Licenses | $ | 27,452 | $ | (19,464 | ) | $ | 7,988 | ||||||
Technology acquired in acquisitions | 8,613 | (6,843 | ) | 1,770 | |||||||||
Customer relationships and other intangible assets acquired in acquisitions | 13,700 | (4,691 | ) | 9,009 | |||||||||
$ | 49,765 | $ | (30,998 | ) | $ | 18,767 | |||||||
The Company has recorded all acquisitions using the purchase method of accounting and, accordingly, included the results of operations in its consolidated results as of the date of each acquisition. The tangible assets, liabilities and intangible assets (including goodwill) acquired were accounted for based on their estimated fair values. The fair value assigned to assets acquired is based on valuations using the Company’s estimates and assumptions. The Company has not presented pro forma results of operations because these acquisitions are not material to its consolidated results of operations on either an individual or an aggregate basis. | |||||||||||||
The Company acquired a 100% interest in a distributor in Italy on April 1, 2013. The Company also acquired certain assets from a distributor in Australia on August 31, 2013. The Company has included the financial results of the Italian distributor in the consolidated financial statements from its acquisition date, and the results from this company were not individually material to the Company’s consolidated financial statements. Pro forma results of operations have not been presented because the effect of the acquisition was not material to our financial results. | |||||||||||||
These transactions had a total purchase price of $4.0 million, of which $3.7 million, net of cash received, was paid in cash and the remainder being contingent cash considerations to be paid over time. These transactions were part of the ongoing expansion of the Company’s distribution network for the Company’s products. A summary of the fair value of the assets acquired and the liabilities assumed is as follows: acquired intangible assets of $2.0 million, property and equipment, inventory and other assets, net of liabilities, of $0.2 million, and goodwill of $1.5 million. | |||||||||||||
The contingent cash considerations will be paid pursuant to a calculation based on product sales of the acquired entities. The amount of the contingent considerations or its potential impact will be immaterial to the Company’s results of operations or financial position. | |||||||||||||
For all acquisitions completed during the year ended December 31, 2013, customer relationships have a weighted-average useful life of 7 years and other intangibles have a weighted-average useful life of 15 years. | |||||||||||||
The Company acquired a 100% interest in a distributor in South Africa and one of our plastics molders in California, United States on February 8, 2012 and December 20, 2012, respectively. The Company also acquired certain assets from a distributor in Germany and a distributor in Australia on January 3, 2012 and December 11, 2012, respectively. The Company included the financial results of these companies in the consolidated financial statements from its respective acquisition dates, and the results from each of these companies were not individually material to the Company’s consolidated financial statements. These transactions had a total purchase price of $30.7 million, of which $24 million, net of cash received, was paid in cash, $1.3 million was to be paid in cash after eighteen months, $4.6 million in common stock and the remainder being contingent consideration to be paid over time. These transactions were part of the ongoing expansion of the Company’s manufacturing capabilities and distribution network for the Company’s products. A summary of the fair value of the assets acquired and the liabilities assumed was as follows: acquired intangible assets of $9.2 million, property and equipment, inventory and other assets, net of liabilities, of $4.0 million, and goodwill of $17.5 million. | |||||||||||||
The contingent cash consideration will be paid pursuant to a contingent consideration calculation based on sales of one of the acquired entities. The amount of the contingent consideration or its potential impact will be immaterial to our results of operations or financial position. | |||||||||||||
For all acquisitions completed during the year ended December 31, 2012, customer relationships had a weighted-average useful life of 5.5 years and other intangibles had a weighted-average useful life of 0.1 years. | |||||||||||||
Revenue and earnings contributions of the acquired entities were not significant or were not separately identifiable due to the integration of these acquired entities into our existing operations. | |||||||||||||
In addition, as part of the legal settlement with Abaxis in September 2012, the Company recorded an intangible asset of $2.1 million. | |||||||||||||
During the fourth quarter of 2013, the Company determined an acquired intangible asset related to existing technology of one of the Company’s legacy products, as well as certain acquired technology assets, were impaired, as there was no future use of the assets. As a result, the Company recorded an impairment expense of $1.3 million primarily to cost of sales in the Statement of Operations in the year ended December 31, 2013. | |||||||||||||
During the fourth quarter of 2012, the Company determined an acquired intangible asset related to existing technology of one of the Company’s legacy products, as well as certain patent licenses, were impaired. The fair value of the impaired assets was determined using the income approach. As a result, the Company recorded an impairment expense of $1.4 million primarily to cost of sales in the Statement of Operations in the year ended December 31, 2012. | |||||||||||||
The Company capitalizes patent licenses and acquired intangible assets and amortizes them over their estimated useful lives on a straight-line basis. Amortization expense of intangible assets was $5.4 million, $5.0 million and $6.5 million for the years ended December 31, 2013, 2012 and 2011, respectively. The expected future annual amortization expense of intangible assets recorded on the Company’s consolidated balance sheet as of December 31, 2013 is as follows, assuming no impairment charges (in thousands): | |||||||||||||
For the Years Ending December 31, | Amortization | ||||||||||||
Expense | |||||||||||||
2014 | $ | 3,638 | |||||||||||
2015 | 3,030 | ||||||||||||
2016 | 2,418 | ||||||||||||
2017 | 2,046 | ||||||||||||
2018 | 1,964 | ||||||||||||
Thereafter | 2,149 | ||||||||||||
Total expected future annual amortization | $ | 15,245 | |||||||||||
Income_Taxes
Income Taxes | 12 Months Ended | ||||||||||||
Dec. 31, 2013 | |||||||||||||
Income Tax Disclosure [Abstract] | ' | ||||||||||||
Income Taxes | ' | ||||||||||||
6. Income Taxes | |||||||||||||
For financial reporting purposes, income before income taxes includes the following components (in thousands): | |||||||||||||
December 31 | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
United States | $ | (19,802 | ) | $ | (26,307 | ) | $ | 3,746 | |||||
Foreign | 2,985 | 4,979 | (1,074 | ) | |||||||||
Total | $ | (16,817 | ) | $ | (21,328 | ) | $ | 2,672 | |||||
The expense (benefit) for income taxes is comprised of (in thousands): | |||||||||||||
Years Ended December 31, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Current | |||||||||||||
Federal | $ | (56 | ) | $ | — | $ | 3 | ||||||
State | (9 | ) | 150 | 189 | |||||||||
Foreign | 1,770 | 207 | 326 | ||||||||||
$ | 1,705 | $ | 357 | $ | 518 | ||||||||
Deferred | |||||||||||||
Federal | $ | — | $ | (312 | ) | $ | — | ||||||
State | — | — | — | ||||||||||
Foreign | (557 | ) | (1,330 | ) | (473 | ) | |||||||
$ | (557 | ) | $ | (1,642 | ) | $ | (473 | ) | |||||
Expense (benefit) | $ | 1,148 | $ | (1,285 | ) | $ | 45 | ||||||
Reconciliation between the Company’s effective tax rate on income from continuing operations and the statutory tax rate is as follows: | |||||||||||||
Years Ended December 31, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
US Federal statutory income tax rate | 34 | % | 34 | % | 34 | % | |||||||
State taxes, net of federal benefit | 0.1 | % | -0.7 | % | 7.4 | % | |||||||
Foreign income taxed at other than U.S. rates | 4.4 | % | 2 | % | -27.5 | % | |||||||
Change in liabilities for uncertain positions | -5.6 | % | -1.9 | % | 0.1 | % | |||||||
Change in valuation allowance | -40 | % | -28.7 | % | -12.1 | % | |||||||
Other | 0.3 | % | 1.3 | % | -0.2 | % | |||||||
Effective tax rate | -6.8 | % | 6 | % | 1.7 | % | |||||||
Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets (liabilities) are as follows (in thousands): | |||||||||||||
December 31, | |||||||||||||
2013 | 2012 | ||||||||||||
Net operating loss carryforwards | $ | 36,314 | $ | 34,354 | |||||||||
Capitalized research and development costs | 64 | 68 | |||||||||||
Research and other credit carryforwards | 13,792 | 12,089 | |||||||||||
Stock option compensation | 15,341 | 13,191 | |||||||||||
Other | 24,955 | 18,516 | |||||||||||
Total deferred tax assets | 90,466 | 78,218 | |||||||||||
Valuation allowance for deferred tax assets | (90,466 | ) | (77,621 | ) | |||||||||
Total deferred tax liability | (927 | ) | (1,819 | ) | |||||||||
Net deferred tax liability | $ | (927 | ) | $ | (1,222 | ) | |||||||
A valuation allowance has been placed against the Company’s United States deferred tax assets, as management cannot conclude that it is more likely than not that these assets will be realized. The valuation allowance against United States deferred tax assets increased by $12.8 million during the year ended December 31, 2013, increased by $8.4 million during the year ended December 31, 2012 and decreased $7.7 million during the year ended December 31, 2011. | |||||||||||||
As of December 31, 2013, the Company had federal and state net operating loss carryforwards of $258.4 million and $298.6 million, respectively, which, if not utilized, will expire in the years 2014 through 2033. As of December 31, 2013, the Company had federal research and development tax credits of $10.7 million, which expire in the years 2018 through 2033, and state research and development tax credits of $12.6 million, which carry forward indefinitely. The Company also had foreign tax credits of $0.1 million which expires in the year 2019. | |||||||||||||
Utilization of the Company’s net operating losses and research credits may be subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Such annual limitation may result in the expiration of net operating loss and research credits before utilization. | |||||||||||||
Undistributed earnings of the Company’s foreign subsidiaries of approximately $5.2 million and $2.9 million at December 31, 2013 and 2012, respectively, are considered to be indefinitely reinvested, and, accordingly, no provisions for federal and state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to both federal income taxes, subject to an adjustment for foreign income tax credits and withholding taxes payable to various foreign countries. The tax impact of the distribution of such foreign earnings to the U.S. parent would not be significant, as the Company’s net operating loss carryforward amount exceeds the amount of undistributed earnings. | |||||||||||||
The Company maintains liabilities for uncertain tax positions. These liabilities involve considerable judgment and estimation and are continuously monitored by management based on the best information available, including changes in tax regulations, the outcome of relevant court cases, and other information. The Company is currently under examination in Sweden. Although the outcome of any tax audit is uncertain, the Company believes that it has adequately provided in its consolidated financial statements for any additional taxes that the Company may be required to pay as a result of such examination. | |||||||||||||
The Company or one of its subsidiaries files income tax returns in the United States federal jurisdiction and various state and foreign jurisdictions. The Company’s United States and state income tax return years 2000 through 2013 remain open to examination. In addition, the Company files tax returns in multiple foreign taxing jurisdictions with open tax years ranging from 2008 to 2013. | |||||||||||||
The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands): | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Balance at beginning of year | $ | 7,397 | $ | 6,979 | $ | 5,186 | |||||||
Increase related to current year tax positions | 1,844 | 829 | — | ||||||||||
Increase (decrease) for tax positions of prior years | — | (276 | ) | 1,793 | |||||||||
Decrease due to lapse of statute | — | (64 | ) | — | |||||||||
Decrease due to settlements | — | (71 | ) | — | |||||||||
Balance at end of year | $ | 9,241 | $ | 7,397 | $ | 6,979 | |||||||
At December 31, 2013 and 2012, the total gross unrecognized tax benefits were $9.2 million and $7.4 million, respectively, which, if recognized, would affect the Company’s effective tax rate, before consideration of certain valuation allowances. The Company anticipates that the total unrecognized tax benefits will not significantly change due to the settlement of audits and the expiration of statutes of limitations in the 12 months following December 31, 2013. | |||||||||||||
The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. In 2013, 2012 and 2011, the Company did not recognize any significant interest or penalties related to uncertain tax positions. As of December 31, 2013 and 2012, the Company had accrued no interest or penalties. |
Notes_Payable
Notes Payable | 12 Months Ended |
Dec. 31, 2013 | |
Debt Disclosure [Abstract] | ' |
Notes Payable | ' |
7. Notes Payable | |
As of December 31, 2013, the Company has notes payable outstanding of $1.7 million related to a loan received from the Company’s landlord in Sweden for tenant improvements. The note carries an interest rate of 4%. There are no debt covenants associated with the note. The note payable balance will be repaid by 2016. |
Commitments_Contingencies_and_
Commitments, Contingencies and Legal Matters | 12 Months Ended | ||||||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||||||
Commitments And Contingencies Disclosure [Abstract] | ' | ||||||||||||||||||||
Commitments, Contingencies and Legal Matters | ' | ||||||||||||||||||||
8. Commitments, Contingencies and Legal Matters | |||||||||||||||||||||
The following table summarizes the Company’s lease, purchase and minimum royalty commitments at December 31, 2013 (in thousands): | |||||||||||||||||||||
Payments Due by Period | |||||||||||||||||||||
Total | Less Than 1 | 1-3 Years | 3-5 Years | More Than | |||||||||||||||||
Year | 5 Years | ||||||||||||||||||||
Operating leases | $ | 84,138 | $ | 10,450 | $ | 21,917 | $ | 21,728 | $ | 30,043 | |||||||||||
Purchase obligations | 42,494 | 37,118 | 3,660 | 1,716 | — | ||||||||||||||||
Minimum royalties | 2,583 | 543 | 1,134 | 646 | 260 | ||||||||||||||||
$ | 129,215 | $ | 48,111 | $ | 26,711 | $ | 24,090 | $ | 30,303 | ||||||||||||
Lease Commitments | |||||||||||||||||||||
As of December 31, 2013, the Company leased approximately 640,000 square feet of building space, primarily in the United States. The building space the Company occupies is pursuant to leases expiring up through May 2029. The Company’s manufacturing sites are located in the United States and Sweden. Certain of these lease arrangements contain escalation clauses whereby monthly rent increases over time. Rent expense is recognized on a straight-line basis over the lease period. As of December 31, 2013 and 2012, the Company accrued $1.0 million of asset retirement obligations for certain buildings currently under lease. Net rent expense for all operating leases for the years ended December 31, 2013, 2012 and 2011 was $10.2 million, $8.4 million and $6.3 million, respectively. | |||||||||||||||||||||
Purchase Commitments | |||||||||||||||||||||
Purchase commitments include purchase orders or contracts for the purchase of raw materials used in the manufacturing of the Company’s systems and reagents. | |||||||||||||||||||||
Minimum Royalty Commitments | |||||||||||||||||||||
The Company has certain minimum royalty commitments associated with the shipment and licensing of certain products. Royalty expense is generally based on a dollar amount per unit shipped or a percentage of the underlying revenue. | |||||||||||||||||||||
Contingencies | |||||||||||||||||||||
The Company responds to claims arising in the ordinary course of business. In certain cases, the Company has accrued estimates of the amounts it expects to pay upon resolution of such matters, and such amounts are included in other accrued liabilities. Should the Company not be able to secure the terms it expects, these estimates may change and will be recognized in the period in which they are identified. | |||||||||||||||||||||
In the normal course of business, the Company provides indemnifications of varying scope to customers against claims of intellectual property infringement made by third parties arising from the use of its products. Historically, costs related to indemnification provisions have not been significant and the Company is unable to estimate the maximum potential impact of these indemnification provisions on its future results of operations. | |||||||||||||||||||||
To the extent permitted under California law, the Company has agreements whereby it indemnifies its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Company’s request in such capacity. The indemnification period covers all pertinent events and occurrences during the director’s or officer’s service. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is not specified in the agreements; however, the Company has director and officer insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal. | |||||||||||||||||||||
Legal Matters | |||||||||||||||||||||
On June 28, 2010, Abaxis, Inc. filed suit in U.S. District Court for the Northern District of California against the Company, alleging that the Company’s Xpert MRSA product infringes U.S. Patent No. 5,413,732, U.S. Patent No. 5,624,597, U.S. Patent No. 5,776,563 and U.S. Patent No. 6,251,684. On July 12, 2010, the Company filed its response to the suit, denying Abaxis’ allegations of infringement and asked the Court to find Abaxis’ patents invalid and not infringed. On August 5, 2010, Abaxis filed its response to the Company’s answer and counterclaim. On November 19, 2010, Abaxis filed an amended complaint in which it added allegations that the Company breached a licensing contract for the above-referenced patents. On December 17, 2010, the Company answered the amended complaint, denying breach of the licensing contract and further amending its defenses and counterclaims against Abaxis. On January 14, 2011, Abaxis filed a motion to dismiss the Company’s defenses and counterclaim alleging that Abaxis committed inequitable conduct in procuring the asserted patents. On March 22, 2011, the Court granted Abaxis’ motion with leave for the Company to amend its counterclaims. On April 12, 2011, the Company filed its amended answer and second amended counterclaims. On June 17, 2011, upon direction by the Court, the Company filed an amended answer and third amended counterclaims. On June 29, 2011, Abaxis filed a motion to dismiss the Company’s defenses and counterclaim of inequitable conduct and filed an answer to the Company’s other counterclaims. On July 15, 2011, the Company filed its opposition to the motion, and on July 22, 2011, Abaxis filed a reply. On August 25, 2011, the Court granted Abaxis’ motion. On August 24, 2011, the Company filed a motion for a partial summary judgment that asserted U.S. Patent No. 5,624,597 did not extend beyond May 9, 2012 and not later as purported by Abaxis. On November 30, 2011, the Court granted the Company’s motion. On May 17, 2012, the Company filed a motion for partial summary judgment that asserted U.S. Patents No. 5,776,563 and 6,251,684 are invalid. On May 31, 2012, Abaxis filed its opposition to the Company’s motion, and on June 7, 2012, the Company filed its reply. On August 8, 2012, the Court issued a written order denying the Company’s motion. On September 24, 2012, the Company and Abaxis entered into a comprehensive agreement (the “Settlement Agreement”) resolving all present and future litigation relating to the alleged infringement of certain Abaxis patents by the Company and counterclaims by the Company against Abaxis. The parties agreed that the settlement was intended solely as a compromise of disputed claims, and was not a concession or determination that either party admitted any liability, wrongdoing, or the truth of any allegations related to such litigation. Under the Settlement Agreement, the Company and Abaxis agreed to terminate all pending and future claims connected with the litigation in exchange for a one-time payment by Cepheid of $17.3 million. The Company accounted for this transaction and allocated the consideration in accordance with ASC 450, Accounting for Contingencies, and ASC 605-25 using the concepts of fair value based on the past and estimated future revenue streams related to the products covered by the patents previously under dispute. Specifically, the amount recorded in the Condensed Consolidated Statement of Operations as Litigation settlement in the three months ended September 30, 2012 represented the fair value of the royalty paid on past revenue streams and the residual amount after allocating value to the future revenue streams. The allocation of the $17.3 million was accounted for as follows: 1) $8.7 million related to the royalty due on past revenues, 2) $2.1 million related to the fair value of the royalty due on the future revenue stream and 3) $6.4 million related to the settlement of litigation. In the quarter ended September 30, 2012, the Company recorded $15.1 million in the Statement of Operations as Litigation settlement which represented the royalty due on past revenues and the settlement of litigation components. As of September 30, 2012, the Company recorded $2.1 million as an intangible asset which represented the fair value of the future royalty. The Company is amortizing this intangible on a straight-line basis through the expiration of the patents in the claim. | |||||||||||||||||||||
In May 2005, the Company entered into a license agreement with Roche that provided us with rights under a broad range of Roche patents, including patents relating to the PCR process, reverse transcription-based methods, nucleic acid quantification methods, real-time PCR detection process and composition, and patents relating to methods for detection of viral and cancer targets. A number of the licensed patents expired in the United States prior to the end of August of 2010 and in Europe prior to the end of August of 2011. In August 2010, the Company terminated the Company’s license to U.S. Patent No. 5,804,375 (the “375 Patent”) and ceased paying U.S.-related royalties. The Company terminated the entire license agreement in the fourth quarter of 2011. In August 2011, Roche initiated an arbitration proceeding against us in the International Chamber of Commerce pursuant to the terms of the terminated agreement. The Company filed an answer challenging arbitral jurisdiction over the issues submitted by Roche and denying that the Company violated any provision of the agreement. A three-member panel has been convened to address these issues in confidential proceedings. On July 30, 2013, the panel determined that it had jurisdiction to decide the claims, a determination that the Company has appealed to the Swiss Federal Supreme Court. On October 2, 2013, the arbitration panel determined that it will proceed with the arbitration while this appeal is pending. The Company believes that it has not violated any provision of the agreement and that the asserted claim of the 375 Patent is expired, invalid, unenforceable, and not infringed. | |||||||||||||||||||||
Management believes that it is reasonably possible that these legal proceedings could result in a material loss (i.e., the chance of the event occurring is more than remote but less than likely). However, given the nature of arbitration and the nature of the claims in this matter, the Company is unable to estimate the amount of such possible loss. | |||||||||||||||||||||
On August 21, 2012 the Company filed a lawsuit against Roche Molecular Systems, Inc., and F. Hoffman-La Roche LTD, for a declaratory judgment of (a) invalidity, expiration, and non-infringement of 375 Patent; and (b) invalidity, unenforceability, expiration, and non-infringement of U.S. Patent No. 6,127,155 (the “155 Patent”). On January 17, 2013, the Court issued an order granting a motion by Roche to stay the suit with respect to the 375 Patent pending resolution of the above noted arbitration proceeding. In the same order, the Court dismissed the Company’s suit with respect to the 155 Patent for lack of subject matter jurisdiction, without considering or ruling on the merits of the Company’s case. The Court left open the possibility that the Company could re-file its case against the 155 Patent in the future. We believe that the possibility that these legal proceedings will result in a material adverse effect on the Company’s business is remote. | |||||||||||||||||||||
The Company may be subject to additional various claims, complaints and legal actions that arise from time to time in the normal course of business. Other than as described above, the Company does not believe it is party to any currently pending legal proceedings that will result in a material adverse effect on its business. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on the Company’s business, consolidated financial position, results of operations or cash flows. | |||||||||||||||||||||
The Company responds to claims arising in the ordinary course of business. Should the Company not be able to secure the terms management expects, these estimates may change and will be recognized in the period in which they are identified. Although the ultimate outcome of such claims is not presently determinable, management believes that the resolution of these matters will not have a material adverse effect on the Company’s financial position, results of operations and cash flows. |
Shareholders_Equity
Shareholders' Equity | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ' | ||||||||||||||||
Shareholders' Equity | ' | ||||||||||||||||
9. Shareholders’ Equity | |||||||||||||||||
Stock Option Plans | |||||||||||||||||
On April 27, 2006, the Company’s shareholders approved the 2006 Plan, which was approved by the Board in February 2006. On April 27, 2006, the Board also terminated the Company’s 1997 Stock Option Plan (“1997 Plan”). No new grants will be made under the 1997 Plan, and options granted or shares issued under the 1997 Plan that were outstanding on the date the 1997 Plan was terminated will remain subject to the terms of the 1997 Plan. Shares of common stock reserved for issuance under the 2006 Plan include (i) an initial authorization of 3,800,000 shares of common stock, (ii) shares reserved but unissued under the 1997 Plan as of the date the 1997 Plan was terminated and (iii) shares subject to awards granted under the 1997 Plan that are cancelled, forfeited or repurchased by the Company or expire after the 1997 Plan termination. On April 24, 2008, shareholders approved an increase to the number of shares of common stock reserved for issuance under the 2006 Plan by 1,800,000. On April 29, 2010, shareholders approved an increase to the number of shares of common stock reserved for issuance under the 2006 Plan by 3,800,000. On April 24, 2012, shareholders approved an increase to the number of shares of common stock reserved for issuance under the 2006 Plan by 5,000,000. | |||||||||||||||||
Under the 2006 Plan, the Company may grant incentive stock options (“ISOs”) and non-qualified stock options (“NQSOs”), restricted stock awards (“RSAs”), stock bonus awards (“SBAs”), stock appreciation rights (“SARs”), restricted stock units (“RSUs”) and performance share awards (“PSAs”). ISOs may be granted only to employees and directors of the Board, and all other awards may be granted to Company employees and directors and to consultants, independent contractors and advisors of the Company for services rendered. Any award, other than a stock option or a SAR, shall reduce the number of shares available for issuance by 1.75 shares for each share subject to such award (for a stock option or a SAR this ratio is 1:1). The 2006 Plan is administered by the Compensation Committee of the Board (“Committee”). RSAs, SBAs, RSUs and PSAs (collectively, “Full Value Equity Awards”) with vesting or settlement restrictions, as applicable, based upon completion of performance goals, have a minimum one-year vesting or settlement restriction period (the “One-Year Restriction Period”) and all other vesting or settlement restrictions, as applicable, for Full Value Equity Awards shall have a minimum three-year vesting or settlement restriction period (the “Three-Year Restriction Period” and together with the One-Year Restriction Period, the “Minimum Restriction Periods”). The Company may grant Full Value Equity Awards without taking into account the Minimum Restriction Periods, provided, that, the Company does not grant more than 10% of the aggregate shares of common stock reserved and available for grant and issuance under the 2006 Plan without the Minimum Restriction Periods. The following provides a general description of each type of award under the 2006 Plan. As of December 31, 2013, the Company had 2,090,798 shares of the Company’s common stock reserved for future issuance under the 2006 Plan. | |||||||||||||||||
Stock options may be granted at no less than the fair market value per share of common stock on the date of the grant (at 110% of fair market value for ISOs granted to 10% shareholders), expire not later than seven years from the date of grant (five years from the date of grant for ISOs granted to 10% shareholders) and generally vest 25% one year after the date of grant and then on a pro rata basis over the following 36 months. | |||||||||||||||||
RSAs may be granted at a purchase price that is less than fair market value on the date of grant, and the restrictions are determined by the Committee and may be based on years of service with the Company or completion of performance goals during a period. The Committee will determine the extent that the RSA is earned prior to the payment for the shares awarded. | |||||||||||||||||
RSUs are awards for past or future services that may be settled in cash or shares of common stock, including restricted stock. The Committee determines the terms of each RSU, including the number of shares of common stock subject to the RSU, the times during which the RSU may be settled, consideration to be made on settlement, and effect of the participant’s termination. If RSUs are awarded based on performance goals, the Committee will determine the extent that the RSU is earned. The number of shares subject to the RSU may be fixed or may vary depending on performance goals determined by the Committee. While the RSU shall be paid currently, under certain circumstances the Committee may permit the participant to defer settlement of the RSU. | |||||||||||||||||
A summary of stock option activity under all plans is as follows (in thousands, except weighted average exercise price and weighted average remaining contractual term): | |||||||||||||||||
Shares | Weighted | Weighted | Instrinsic | ||||||||||||||
Average | Average | Value | |||||||||||||||
Exercise Price | Remaining | ||||||||||||||||
Contractual Term | |||||||||||||||||
(in years) | |||||||||||||||||
Outstanding December 31, 2010 | 9,514 | $ | 13.03 | ||||||||||||||
Granted | 1,501 | $ | 32.12 | ||||||||||||||
Exercised | (3,083 | ) | $ | 10.73 | |||||||||||||
Forfeited | (233 | ) | $ | 18.63 | |||||||||||||
Outstanding December 31, 2011 | 7,699 | $ | 17.54 | ||||||||||||||
Granted | 1,141 | $ | 36.68 | ||||||||||||||
Exercised | (1,920 | ) | $ | 12.93 | |||||||||||||
Forfeited | (110 | ) | $ | 32.23 | |||||||||||||
Outstanding December 31, 2012 | 6,810 | $ | 21.81 | ||||||||||||||
Granted | 1,553 | $ | 38.55 | ||||||||||||||
Exercised | (1,579 | ) | $ | 16.19 | |||||||||||||
Forfeited | (308 | ) | $ | 32.19 | |||||||||||||
Outstanding December 31, 2013 | 6,476 | $ | 26.7 | 3.83 | $ | 129,358 | |||||||||||
Exercisable, December 31, 2013 | 3,935 | $ | 20.45 | 2.62 | $ | 103,182 | |||||||||||
Vested and expected to vest December 31, 2013 | 6,241 | $ | 26.28 | 3.75 | $ | 127,241 | |||||||||||
The aggregate intrinsic value in the table above represents the total pretax intrinsic value (i.e., the difference between the Company’s closing stock price of $46.67 on the last trading day of 2013 and the exercise price, times the number of shares for options where the exercise price is below the closing stock price) that would have been received by the option holders had all option holders exercised their options on that date. This amount changes based on the fair market value of the Company’s stock. The total intrinsic value of options exercised was $37.0 million, $54.5 million, and $69.8 million for the years ended December 31, 2013, 2012, and 2011, respectively. | |||||||||||||||||
A summary of all award activity, which consists of RSAs and RSUs, is as follows (in thousands, except weighted average grant date fair value): | |||||||||||||||||
Shares | Weighted | ||||||||||||||||
Average | |||||||||||||||||
Grant Date | |||||||||||||||||
Fair Value | |||||||||||||||||
Outstanding, December 31, 2010 | 403 | $ | 17.92 | ||||||||||||||
Granted | 374 | $ | 32.3 | ||||||||||||||
Vested | (143 | ) | $ | 19.89 | |||||||||||||
Cancelled | (38 | ) | $ | 27.42 | |||||||||||||
Outstanding, December 31, 2011 | 596 | $ | 25.87 | ||||||||||||||
Granted | 271 | $ | 36.9 | ||||||||||||||
Vested | (209 | ) | $ | 27.62 | |||||||||||||
Cancelled | (16 | ) | $ | 34.29 | |||||||||||||
Outstanding, December 31, 2012 | 642 | $ | 29.74 | ||||||||||||||
Granted | 412 | $ | 38.23 | ||||||||||||||
Vested | (262 | ) | $ | 29.81 | |||||||||||||
Cancelled | (50 | ) | $ | 34.17 | |||||||||||||
Outstanding, December 31, 2013 | 742 | $ | 34.13 | ||||||||||||||
In accordance with the 2006 Plan, RSAs and RSUs granted in 2013, 2012 and 2011, reduced the number of shares available for future grant by a factor of 1.75 for each share subject to such award. Based on the closing price per share of the Company’s common stock of $46.67 and $33.86 on the last trading day in 2013 and in 2012, respectively, the total pre-tax intrinsic value of all outstanding stock awards as of December 31, 2013 and December 31, 2012 was $34.5 million and $21.7 million, respectively. Total fair value of stock awards vested was $10.0 million, $7.4 million, and $4.8 million for the years ended December 31, 2013, 2012 and 2011, respectively. | |||||||||||||||||
Employee Stock Purchase Plan | |||||||||||||||||
The 2000 Employee Stock Purchase Plan (“2000 ESPP”) was adopted in April 2000, amended in June 2003, April 2009 and April 2012 and terminated effective August 1, 2012. The 2000 ESPP permitted eligible employees of the Company and its participating subsidiaries to purchase common stock at a discount up to a maximum of 15% of compensation through payroll deductions during defined two-year offering periods consisting of four, six-month purchase periods. The price at which stock was purchased under the 2000 ESPP was equal to 85% of the fair market value of the common stock on the first day of the two-year offering period or the last day of the six-month purchase period, whichever was lower. | |||||||||||||||||
The 2012 Employee Stock Purchase Plan (“2012 ESPP”) was approved by the Company’s Board of Directors in February 2012 and adopted by the Company’s stockholders in April 2012. The 2012 ESPP permits eligible employees of the Company and its participating subsidiaries to purchase common stock at a discount up to a maximum of 15% of compensation through payroll deductions during defined two-year offering periods consisting of four, six-month purchase periods. The price at which stock is purchased under the 2012 ESPP is equal to 85% of the fair market value of the common stock on the first day of the two-year offering period or the last day of the six-month purchase period, whichever is lower. The number of shares available for future issuance increase annually equal to the lesser of (a) 500,000 shares or (b) an amount determined by the Compensation Committee of the Board. | |||||||||||||||||
Reserved Shares | |||||||||||||||||
As of December 31, 2013, the Company has reserved shares of common stock for future issuance as follows (in thousands): | |||||||||||||||||
2006 Plan: | |||||||||||||||||
Options, RSUs and awards outstanding for all plans | 7,218 | ||||||||||||||||
Reserved for future grants | 2,091 | ||||||||||||||||
2012 ESPP | 1,914 | ||||||||||||||||
11,223 | |||||||||||||||||
Stock-Based Compensation | |||||||||||||||||
Fair Value—The fair value of the Company’s stock options granted to employees and shares purchased by employees under the 2000 ESPP and 2012 ESPP, as applicable, for the years ended December 31, 2013, 2012 and 2011 was estimated using the following assumptions: | |||||||||||||||||
Years Ended December 31, | |||||||||||||||||
2013 | 2012 | 2011 | |||||||||||||||
OPTION SHARES: | |||||||||||||||||
Expected Term (in years) | 4.41 | 4.38 | 4.58 | ||||||||||||||
Volatility | 0.44 | 0.53 | 0.54 | ||||||||||||||
Expected Dividends | 0 | % | 0 | % | 0 | % | |||||||||||
Risk Free Interest Rates | 0.9 | % | 0.8 | % | 1.64 | % | |||||||||||
Estimated Forfeitures | 7.61 | % | 7.63 | % | 7.74 | % | |||||||||||
Weighted Average Fair Value | $ | 14.17 | $ | 15.7 | $ | 14.76 | |||||||||||
ESPP SHARES: | |||||||||||||||||
Expected Term (in years) | 1.25 | 1.25 | 1.25 | ||||||||||||||
Volatility | 0.42 | 0.54 | 0.51 | ||||||||||||||
Expected Dividends | 0 | % | 0 | % | 0 | % | |||||||||||
Risk Free Interest Rates | 0.19 | % | 0.18 | % | 0.34 | % | |||||||||||
Weighted Average Fair Value | $ | 12.1 | $ | 13.13 | $ | 9.84 | |||||||||||
Stock-Based Compensation Cost—The following table is a summary of the major categories of stock compensation expense recognized in accordance with ASC 718, “Compensation—Stock Compensation” (“ASC 718”) for the years ended December 31, 2013, 2012 and 2011 (in thousands). | |||||||||||||||||
Years Ended December 31, | |||||||||||||||||
2013 | 2012 | 2011 | |||||||||||||||
Cost of sales | $ | 2,930 | $ | 3,087 | $ | 1,679 | |||||||||||
Research and develompent | 8,540 | 7,563 | 6,551 | ||||||||||||||
Sales and marketing | 5,636 | 5,032 | 4,311 | ||||||||||||||
General and administrative | 10,529 | 8,814 | 7,227 | ||||||||||||||
Total stock-based compensation cost | $ | 27,635 | $ | 24,496 | $ | 19,768 | |||||||||||
The above stock-based compensation cost includes $3.6 million related to the 2000 ESPP and 2012 ESPP for 2013, $2.4 million for 2012 related to the 2000 ESPP and 2012 ESPP and $2.6 million related to the 2000 ESPP for 2011. | |||||||||||||||||
As of December 31, 2013, the total compensation cost related to unvested stock-based grants awarded under the Company’s 1997 Plan and 2006 Plan but not yet recognized was $29.3 million, which is net of estimated forfeitures of $7.0 million. This cost will be amortized on a straight line basis over a weighted average period of 2.7 years and will be adjusted for subsequent changes in estimated forfeitures. | |||||||||||||||||
As of December 31, 2013, the total compensation cost related to RSUs under the 2006 Plan not yet recognized was $19.2 million, which is net of estimated forfeitures of $4.7 million. This cost will be amortized on a straight line basis over a weighted average period of 2.5 years and will be adjusted for subsequent changes in estimated forfeitures. | |||||||||||||||||
At December 31, 2013, the total compensation cost related to options to purchase the Company’s common shares under the 2012 ESPP but not yet recognized was $2.1 million. The cost will be amortized on a straight-line basis over the two year offering period, as such term is defined in the 2012 ESPP. |
Employee_Benefit_Plan
Employee Benefit Plan | 12 Months Ended |
Dec. 31, 2013 | |
Text Block [Abstract] | ' |
Employee Benefit Plan | ' |
10. Employee Benefit Plan | |
The Company’s 401(k) plan allows eligible employees to contribute a percentage of their qualified compensation subject to IRS limits. The Company has the discretion to make matching contributions each year. Contributions made by the Company for the years ended December 31, 2013, 2012 and 2011 were $1.5 million, $1.2 million, and $0.7 million, respectively. | |
On December 9, 2013, the Compensation Committee of the Board of Directors of the Company approved the establishment of the Cepheid Executive Deferred Compensation Plan (the “Plan”). The Plan is an unfunded deferred compensation plan and participants in the Plan will at all times have the status of unsecured general creditors of Cepheid with respect to the payment of any Plan benefits. The Plan is designed to provide designated executives of Cepheid, currently set at Vice Presidents and above, with the opportunity to defer the payment of | |
(1) between 5% and 75% of their base salary and | |
(2) between 5% and 100% of any cash-based incentive awards payable to a participant. | |
The Plan’s Administrative Committee will select investment options from which the participants may make elections for the deemed investment of their accounts under the Plan. Plan participants shall at all times be fully vested in any amounts deferred pursuant to the Plan. The Plan became effective beginning January 1, 2014. |
Segment_and_Significant_Concen
Segment and Significant Concentrations | 12 Months Ended | ||||||||||||
Dec. 31, 2013 | |||||||||||||
Segment Reporting [Abstract] | ' | ||||||||||||
Segment and Significant Concentrations | ' | ||||||||||||
11. Segment and Significant Concentrations | |||||||||||||
The Company and its wholly owned subsidiaries operate in one business segment. | |||||||||||||
The following table summarizes total sales (in thousands): | |||||||||||||
Years Ended December 31, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Sales: | |||||||||||||
System and other sales | $ | 76,763 | $ | 65,111 | $ | 73,999 | |||||||
Reagent and disposable sales | 324,529 | 266,101 | 203,576 | ||||||||||
Total sales | $ | 401,292 | $ | 331,212 | $ | 277,575 | |||||||
The following table summarizes sales in the Clinical and Non-Clinical markets (in thousands): | |||||||||||||
Years Ended December 31, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Sales by market: | |||||||||||||
Clinical Systems | $ | 66,980 | $ | 52,805 | $ | 58,634 | |||||||
Clinical Reagents | 292,941 | 233,503 | 177,435 | ||||||||||
Total Clinical | $ | 359,921 | $ | 286,308 | $ | 236,069 | |||||||
Non-Clinical | 41,371 | 44,904 | 41,506 | ||||||||||
Total sales | $ | 401,292 | $ | 331,212 | $ | 277,575 | |||||||
The Company has distribution agreements to distribute products in the United States and has several regional distribution arrangements throughout Europe, Japan, China, Latin America, South America, Canada and other parts of the world. | |||||||||||||
The following table summarizes sales by geographic region (in thousands): | |||||||||||||
Years Ended December 31, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Geographic sales information: | |||||||||||||
North America | |||||||||||||
Clinical | $ | 212,362 | $ | 190,021 | $ | 167,966 | |||||||
Non-Clinical | 36,998 | 38,632 | 37,038 | ||||||||||
Total North America | 249,360 | 228,653 | 205,004 | ||||||||||
International | |||||||||||||
Clinical | $ | 147,559 | $ | 96,286 | $ | 68,103 | |||||||
Non-Clinical | 4,373 | 6,273 | 4,468 | ||||||||||
Total International | 151,932 | 102,559 | 72,571 | ||||||||||
Total sales | $ | 401,292 | $ | 331,212 | $ | 277,575 | |||||||
The Company recognized sales of $237.8 million, $216.6 million and $189.0 million for sales to U.S. customers for the years ended December 31, 2013, 2012 and 2011. The Company recognized sales of $41.6 million, $22.8 million and $12.9 million to customers in South Africa for the years ended December 31, 2013, 2012 and 2011, respectively. As of December 31, 2013 and 2012, the Company has long lived-assets (excluding intangible assets) of $63.9 million and $36.6 million, respectively, which reside in the United States As of December 31, 2013 and 2012, the Company has long-lived assets of $21.0 million and $18.2 million, respectively, which reside primarily in Sweden and countries in the European Monetary Union. |
Collaboration_Profit_Sharing
Collaboration Profit Sharing | 12 Months Ended |
Dec. 31, 2013 | |
Text Block [Abstract] | ' |
Collaboration Profit Sharing | ' |
12. Collaboration Profit Sharing | |
Collaboration profit sharing represents the amount that the Company pays to LIFE under its collaboration agreement to develop reagents for use in the USPS BDS program. Under the agreement, computed gross margin on anthrax cartridge sales are shared equally between the two parties. Collaboration profit sharing expense was $7.5 million, $7.2 million and $4.9 million for the years ended December 31, 2013, 2012, 2011 respectively. The total revenues and cost of sales related to these cartridge sales are included in the respective balances in the consolidated statement of operations. |
Collaborative_Agreements_and_C
Collaborative Agreements and Contracts | 12 Months Ended |
Dec. 31, 2013 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | ' |
Collaborative Agreements and Contracts | ' |
13. Collaborative Agreements and Contracts | |
Foundation for Innovative New Diagnostics | |
In May 2006, the Company entered into an agreement with the FIND to develop a simple, rapid test that can detect mycobactrium tuberculosis and associated rifampin resistance from human sputum samples. Under the agreement, the Company was responsible for the development of a 6-color GeneXpert instrument to accomplish such test and the development of an enhanced manufacturing line for the manufacture of test cartridges used in the test. FIND reimbursed the Company at agreed upon amounts. The term of the development portion of the agreement was 30 months, which was subsequently extended an additional five months. In July 2009, the agreement was extended for another year for further specified enhancements. The supply term of the agreement is for 12 years, unless terminated by either party in accordance with relevant provisions of the agreement. In January 2011, the agreement was extended for another year and a new agreement was signed for the development of the Company’s Xpert HIV Viral Load test. Under the Xpert HIV agreement, FIND agreed to fund $5.1 million in development costs throughout the two-year contract. In the first quarter of 2011, the Company and FIND entered into a $1.0 million agreement with FIND to fund the development of a remote calibration kit for its GeneXpert system family. The Company recognized revenue from FIND of $0.8 million, $2.2 million and $1.8 million for the years ended December 31, 2013, 2012 and 2011, respectively. | |
MTB/RIF Buy Down Program for the HBDC Market | |
During 2012, the Company entered into agreements with The Bill and Melinda Gates Foundation (“BMGF”), The United States Agency for International Development (“USAID”) and UNITAID to reduce the price of the Company’s Multi-Drug Resistant Tuberculosis test to $9.98 for customers in the HBDC program. The Company received one-time payments of $3.5 million each from BMGF and USAID in 2012 and $3.2 million from UNITAID during 2013. Based on the terms of the agreements, the Company recognized revenue related to the BMGF and USAID agreements on a per-unit basis. Under the UNITAID agreement, the Company will recognize the $3.2 million of revenue on a straight line basis over a period of ten years. For the years ended December 31, 2013 and 2012, the Company recognized revenue of $2.7 million and $4.8 million, respectively, related to the BMGF, USAID and UNITAID agreements. | |
LIFE and Northrop Grumman Corporation | |
In October 2002, the Company entered into a collaboration agreement with LIFE to develop reagents for use in the USPS BDS program, which was developed by the consortium led by Northrop Grumman Corporation. Under the agreement, reagents will be manufactured by LIFE for packaging by the Company into its GeneXpert test cartridges and sold by the Company for use in the BDS. This agreement calls for the computed gross margin on sales of anthrax cartridges for the USPS BDS program to be equally shared between the Company and LIFE. | |
In August 2007, the Company entered into a five-year master purchase agreement with Northrop Grumman for the purchase of up to $200 million in anthrax test cartridges and associated materials used in BDS. In the fourth quarter of 2011, the Company entered into another five-year master purchase agreement with Northrop Grumman for the purchase of up to $112 million of anthrax test cartridges and associated materials used in BDS. The agreement and subsequent purchase orders cover the period through September 30, 2016. In the fourth quarter of 2012, the Company entered into an agreement directly with the USPS to sell the anthrax test cartridges and associated materials used in BDS directly to USPS through the period ending September 30, 2016. |
Subsequent_Event
Subsequent Event | 12 Months Ended | |||
Dec. 31, 2013 | ||||
Subsequent Events [Abstract] | ' | |||
Subsequent Event | ' | |||
14. Subsequent Event | ||||
Convertible Senior Note | ||||
In February 2014, the Company issued 1.25% convertible senior notes due February 1, 2021 (“Notes”) with a principal amount of $345 million, which included the exercise of the initial purchasers’ over-allotment option. The Notes are unsecured, unsubordinated obligations of the Company, and interest is payable in cash in arrears at a fixed rate of 1.25% on February 1 and August 1 of each year, beginning on August 1, 2014. The Notes mature on February 1, 2021 unless repurchased or converted in accordance with their terms prior to such date. The Company cannot redeem the 2021 Notes prior to maturity. The Company estimates that the net proceeds from the offering were approximately $336.4 million, after deducting the initial purchasers’ discount and estimated offering expenses payable by the Company. | ||||
The terms of the Notes are governed by an Indenture between the Company and Wells Fargo Bank, National Association, as Trustee (the Indentures). Upon conversion, the Notes may be settled in cash, shares of Common Stock or a combination of cash and shares of Common Stock, at the Company’s election. | ||||
The Notes have an initial conversion rate of 15.3616 shares of Common Stock per $1,000 principal amount of Notes, which is equal to an initial effective conversion price of approximately $65.10 per share of Common Stock, subject to adjustment. Prior to the close of business on August 1, 2020, the conversion is subject to the satisfaction of certain conditions as described below. | ||||
Holders of the Notes who convert their Notes in connection with certain corporate events that constitute a make-whole fundamental change (as defined in the Indentures) are, under certain circumstances, entitled to an increase in the conversion rate. Additionally, in the event of a fundamental change, holders of the Notes may require the Company to repurchase all or a portion of their Notes at a price equal to 100% of the principal amount of the Notes, plus any accrued and unpaid interest. | ||||
Holders of the Notes may convert all or a portion of their Notes prior to the close of business on August 1, 2020, in multiples of $1,000 principal amount, only under the following circumstances: | ||||
• | during any calendar quarter commencing after the calendar quarter ending on March 31, 2014 (and only during such calendar quarter), if the last reported sale price of Common Stock for at least twenty trading days during a period of thirty consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price of the respective Notes on each applicable trading day; | |||
• | during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of the respective Notes for each day of that five day consecutive trading day period was less than 98% of the product of the last reported sale price of Common Stock and the conversion rate of the respective Notes on such trading day; or | |||
• | upon the occurrence of specified corporate events specified in the Indenture. | |||
In accounting for the issuance of the Notes, the Company will separate each of the Notes into liability and equity components. The carrying amounts of the liability components will be calculated by measuring the fair value of similar liabilities that do not have associated convertible features. The carrying amount of the equity components representing the conversion option will be determined by deducting the fair value of the liability components from the par value of the respective Note. These differences represent debt discounts that will be amortized to interest expense over the respective terms of the Notes. The equity components will not be re-measured as long as they continue to meet the conditions for equity classification. | ||||
In connection with the issuance of the Notes, the Company entered into capped call transactions with one or more of the underwriters of the notes or their respective affiliates or other financial institutions. The capped call transactions are expected to reduce potential dilution to the common stock upon conversion of the Notes. Under the capped call transactions, the Company purchased capped call options for approximately $25 million that in the aggregate relate to the total number of shares of the Company’s common stock underlying the Convertible Notes, with a strike price equal to the conversion price of the notes and with a cap price equal to approximately $78.61 per share. The fair value of the purchased capped calls will be recorded to stockholders’ equity. |
Quarterly_Financial_Informatio
Quarterly Financial Information | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Quarterly Financial Information Disclosure [Abstract] | ' | ||||||||||||||||
Quarterly Financial Information | ' | ||||||||||||||||
SUPPLEMENTARY DATA: | |||||||||||||||||
QUARTERLY FINANCIAL INFORMATION | |||||||||||||||||
31-Mar | June 30 | 30-Sep | 31-Dec | ||||||||||||||
(Unaudited) | |||||||||||||||||
(In thousands, except per share data) | |||||||||||||||||
2013 | |||||||||||||||||
Total sales | $ | 91,938 | $ | 96,012 | $ | 100,081 | $ | 113,261 | |||||||||
Costs and operating expenses: | |||||||||||||||||
Cost of sales | 42,892 | 52,889 | 51,669 | $ | 60,483 | ||||||||||||
Collaboration profit sharing | 2,110 | 1,425 | 1,410 | 2,567 | |||||||||||||
Research and development | 17,727 | 18,572 | 18,558 | 25,340 | |||||||||||||
Sales and marketing | 19,126 | 19,105 | 19,788 | 21,922 | |||||||||||||
General and administrative | 9,763 | 9,612 | 9,490 | 12,854 | |||||||||||||
Total cost and operating expenses | 91,618 | 101,603 | 100,915 | 123,166 | |||||||||||||
Income (loss) from operations | 320 | (5,591 | ) | (834 | ) | (9,905 | ) | ||||||||||
Other income (expense), net | 374 | (717 | ) | (200 | ) | (264 | ) | ||||||||||
Income (loss) before income tax expense | 694 | (6,308 | ) | (1,034 | ) | (10,169 | ) | ||||||||||
Provision for income tax expense | (381 | ) | (272 | ) | (347 | ) | (148 | ) | |||||||||
Net income (loss) | $ | 313 | $ | (6,580 | ) | $ | (1,381 | ) | $ | (10,317 | ) | ||||||
Basic net income (loss) per share | 0 | (0.10 | ) | (0.02 | ) | (0.15 | ) | ||||||||||
Diluted net income (loss) per share | $ | 0 | $ | (0.10 | ) | $ | (0.02 | ) | $ | (0.15 | ) | ||||||
Weighted average shares used in computing basic net income (loss) per share | 66,824 | 67,295 | 67,573 | 68,230 | |||||||||||||
Weighted average shares used in computing diluted net income (loss) per share | 69,406 | 67,295 | 67,573 | 68,230 | |||||||||||||
Gross profit on sales: | |||||||||||||||||
Sales | $ | 91,938 | $ | 96,012 | $ | 100,081 | $ | 113,261 | |||||||||
Cost of sales | (42,892 | ) | (52,889 | ) | (51,669 | ) | (60,483 | ) | |||||||||
$ | 49,046 | $ | 43,123 | $ | 48,412 | $ | 52,778 | ||||||||||
Diluted net income per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued. | |||||||||||||||||
Quarters Ended | |||||||||||||||||
31-Mar | June 30 | 30-Sep | 31-Dec | ||||||||||||||
(Unaudited) | |||||||||||||||||
(In thousands, except per share data) | |||||||||||||||||
2012 | |||||||||||||||||
Total sales | $ | 77,292 | $ | 81,015 | $ | 80,472 | $ | 92,433 | |||||||||
Costs and operating expenses: | |||||||||||||||||
Cost of sales | 35,608 | 35,072 | 39,789 | 42,896 | |||||||||||||
Collaboration profit sharing | 1,684 | 1,645 | 2,438 | 1,416 | |||||||||||||
Research and development | 22,102 | 16,118 | 16,154 | 17,299 | |||||||||||||
Sales and marketing | 14,512 | 15,108 | 15,993 | 16,294 | |||||||||||||
General and administrative | 11,051 | 11,011 | 11,766 | 9,470 | |||||||||||||
Litigation settlement | — | — | 15,110 | — | |||||||||||||
Total cost and operating expenses | 84,957 | 78,954 | 101,250 | 87,375 | |||||||||||||
Income (loss) from operations | (7,665 | ) | 2,061 | (20,778 | ) | 5,058 | |||||||||||
Other income (expense), net | 238 | (572 | ) | 89 | 241 | ||||||||||||
Income (loss) before income tax expense | (7,427 | ) | 1,489 | (20,689 | ) | 5,299 | |||||||||||
Benefit from (provision for) income taxes | 1,901 | (354 | ) | (607 | ) | 345 | |||||||||||
Net income (loss) | $ | (5,526 | ) | $ | 1,135 | $ | (21,296 | ) | $ | 5,644 | |||||||
Basic net income (loss) per share | $ | (0.08 | ) | $ | 0.02 | $ | (0.32 | ) | $ | 0.09 | |||||||
Diluted net income (loss) per share | $ | (0.08 | ) | $ | 0.02 | $ | (0.32 | ) | $ | 0.08 | |||||||
Weighted average shares used in computing basic net income (loss) per share | 65,027 | 65,695 | 66,145 | 66,370 | |||||||||||||
Weighted average shares used in computing diluted net income (loss) per share | 65,207 | 68,869 | 66,145 | 68,787 | |||||||||||||
Gross profit on sales: | |||||||||||||||||
Sales | $ | 77,292 | $ | 81,015 | $ | 80,472 | $ | 92,433 | |||||||||
Cost of sales | (35,608 | ) | (35,072 | ) | (39,789 | ) | (42,896 | ) | |||||||||
$ | 41,684 | $ | 45,943 | $ | 40,683 | $ | 49,537 |
Schedule_II_Valuation_and_Qual
Schedule II - Valuation and Qualifying Accounts | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Valuation And Qualifying Accounts [Abstract] | ' | ||||||||||||||||
Schedule II - Valuation and Qualifying Accounts | ' | ||||||||||||||||
SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS | |||||||||||||||||
Description | Balance at | Costs and | Deductions | Balance at | |||||||||||||
Beginning of | Expenses | End of Year | |||||||||||||||
Year | |||||||||||||||||
(In thousands) | |||||||||||||||||
Allowance for doubtful accounts: | |||||||||||||||||
Year ended December 31, 2011 | $ | 61 | $ | 81 | $ | (81 | ) | $ | 61 | ||||||||
Year ended December 31, 2012 | 61 | 135 | (20 | ) | 176 | ||||||||||||
Year ended December 31, 2013 | 176 | 63 | (41 | ) | 198 |
Organization_and_Summary_of_Si1
Organization and Summary of Significant Accounting Policies (Policies) | 12 Months Ended | ||||||||||||
Dec. 31, 2013 | |||||||||||||
Text Block [Abstract] | ' | ||||||||||||
Organization and Business | ' | ||||||||||||
Organization and Business | |||||||||||||
Cepheid (the “Company”) was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for testing in the Clinical market, as well as for application in the Company’s legacy Non-Clinical market. The Company’s systems enable rapid, sophisticated molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. | |||||||||||||
Principles of Consolidation | ' | ||||||||||||
Principles of Consolidation | |||||||||||||
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances. On July 1, 2012, the Company changed the functional currency for certain foreign subsidiaries from the local currency to the U.S. dollar due to changes in the way these businesses and their operations are structured and managed. As a result, all foreign subsidiaries are using the U.S. dollar as the functional currency effective July 1, 2012. Prior to this change, adjustments resulting from translating the foreign currency financial statements of these subsidiaries into the U.S. dollar had been included as a separate component of accumulated other comprehensive income (loss). Upon the change of the functional currency, these subsidiaries no longer generate further translation adjustments, and the accumulated translation adjustments from prior periods will continue to remain a component of accumulated other comprehensive income (loss). | |||||||||||||
Net income (loss) includes the gains and losses arising from transactions denominated in a currency other than the functional currency of a location, the remeasurement of assets and liabilities of foreign subsidiaries using U.S. dollars as their functional currency, and the realized results of the Company’s foreign currency hedging activities. | |||||||||||||
Within the consolidated statements of cash flows from operating and investing activities, certain amounts were reclassified to conform to the current period presentation. | |||||||||||||
Use of Estimates | ' | ||||||||||||
Use of Estimates | |||||||||||||
The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. | |||||||||||||
Fair Value of Financial Instruments | ' | ||||||||||||
Fair Value of Financial Instruments | |||||||||||||
The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company’s valuation techniques used to measure fair value maximized the use of observable inputs and minimized the use of unobservable inputs. The fair value hierarchy is based on the following three levels of inputs: | |||||||||||||
• | Level 1—Quoted prices in active markets for identical assets or liabilities. | ||||||||||||
• | Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. | ||||||||||||
• | Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. | ||||||||||||
See Note 2, “Fair Value”, for information and related disclosures regarding the Company’s fair value measurements. | |||||||||||||
Cash, Cash Equivalents, Short-Term Investments and Investments | ' | ||||||||||||
Cash, Cash Equivalents, Short-Term Investments and Investments | |||||||||||||
Cash and cash equivalents consist of cash on deposit with banks and money market instruments. Interest income includes interest, dividends, amortization of purchase premiums and discounts and realized gains and losses on sales of securities. | |||||||||||||
All highly liquid investments with maturities of three months or less at the date of purchase are classified as cash equivalents. The Company’s marketable debt securities have been classified and accounted for as available-for-sale. The Company determines the appropriate classification of its investments at the time of purchase and re-evaluates the designations at each balance sheet date. The Company classifies its marketable debt securities as either short-term or long-term based on each instrument’s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. The Company’s marketable debt securities are carried at fair value, with the unrealized gains and losses reported as a component of shareholders’ equity. The cost of securities sold is based upon the specific identification method. | |||||||||||||
The Company assesses whether an other-than-temporary impairment loss on its investments has occurred due to declines in fair value or other market conditions. With respect to the Company’s debt securities, this assessment takes into account the severity and duration of the decline in value, the Company’s intent to sell the security, whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis, and whether or not the Company expects to recover the entire amortized cost basis of the security (that is, a credit loss exists). | |||||||||||||
See Note 3, “Investments”, for information and related disclosures regarding the Company’s investments. | |||||||||||||
Concentration of Credit Risks and Other Uncertainties | ' | ||||||||||||
Concentration of Credit Risks and Other Uncertainties | |||||||||||||
The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments and investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s derivative instruments consist of large financial institutions of high credit standing. | |||||||||||||
The Company’s main financial institution for banking operations held 55% and 71% of the Company’s cash and cash equivalents as of December 31, 2013 and 2012, respectively. | |||||||||||||
The Company’s accounts receivable are derived from net revenue to customers and distributors located in the United States and other countries. The Company performs credit evaluations of its customers’ financial condition. The Company provides reserves for potential credit losses but has not experienced significant losses to date. There was one direct customer whose accounts receivable balance represented 14% and 7% of total accounts receivable as of December 31, 2013 and 2012, respectively. | |||||||||||||
The Company currently sells products through its direct sales force and distributors. There were no direct customers that accounted for 10% or more of total sales for the years ended December 31, 2013, 2012 and 2011. No single country outside of the United States or South Africa represented more than 10% of the Company’s total revenues or total assets in any period presented. | |||||||||||||
Inventory | ' | ||||||||||||
Inventory | |||||||||||||
Inventory is stated at the lower of standard cost (which approximates actual cost) or market, with cost determined on the first-in-first-out method. Accordingly, allocation of fixed production overheads to conversion costs is based on normal capacity of production. Abnormal amounts of idle facility expense, freight, handling costs and spoilage are expensed as incurred and not included in overhead. In addition, stock-based compensation expenses of approximately $2.1 million and $1.1 million were included in inventory as of December 31, 2013 and 2012, respectively. | |||||||||||||
The components of inventories were as follows (in thousands): | |||||||||||||
December 31 | |||||||||||||
2013 | 2012 | ||||||||||||
Raw Materials | $ | 35,760 | $ | 26,041 | |||||||||
Work in Process | 36,580 | 30,113 | |||||||||||
Finished Goods | 31,526 | 13,960 | |||||||||||
$ | 103,866 | $ | 70,114 | ||||||||||
Property and Equipment | ' | ||||||||||||
Property and Equipment | |||||||||||||
Property and equipment are stated at cost. Depreciation is calculated using the straight-line method, and the cost is depreciated over the respective estimated useful lives of the assets, which range from 3 to 7 years. Leasehold improvements are amortized using the straight-line method over the estimated useful lives of the assets or the term of the lease, whichever is shorter. During the fourth quarter of 2013, the Company concluded that certain manufacturing capital assets will not be utilized and therefore have no future realizable value and thus an impairment was recorded of approximately $1.3 million as cost of sales. | |||||||||||||
Property and equipment consisted of the following (in thousands): | |||||||||||||
December 31 | |||||||||||||
2013 | 2012 | ||||||||||||
Land | $ | 21 | $ | 21 | |||||||||
Building | 3,970 | 3,044 | |||||||||||
Scientific equipment | 42,845 | 35,248 | |||||||||||
Manufacturing equipment | 45,339 | 26,226 | |||||||||||
Office furniture, computers and equipment | 21,810 | 17,994 | |||||||||||
Leasehold improvements | 48,879 | 31,166 | |||||||||||
$ | 162,864 | $ | 113,699 | ||||||||||
Less accumulated depreciation and amortization | (77,978 | ) | (58,869 | ) | |||||||||
$ | 84,886 | $ | 54,830 | ||||||||||
Total depreciation and amortization expense on our property and equipment in the years ended December 31, 2013, 2012 and 2011 totaled $17.8 million, $13.4 million and $10.3 million, respectively. | |||||||||||||
Intangible Assets and Goodwill | ' | ||||||||||||
Intangible Assets and Goodwill | |||||||||||||
Intangible assets related to licenses are recorded at cost, less accumulated amortization. Intangible assets related to technology and other intangible assets acquired in acquisitions are recorded at fair value at the date of acquisition, less accumulated amortization. Intangible assets are amortized over their estimated useful lives, ranging from 3 to 15 years, primarily on a straight-line basis. Amortization of intangible assets is included in cost of sales, research and development and sales and marketing in the Consolidated Statements of Operations. | |||||||||||||
The Company reviews its intangible assets for impairment and conducts the impairment review when events or circumstances indicate the carrying value of a long-lived asset may be impaired by estimating the future undiscounted cash flows to be derived from an asset to assess whether or not a potential impairment exists. If the carrying value exceeds the Company’s estimate of future undiscounted cash flows, an impairment value is calculated as the excess of the carrying value of the asset over the Company’s estimate of its fair market value. Events or circumstances which could trigger an impairment review include a significant adverse change in the business climate, an adverse action or assessment by a regulator, unanticipated competition, significant changes in the Company’s use of acquired assets, the Company’s overall business strategy, or significant negative industry or economic trends. In 2013 and 2012, the Company recorded an impairment charge of $1.3 million and $1.4 million, respectively to cost of sales primarily related to acquired technology for one of its legacy products. In 2011, the Company terminated a license agreement with Roche which resulted in accelerating the amortization of the remaining up-front license fee of $5.4 million to cost of sales. | |||||||||||||
Goodwill is tested for impairment at a minimum on an annual basis and at the reporting unit level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the reporting unit does not pass the qualitative assessment, then the reporting unit’s carrying value is compared to its fair value. The fair values of the reporting units are estimated using market and discounted cash flow approaches. Goodwill is considered impaired if the carrying value of the reporting unit exceeds its fair value. The discounted cash flow approach uses expected future operating results. Failure to achieve these expected results may cause a future impairment of goodwill at the reporting unit. We conducted our annual impairment tests of goodwill in the fourth quarters of 2013 and 2012. As a result of these tests, we determined that no adjustment to the carrying value of goodwill for any reporting units was required. | |||||||||||||
Warranty Reserve | ' | ||||||||||||
Warranty Reserve | |||||||||||||
The Company warrants its systems to be free from defects for a period of generally 12 to 24 months from the date of sale and its disposable products to be free from defects, when handled according to product specifications, for the stated life of such products. Accordingly, a provision for the estimated cost of warranty repair or replacement is recorded at the time revenue is recognized. The Company’s warranty provision is established using management’s estimate of future failure rates and future costs of repairing any failures during the warranty period or replacing any disposable products with defects. The activities in the warranty provision consisted of the following (in thousands): | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Balance at beginning of year | $ | 1,953 | $ | 1,981 | $ | 969 | |||||||
Costs incurred and charged against reserve | (783 | ) | (690 | ) | (571 | ) | |||||||
Accrual related to current year product sales | 2,156 | 662 | 1,583 | ||||||||||
Balance at end of year | $ | 3,326 | $ | 1,953 | $ | 1,981 | |||||||
Revenue Recognition | ' | ||||||||||||
Revenue Recognition | |||||||||||||
The Company recognizes revenue from sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. No right of return exists for the Company’s products except in the case of damaged goods. The Company has not experienced any significant returns of its products. Shipping and handling costs are expensed as incurred and included in cost of sales. In those cases where the Company bills shipping and handling costs to customers, the amounts billed are classified as revenue. | |||||||||||||
The Company enters into revenue arrangements that may consist of multiple deliverables of its products and services. In situations with multiple deliverables, revenue is recognized upon the delivery of the separate elements. The Company sells service contracts for which revenue is deferred and recognized ratably over the contract period. | |||||||||||||
For multiple element arrangements entered into or materially modified on or subsequent to January 1, 2011, the total consideration for an arrangement is allocated among the separate elements in the arrangement based on a selling price hierarchy. The selling price hierarchy for a deliverable is based on: 1) vendor specific objective evidence (VSOE), if available; 2) third party evidence of selling price if VSOE is not available; or 3) an estimated selling price, if neither VSOE nor third party evidence is available. Estimated selling price is the Company’s best estimate of the selling price of an element in a transaction. The Company limits the amount of revenue recognized for delivered elements to the amount that is not contingent on the future delivery of products or services or other future performance obligations. The Company recognizes revenue for delivered elements only when the Company determines there are no uncertainties regarding customer acceptance. | |||||||||||||
Revenue includes fees for technology licenses and research and development services, including research and development under grants and government sponsored research, royalties under license and collaboration agreements. Fees for technology licenses are generally fully recognized only after the license period has commenced, the technology has been delivered and no further involvement of the Company is required. When the Company has continuing involvement related to a technology license, revenue is recognized over the license term. Revenue related to research and development services is recognized as the related service is performed based on the performance requirements of the relevant contract. Under such agreements, the Company is required to perform specific research and development activities and is compensated either based on the costs or costs plus a mark-up associated with each specific contract over the term of the agreement or based on the Company’s progress to completion and recoverability is reasonably assured. Royalties are typically based on licensees’ net sales of products that utilize the Company’s technology and royalty revenues are recognized as earned in accordance with the contract terms when the royalties can be reliably measured and their collectability is reasonably assured, such as upon the receipt of a royalty statement from the customer. Advance payments received in excess of amounts earned, such as funds received in advance of products to be delivered or services to be performed, are classified as deferred revenue until earned. | |||||||||||||
During 2012, the Company entered into agreements with The Bill and Melinda Gates Foundation (“BMGF”), The United States Agency for International Development (“USAID”) and UNITAID to reduce the price of the Company’s Multi-Drug Resistant Tuberculosis test to $9.98 for customers in the HBDC program. The Company received one-time payments of $3.5 million each from BMGF and USAID in 2012 and $3.2 million from UNITAID during 2013. Based on the terms of the agreements, the Company recognized revenue related to the BMGF and USAID agreements on a per-unit basis. Under the UNITAID agreement, the Company will recognize the $3.2 million of revenue on a straight line basis over a period of ten years. For the years ended December 31, 2013 and 2012, the Company recognized revenue of $2.7 million and $4.8 million, respectively, related to the BMGF, USAID and UNITAID agreements. | |||||||||||||
Research and Development | ' | ||||||||||||
Research and Development | |||||||||||||
Research and development expenses consist of costs incurred for company-sponsored and collaborative research and development activities. These costs include direct and research-related overhead expenses and amortization of certain intangible assets. The Company expenses research and development costs, including the expenses for research under collaborative agreements, as such costs are incurred. | |||||||||||||
Stock-Based Compensation | ' | ||||||||||||
Stock-Based Compensation | |||||||||||||
Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s condensed consolidated statements of operations. The Company recognizes the fair value of the Company’s stock option awards as compensation expense over the requisite service period of each award, which is generally four years. | |||||||||||||
In determining fair value of the stock-based compensation payments, the Company uses the Black–Scholes model and a single option award approach, which requires the input of subjective assumptions. These assumptions include: estimating the length of time employees will retain their vested stock options before exercising them (expected term), the estimated volatility of the Company’s common stock price over the expected term (expected volatility), the risk-free interest rate (interest rate), expected dividends and the number of shares subject to options that will ultimately not complete their vesting requirements (forfeitures). Changes in the following assumptions can materially affect the estimate of the fair value of stock–based compensation. | |||||||||||||
• | Expected term is determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior as influenced by changes to the terms of its stock-based awards. | ||||||||||||
• | Expected volatility is based on the blend of historical volatility of the past period equal to the Company’s expected term and the current implied volatility. | ||||||||||||
• | Risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award. | ||||||||||||
• | Expected dividend is based on the Company’s expectation of issuing a dividend over the expected term. The Company has never issued dividends. | ||||||||||||
• | Estimated forfeitures are based on voluntary termination behavior as well as analysis of actual option forfeitures. | ||||||||||||
Foreign Currency Hedging | ' | ||||||||||||
Foreign Currency Hedging | |||||||||||||
The Company uses forward contracts designated as cash flow hedges to protect against the foreign currency exchange rate risks inherent in its forecasted net revenue, cost of sales and operating expenses denominated in currencies other than the U.S. dollar. The Company also enters into non-qualifying foreign currency forward contracts to partially offset the foreign currency exchange gains and losses generated by the re-measurement of certain assets and liabilities. The Company’s foreign currency cash flow hedges mature generally within twelve months. For derivative instruments that are designated and qualify as cash flow hedges, the Company initially records the effective portion of the gain or loss on the derivative instrument in accumulated other comprehensive income or loss as a separate component of stockholders’ equity and subsequently reclassifies these amounts into earnings in the period during which the hedged transaction is recognized in earnings. The effective portion of cash flow hedges is reported in the same financial statement line item as the changes in value of the hedged item. For non-qualifying derivative instruments, the Company records the gain or loss for each period in earnings. During fiscal year 2013, there was no significant impact to the results of operations as a result of ineffective cash flow hedges. | |||||||||||||
Net Income (Loss) Per Share | ' | ||||||||||||
Net Income (Loss) Per Share | |||||||||||||
Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. Stock options, employee stock purchases, restricted stock awards and restricted stock units that could potentially dilute basic earnings per share in the future were not included in the computation of diluted earnings per share because to do so would have been antidilutive for the periods presented. These anti-dilutive common stock equivalent shares totaled 5,267,000, 4,145,000 and 1,011,000 for the years ended December 31, 2013, 2012 and 2011, respectively. | |||||||||||||
The following summarizes the computation of basic and diluted income (loss) per share (in thousands, except for per share amounts): | |||||||||||||
Years ended December 31, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Basic: | |||||||||||||
Net income (loss) | $ | (17,965 | ) | $ | (20,043 | ) | $ | 2,627 | |||||
Basic weighted shares outstanding | 67,485 | 65,812 | 62,735 | ||||||||||
Net income (loss) per share | $ | (0.27 | ) | $ | (0.30 | ) | $ | 0.04 | |||||
Diluted: | |||||||||||||
Net income (loss) | $ | (17,965 | ) | $ | (20,043 | ) | $ | 2,627 | |||||
Basic weighted shares outstanding | 67,485 | 65,812 | 62,735 | ||||||||||
Effect of dilutive securities: | |||||||||||||
Stock options, ESPP, restricted stock units and restricted stock awards | — | — | 4,015 | ||||||||||
Diluted weighted shares outstanding | 67,485 | 65,812 | 66,750 | ||||||||||
Net income (loss) per share | $ | (0.27 | ) | $ | (0.30 | ) | $ | 0.04 | |||||
Income Taxes | ' | ||||||||||||
Income Taxes | |||||||||||||
The Company accounts for income taxes using an asset and liability approach, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s consolidated financial statements, but have not been reflected in the its taxable income. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. Therefore, the Company provides a valuation allowance to the extent that the Company does not believe it is more likely than not that it will generate sufficient taxable income in future periods to realize the benefit of its deferred tax assets. |
Organization_and_Summary_of_Si2
Organization and Summary of Significant Accounting Policies (Tables) | 12 Months Ended | ||||||||||||
Dec. 31, 2013 | |||||||||||||
Text Block [Abstract] | ' | ||||||||||||
Components of Inventories | ' | ||||||||||||
The components of inventories were as follows (in thousands): | |||||||||||||
December 31 | |||||||||||||
2013 | 2012 | ||||||||||||
Raw Materials | $ | 35,760 | $ | 26,041 | |||||||||
Work in Process | 36,580 | 30,113 | |||||||||||
Finished Goods | 31,526 | 13,960 | |||||||||||
$ | 103,866 | $ | 70,114 | ||||||||||
Schedule of Property and Equipment | ' | ||||||||||||
Property and equipment consisted of the following (in thousands): | |||||||||||||
December 31 | |||||||||||||
2013 | 2012 | ||||||||||||
Land | $ | 21 | $ | 21 | |||||||||
Building | 3,970 | 3,044 | |||||||||||
Scientific equipment | 42,845 | 35,248 | |||||||||||
Manufacturing equipment | 45,339 | 26,226 | |||||||||||
Office furniture, computers and equipment | 21,810 | 17,994 | |||||||||||
Leasehold improvements | 48,879 | 31,166 | |||||||||||
$ | 162,864 | $ | 113,699 | ||||||||||
Less accumulated depreciation and amortization | (77,978 | ) | (58,869 | ) | |||||||||
$ | 84,886 | $ | 54,830 | ||||||||||
Activities in Warranty Provision | ' | ||||||||||||
The activities in the warranty provision consisted of the following (in thousands): | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Balance at beginning of year | $ | 1,953 | $ | 1,981 | $ | 969 | |||||||
Costs incurred and charged against reserve | (783 | ) | (690 | ) | (571 | ) | |||||||
Accrual related to current year product sales | 2,156 | 662 | 1,583 | ||||||||||
Balance at end of year | $ | 3,326 | $ | 1,953 | $ | 1,981 | |||||||
Computation of Basic and Diluted Income (Loss) Per Share | ' | ||||||||||||
The following summarizes the computation of basic and diluted income (loss) per share (in thousands, except for per share amounts): | |||||||||||||
Years ended December 31, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Basic: | |||||||||||||
Net income (loss) | $ | (17,965 | ) | $ | (20,043 | ) | $ | 2,627 | |||||
Basic weighted shares outstanding | 67,485 | 65,812 | 62,735 | ||||||||||
Net income (loss) per share | $ | (0.27 | ) | $ | (0.30 | ) | $ | 0.04 | |||||
Diluted: | |||||||||||||
Net income (loss) | $ | (17,965 | ) | $ | (20,043 | ) | $ | 2,627 | |||||
Basic weighted shares outstanding | 67,485 | 65,812 | 62,735 | ||||||||||
Effect of dilutive securities: | |||||||||||||
Stock options, ESPP, restricted stock units and restricted stock awards | — | — | 4,015 | ||||||||||
Diluted weighted shares outstanding | 67,485 | 65,812 | 66,750 | ||||||||||
Net income (loss) per share | $ | (0.27 | ) | $ | (0.30 | ) | $ | 0.04 | |||||
Fair_Value_Tables
Fair Value (Tables) | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Fair Value Disclosures [Abstract] | ' | ||||||||||||||||
Assets and Liabilities Measured at Fair Value on Recurring Basis | ' | ||||||||||||||||
The following table summarizes the fair value hierarchy for the Company’s financial assets (cash, cash equivalents, short-term investments and long-term investments) and financial liabilities (foreign currency derivatives and contingent consideration) measured at fair value on a recurring basis as of December 31, 2013 and December 31, 2012 (in thousands): | |||||||||||||||||
Balance as of December 31, 2013: | |||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | ||||||||||||||
Assets: | |||||||||||||||||
Cash and cash equivalents | $ | 64,772 | $ | 1,300 | $ | — | $ | 66,072 | |||||||||
Short-term investments: | |||||||||||||||||
Corporate debt securities | — | 1,881 | — | 1,881 | |||||||||||||
Commercial paper | — | 5,448 | — | 5,448 | |||||||||||||
Government agency securities | — | 1,508 | — | 1,508 | |||||||||||||
Total short-term investments | — | 8,837 | — | 8,837 | |||||||||||||
Foreign currency derivatives | — | 873 | — | 873 | |||||||||||||
Investments: | |||||||||||||||||
United States government securities | — | 2,149 | — | 2,149 | |||||||||||||
Government agency securities | — | 3,405 | — | 3,405 | |||||||||||||
Corporate debt securities | — | 1,975 | — | 1,975 | |||||||||||||
Other | — | 2,291 | — | 2,291 | |||||||||||||
Total investments | — | 9,820 | — | 9,820 | |||||||||||||
Total | $ | 64,772 | $ | 20,830 | $ | — | $ | 85,602 | |||||||||
Liabilities: | |||||||||||||||||
Foreign currency derivatives | $ | — | $ | 1,555 | $ | — | $ | 1,555 | |||||||||
Contingent consideration | — | — | 310 | 310 | |||||||||||||
Total | $ | — | $ | 1,555 | $ | 310 | $ | 1,865 | |||||||||
Balance as of December 31, 2012: | |||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | ||||||||||||||
Assets: | |||||||||||||||||
Cash | $ | 84,906 | $ | — | $ | — | $ | 84,906 | |||||||||
Cash equivalents - money market funds | 10,873 | — | — | 10,873 | |||||||||||||
Foreign currency derivatives | — | 1,458 | — | 1,458 | |||||||||||||
Total | $ | 95,779 | $ | 1,458 | $ | — | $ | 97,237 | |||||||||
Liabilities: | |||||||||||||||||
Foreign currency derivatives | $ | — | $ | 1,572 | $ | — | $ | 1,572 | |||||||||
Contingent consideration | — | — | 550 | 550 | |||||||||||||
Total | $ | — | $ | 1,572 | $ | 550 | $ | 2,122 | |||||||||
Investments_Tables
Investments (Tables) | 12 Months Ended | ||||||||||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||||||||||
Investments Schedule [Abstract] | ' | ||||||||||||||||||||||||
Schedule of Available-for-Sale Marketable Securities | ' | ||||||||||||||||||||||||
The following tables summarize available-for-sale marketable securities at December 31, 2013 (in thousands): | |||||||||||||||||||||||||
Balance as of December 31, 2013: | |||||||||||||||||||||||||
Cost | Gross Unrealized | Gross Unrealized | Estimated Fair | ||||||||||||||||||||||
Gain | Loss | Value | |||||||||||||||||||||||
Short-term investments: | |||||||||||||||||||||||||
Commercial paper | $ | 6,747 | $ | 1 | $ | — | $ | 6,748 | |||||||||||||||||
Corporate debt securities | 1,881 | — | — | 1,881 | |||||||||||||||||||||
Government agency securities | 1,506 | 2 | — | 1,508 | |||||||||||||||||||||
Amounts classified as cash equivalents | (1,300 | ) | — | — | (1,300 | ) | |||||||||||||||||||
Total short-term investments | $ | 8,834 | $ | 3 | $ | — | $ | 8,837 | |||||||||||||||||
Investments: | |||||||||||||||||||||||||
United States government securities | $ | 2,145 | $ | 4 | $ | — | $ | 2,149 | |||||||||||||||||
Government agency securities | 3,405 | 1 | (1 | ) | 3,405 | ||||||||||||||||||||
Corporate debt securities | 1,970 | 5 | — | 1,975 | |||||||||||||||||||||
Other | 2,290 | 1 | — | 2,291 | |||||||||||||||||||||
Total investments | $ | 9,810 | $ | 11 | $ | (1 | ) | $ | 9,820 | ||||||||||||||||
Schedule of Gross Realized Gains and Losses of Marketable Securities | ' | ||||||||||||||||||||||||
Gross realized gains and losses from sales of marketable securities, all of which are reported as a component of “Foreign currency exchange gain (loss) and other, net” in the consolidated statements of operations, were for the years ended December 31, 2013 and 2012 (in thousands): | |||||||||||||||||||||||||
Years Ended December 31, | |||||||||||||||||||||||||
2013 | 2012 | ||||||||||||||||||||||||
Gross realized gains | $ | 2 | $ | — | |||||||||||||||||||||
Gross realized losses | — | — | |||||||||||||||||||||||
Realized gains, net | $ | 2 | $ | — | |||||||||||||||||||||
Schedule of Marketable Securities with Unrealized Losses | ' | ||||||||||||||||||||||||
The fair value of the Company’s marketable securities with unrealized losses at December 31, 2013 and December 31, 2012, and the duration of time that such losses had been unrealized (in thousands) were: | |||||||||||||||||||||||||
Balance at December 31, 2013: | |||||||||||||||||||||||||
Less Than 12 months | More than 12 months | Total | |||||||||||||||||||||||
Fair Value | Unrealized Loss | Fair Value | Unrealized Loss | Fair Value | Unrealized Loss | ||||||||||||||||||||
Corporate debt securities | $ | 1,180 | $ | — | $ | — | $ | — | $ | 1,180 | $ | — | |||||||||||||
Government agency securities | 1,104 | 1 | — | — | 1,104 | 1 | |||||||||||||||||||
Other | 800 | — | — | — | 800 | — | |||||||||||||||||||
Total | $ | 3,084 | $ | 1 | $ | — | $ | — | $ | 3,084 | $ | 1 | |||||||||||||
Balance at December 31, 2012: | |||||||||||||||||||||||||
Less Than 12 months | More than 12 months | Total | |||||||||||||||||||||||
Fair Value | Unrealized Loss | Fair Value | Unrealized Loss | Fair Value | Unrealized Loss | ||||||||||||||||||||
Corporate debt securities | $ | — | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||||||
Government agency securities | — | — | — | — | — | — | |||||||||||||||||||
Other | — | — | — | — | — | — | |||||||||||||||||||
Total | $ | — | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||||||
Schedule of Amortized Cost and Estimated Fair Value of Available-for-Sale Debt Securities by Contractual Maturity | ' | ||||||||||||||||||||||||
The following table summarizes the amortized cost and estimated fair value of available-for-sale debt securities at December 31, 2013 and December 31, 2012, by contractual maturity (in thousands): | |||||||||||||||||||||||||
December 31, 2013 | December 31, 2012 | ||||||||||||||||||||||||
Amortized Cost | Estimated Fair Value | Amortized Cost | Estimated Fair Value | ||||||||||||||||||||||
Debt securities: | |||||||||||||||||||||||||
Mature in one year or less | $ | 10,134 | $ | 10,137 | $ | — | $ | — | |||||||||||||||||
Mature after one year through three years | 9,810 | 9,820 | — | — | |||||||||||||||||||||
Mature in more than three years | — | — | — | — | |||||||||||||||||||||
Total debt securities | 19,944 | 19,957 | — | — | |||||||||||||||||||||
Securities with no contractual maturity | 55 | 55 | — | — | |||||||||||||||||||||
Total | $ | 19,999 | $ | 20,012 | $ | — | $ | — | |||||||||||||||||
Derivative_Financial_Instrumen1
Derivative Financial Instruments (Tables) | 12 Months Ended | ||||||||||||||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||||||||||||||
Derivative Instruments And Hedging Activities Disclosure [Abstract] | ' | ||||||||||||||||||||||||||||
Derivative Instruments at Gross Fair Value Reflected in Consolidated Balance Sheets | ' | ||||||||||||||||||||||||||||
The following tables show the Company’s derivative instruments at gross fair value as reflected in the Consolidated Balance Sheets as of December 31, 2013 and 2012 (in thousands): | |||||||||||||||||||||||||||||
December 31, 2013 | |||||||||||||||||||||||||||||
Fair Value of Derivatives | Fair Value of Derivatives | Total Fair Value | |||||||||||||||||||||||||||
Designated as Hedge | Not Designated as Hedge | ||||||||||||||||||||||||||||
Instruments | Instruments | ||||||||||||||||||||||||||||
Derivative Assets (a): | |||||||||||||||||||||||||||||
Foreign exchange contracts | $ | 782 | $ | 91 | $ | 873 | |||||||||||||||||||||||
Derivative Liabilities (b): | |||||||||||||||||||||||||||||
Foreign exchange contracts | (1,446 | ) | (109 | ) | (1,555 | ) | |||||||||||||||||||||||
December 31, 2012 | |||||||||||||||||||||||||||||
Fair Value of Derivatives | Fair Value of Derivatives | Total Fair Value | |||||||||||||||||||||||||||
Designated as Hedge | Not Designated as Hedge | ||||||||||||||||||||||||||||
Instruments | Instruments | ||||||||||||||||||||||||||||
Derivative Assets (a): | |||||||||||||||||||||||||||||
Foreign exchange contracts | $ | 1,457 | $ | 1 | $ | 1,458 | |||||||||||||||||||||||
Derivative Liabilities (b): | |||||||||||||||||||||||||||||
Foreign exchange contracts | (1,561 | ) | (11 | ) | (1,572 | ) | |||||||||||||||||||||||
a) | The fair value of derivative assets is measured using Level 2 fair value inputs and is recorded as other current assets in the Condensed Consolidated Balance Sheets. | ||||||||||||||||||||||||||||
b) | The fair value of derivative liabilities is measured using Level 2 fair value inputs and is recorded as accrued other liabilities in the Condensed Consolidated Balance Sheets. | ||||||||||||||||||||||||||||
Pre-tax Effect of Derivative Instruments Designated as Cash Flow Hedges in Condensed Consolidated Statements of Operations | ' | ||||||||||||||||||||||||||||
The following tables show the pre-tax effect of the Company’s derivative instruments designated as cash flow hedges in the Condensed Consolidated Statements of Operations for the years ended December 31, 2013 and 2012 (in thousands): | |||||||||||||||||||||||||||||
Years Ended | |||||||||||||||||||||||||||||
Gains/(Losses) Recognized in | Gains/(Losses) Reclassified | Gains/(Losses) Recognized - Ineffective Portion | |||||||||||||||||||||||||||
OCI - Effective Portion | from AOCI into Income - | and Amount Excluded from Effectiveness | |||||||||||||||||||||||||||
Effective Portion | Testing | ||||||||||||||||||||||||||||
December 31, | December 31, | December 31, | December 31, | Location | December 31, | December 31, | |||||||||||||||||||||||
2013 | 2012 | 2013 (a) | 2012 (b) | 2013 | 2012 | ||||||||||||||||||||||||
Cash flow hedges | |||||||||||||||||||||||||||||
Foreign exchange contracts | $ | (118 | ) | $ | (401 | ) | $ | 427 | $ | (285 | ) | Other income | $ | (10 | ) | $ | 38 | ||||||||||||
and expense | |||||||||||||||||||||||||||||
$ | (118 | ) | $ | (401 | ) | $ | 427 | $ | (285 | ) | $ | (10 | ) | $ | 38 | ||||||||||||||
a) | Includes gains (losses) reclassified from AOCI into net income for the effective portion of cash flow hedges, of which a gain of $1.3 million within cost of sales and operating expenses and a loss of $0.9 million within net sales, respectively, were recognized within the Condensed Consolidated Statement of Operations for the year ended December 31, 2013. | ||||||||||||||||||||||||||||
b) | Includes gains (losses) reclassified from AOCI into net income for the effective portion of cash flow hedges, of which a gain of $0.6 million within cost of sales and operating expenses and a loss of $0.9 million within net sales, respectively, were recognized within the Condensed Consolidated Statement of Operations for the year ended December 31, 2012. |
Intangible_Assets_Tables
Intangible Assets (Tables) | 12 Months Ended | ||||||||||||
Dec. 31, 2013 | |||||||||||||
Goodwill And Intangible Assets Disclosure [Abstract] | ' | ||||||||||||
Net Carrying Value and Accumulated Amortization of Major Classes of Intangible Assets | ' | ||||||||||||
The recorded value and accumulated amortization of major classes of intangible assets were as follows (in thousands): | |||||||||||||
Gross Carrying | Accumulated | Net Carrying | |||||||||||
Amount | Amortization | Amount | |||||||||||
Balance, December 31, 2013 | |||||||||||||
Licenses | $ | 28,577 | $ | (21,597 | ) | $ | 6,980 | ||||||
Technology acquired in acquisitions | 8,613 | (8,613 | ) | — | |||||||||
Customer relationships and other intangible assets acquired in acquisitions | 15,748 | (7,483 | ) | 8,265 | |||||||||
$ | 52,938 | $ | (37,693 | ) | $ | 15,245 | |||||||
Balance, December 31, 2012 | |||||||||||||
Licenses | $ | 27,452 | $ | (19,464 | ) | $ | 7,988 | ||||||
Technology acquired in acquisitions | 8,613 | (6,843 | ) | 1,770 | |||||||||
Customer relationships and other intangible assets acquired in acquisitions | 13,700 | (4,691 | ) | 9,009 | |||||||||
$ | 49,765 | $ | (30,998 | ) | $ | 18,767 | |||||||
Expected Future Annual Amortization Expense of Intangible Assets | ' | ||||||||||||
The expected future annual amortization expense of intangible assets recorded on the Company’s consolidated balance sheet as of December 31, 2013 is as follows, assuming no impairment charges (in thousands): | |||||||||||||
For the Years Ending December 31, | Amortization | ||||||||||||
Expense | |||||||||||||
2014 | $ | 3,638 | |||||||||||
2015 | 3,030 | ||||||||||||
2016 | 2,418 | ||||||||||||
2017 | 2,046 | ||||||||||||
2018 | 1,964 | ||||||||||||
Thereafter | 2,149 | ||||||||||||
Total expected future annual amortization | $ | 15,245 | |||||||||||
Income_Taxes_Tables
Income Taxes (Tables) | 12 Months Ended | ||||||||||||
Dec. 31, 2013 | |||||||||||||
Income Tax Disclosure [Abstract] | ' | ||||||||||||
Components of Income Before Income Taxes | ' | ||||||||||||
For financial reporting purposes, income before income taxes includes the following components (in thousands): | |||||||||||||
December 31 | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
United States | $ | (19,802 | ) | $ | (26,307 | ) | $ | 3,746 | |||||
Foreign | 2,985 | 4,979 | (1,074 | ) | |||||||||
Total | $ | (16,817 | ) | $ | (21,328 | ) | $ | 2,672 | |||||
Schedule of Expense (Benefit) for Income Taxes | ' | ||||||||||||
The expense (benefit) for income taxes is comprised of (in thousands): | |||||||||||||
Years Ended December 31, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Current | |||||||||||||
Federal | $ | (56 | ) | $ | — | $ | 3 | ||||||
State | (9 | ) | 150 | 189 | |||||||||
Foreign | 1,770 | 207 | 326 | ||||||||||
$ | 1,705 | $ | 357 | $ | 518 | ||||||||
Deferred | |||||||||||||
Federal | $ | — | $ | (312 | ) | $ | — | ||||||
State | — | — | — | ||||||||||
Foreign | (557 | ) | (1,330 | ) | (473 | ) | |||||||
$ | (557 | ) | $ | (1,642 | ) | $ | (473 | ) | |||||
Expense (benefit) | $ | 1,148 | $ | (1,285 | ) | $ | 45 | ||||||
Schedule of Reconciliation of Effective Tax Rate on Income from Continuing Operations and Statutory Tax Rate | ' | ||||||||||||
Reconciliation between the Company’s effective tax rate on income from continuing operations and the statutory tax rate is as follows: | |||||||||||||
Years Ended December 31, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
US Federal statutory income tax rate | 34 | % | 34 | % | 34 | % | |||||||
State taxes, net of federal benefit | 0.1 | % | -0.7 | % | 7.4 | % | |||||||
Foreign income taxed at other than U.S. rates | 4.4 | % | 2 | % | -27.5 | % | |||||||
Change in liabilities for uncertain positions | -5.6 | % | -1.9 | % | 0.1 | % | |||||||
Change in valuation allowance | -40 | % | -28.7 | % | -12.1 | % | |||||||
Other | 0.3 | % | 1.3 | % | -0.2 | % | |||||||
Effective tax rate | -6.8 | % | 6 | % | 1.7 | % | |||||||
Schedule of Deferred Tax Assets (Liabilities) | ' | ||||||||||||
Significant components of the Company’s deferred tax assets (liabilities) are as follows (in thousands): | |||||||||||||
December 31, | |||||||||||||
2013 | 2012 | ||||||||||||
Net operating loss carryforwards | $ | 36,314 | $ | 34,354 | |||||||||
Capitalized research and development costs | 64 | 68 | |||||||||||
Research and other credit carryforwards | 13,792 | 12,089 | |||||||||||
Stock option compensation | 15,341 | 13,191 | |||||||||||
Other | 24,955 | 18,516 | |||||||||||
Total deferred tax assets | 90,466 | 78,218 | |||||||||||
Valuation allowance for deferred tax assets | (90,466 | ) | (77,621 | ) | |||||||||
Total deferred tax liability | (927 | ) | (1,819 | ) | |||||||||
Net deferred tax liability | $ | (927 | ) | $ | (1,222 | ) | |||||||
Summary of Activity Related to Unrecognized Tax Benefits | ' | ||||||||||||
The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands): | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Balance at beginning of year | $ | 7,397 | $ | 6,979 | $ | 5,186 | |||||||
Increase related to current year tax positions | 1,844 | 829 | — | ||||||||||
Increase (decrease) for tax positions of prior years | — | (276 | ) | 1,793 | |||||||||
Decrease due to lapse of statute | — | (64 | ) | — | |||||||||
Decrease due to settlements | — | (71 | ) | — | |||||||||
Balance at end of year | $ | 9,241 | $ | 7,397 | $ | 6,979 | |||||||
Commitments_Contingencies_and_1
Commitments, Contingencies and Legal Matters (Tables) | 12 Months Ended | ||||||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||||||
Commitments And Contingencies Disclosure [Abstract] | ' | ||||||||||||||||||||
Summary of Lease, Purchase and Minimum Royalty Commitments | ' | ||||||||||||||||||||
The following table summarizes the Company’s lease, purchase and minimum royalty commitments at December 31, 2013 (in thousands): | |||||||||||||||||||||
Payments Due by Period | |||||||||||||||||||||
Total | Less Than 1 | 1-3 Years | 3-5 Years | More Than | |||||||||||||||||
Year | 5 Years | ||||||||||||||||||||
Operating leases | $ | 84,138 | $ | 10,450 | $ | 21,917 | $ | 21,728 | $ | 30,043 | |||||||||||
Purchase obligations | 42,494 | 37,118 | 3,660 | 1,716 | — | ||||||||||||||||
Minimum royalties | 2,583 | 543 | 1,134 | 646 | 260 | ||||||||||||||||
$ | 129,215 | $ | 48,111 | $ | 26,711 | $ | 24,090 | $ | 30,303 | ||||||||||||
Shareholders_Equity_Tables
Shareholders' Equity (Tables) | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ' | ||||||||||||||||
Summary of Stock Option Activity | ' | ||||||||||||||||
A summary of stock option activity under all plans is as follows (in thousands, except weighted average exercise price and weighted average remaining contractual term): | |||||||||||||||||
Shares | Weighted | Weighted | Instrinsic | ||||||||||||||
Average | Average | Value | |||||||||||||||
Exercise Price | Remaining | ||||||||||||||||
Contractual Term | |||||||||||||||||
(in years) | |||||||||||||||||
Outstanding December 31, 2010 | 9,514 | $ | 13.03 | ||||||||||||||
Granted | 1,501 | $ | 32.12 | ||||||||||||||
Exercised | (3,083 | ) | $ | 10.73 | |||||||||||||
Forfeited | (233 | ) | $ | 18.63 | |||||||||||||
Outstanding December 31, 2011 | 7,699 | $ | 17.54 | ||||||||||||||
Granted | 1,141 | $ | 36.68 | ||||||||||||||
Exercised | (1,920 | ) | $ | 12.93 | |||||||||||||
Forfeited | (110 | ) | $ | 32.23 | |||||||||||||
Outstanding December 31, 2012 | 6,810 | $ | 21.81 | ||||||||||||||
Granted | 1,553 | $ | 38.55 | ||||||||||||||
Exercised | (1,579 | ) | $ | 16.19 | |||||||||||||
Forfeited | (308 | ) | $ | 32.19 | |||||||||||||
Outstanding December 31, 2013 | 6,476 | $ | 26.7 | 3.83 | $ | 129,358 | |||||||||||
Exercisable, December 31, 2013 | 3,935 | $ | 20.45 | 2.62 | $ | 103,182 | |||||||||||
Vested and expected to vest December 31, 2013 | 6,241 | $ | 26.28 | 3.75 | $ | 127,241 | |||||||||||
Summary of Restricted Stock Plan Activity | ' | ||||||||||||||||
A summary of all award activity, which consists of RSAs and RSUs, is as follows (in thousands, except weighted average grant date fair value): | |||||||||||||||||
Shares | Weighted | ||||||||||||||||
Average | |||||||||||||||||
Grant Date | |||||||||||||||||
Fair Value | |||||||||||||||||
Outstanding, December 31, 2010 | 403 | $ | 17.92 | ||||||||||||||
Granted | 374 | $ | 32.3 | ||||||||||||||
Vested | (143 | ) | $ | 19.89 | |||||||||||||
Cancelled | (38 | ) | $ | 27.42 | |||||||||||||
Outstanding, December 31, 2011 | 596 | $ | 25.87 | ||||||||||||||
Granted | 271 | $ | 36.9 | ||||||||||||||
Vested | (209 | ) | $ | 27.62 | |||||||||||||
Cancelled | (16 | ) | $ | 34.29 | |||||||||||||
Outstanding, December 31, 2012 | 642 | $ | 29.74 | ||||||||||||||
Granted | 412 | $ | 38.23 | ||||||||||||||
Vested | (262 | ) | $ | 29.81 | |||||||||||||
Cancelled | (50 | ) | $ | 34.17 | |||||||||||||
Outstanding, December 31, 2013 | 742 | $ | 34.13 | ||||||||||||||
Common Stock Reserved for Future Issuance | ' | ||||||||||||||||
As of December 31, 2013, the Company has reserved shares of common stock for future issuance as follows (in thousands): | |||||||||||||||||
2006 Plan: | |||||||||||||||||
Options, RSUs and awards outstanding for all plans | 7,218 | ||||||||||||||||
Reserved for future grants | 2,091 | ||||||||||||||||
2012 ESPP | 1,914 | ||||||||||||||||
11,223 | |||||||||||||||||
Summary of Assumptions to Estimate Fair Value | ' | ||||||||||||||||
The fair value of the Company’s stock options granted to employees and shares purchased by employees under the 2000 ESPP and 2012 ESPP, as applicable, for the years ended December 31, 2013, 2012 and 2011 was estimated using the following assumptions: | |||||||||||||||||
Years Ended December 31, | |||||||||||||||||
2013 | 2012 | 2011 | |||||||||||||||
OPTION SHARES: | |||||||||||||||||
Expected Term (in years) | 4.41 | 4.38 | 4.58 | ||||||||||||||
Volatility | 0.44 | 0.53 | 0.54 | ||||||||||||||
Expected Dividends | 0 | % | 0 | % | 0 | % | |||||||||||
Risk Free Interest Rates | 0.9 | % | 0.8 | % | 1.64 | % | |||||||||||
Estimated Forfeitures | 7.61 | % | 7.63 | % | 7.74 | % | |||||||||||
Weighted Average Fair Value | $ | 14.17 | $ | 15.7 | $ | 14.76 | |||||||||||
ESPP SHARES: | |||||||||||||||||
Expected Term (in years) | 1.25 | 1.25 | 1.25 | ||||||||||||||
Volatility | 0.42 | 0.54 | 0.51 | ||||||||||||||
Expected Dividends | 0 | % | 0 | % | 0 | % | |||||||||||
Risk Free Interest Rates | 0.19 | % | 0.18 | % | 0.34 | % | |||||||||||
Weighted Average Fair Value | $ | 12.1 | $ | 13.13 | $ | 9.84 | |||||||||||
Summary of Stock-Based Compensation Expense | ' | ||||||||||||||||
The following table is a summary of the major categories of stock compensation expense recognized in accordance with ASC 718, “Compensation—Stock Compensation” (“ASC 718”) for the years ended December 31, 2013, 2012 and 2011 (in thousands). | |||||||||||||||||
Years Ended December 31, | |||||||||||||||||
2013 | 2012 | 2011 | |||||||||||||||
Cost of sales | $ | 2,930 | $ | 3,087 | $ | 1,679 | |||||||||||
Research and develompent | 8,540 | 7,563 | 6,551 | ||||||||||||||
Sales and marketing | 5,636 | 5,032 | 4,311 | ||||||||||||||
General and administrative | 10,529 | 8,814 | 7,227 | ||||||||||||||
Total stock-based compensation cost | $ | 27,635 | $ | 24,496 | $ | 19,768 | |||||||||||
Segment_and_Significant_Concen1
Segment and Significant Concentrations (Tables) | 12 Months Ended | ||||||||||||
Dec. 31, 2013 | |||||||||||||
Segment Reporting [Abstract] | ' | ||||||||||||
Summary of Total Sales | ' | ||||||||||||
The following table summarizes total sales (in thousands): | |||||||||||||
Years Ended December 31, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Sales: | |||||||||||||
System and other sales | $ | 76,763 | $ | 65,111 | $ | 73,999 | |||||||
Reagent and disposable sales | 324,529 | 266,101 | 203,576 | ||||||||||
Total sales | $ | 401,292 | $ | 331,212 | $ | 277,575 | |||||||
Sales Information by Segments | ' | ||||||||||||
The following table summarizes sales in the Clinical and Non-Clinical markets (in thousands): | |||||||||||||
Years Ended December 31, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Sales by market: | |||||||||||||
Clinical Systems | $ | 66,980 | $ | 52,805 | $ | 58,634 | |||||||
Clinical Reagents | 292,941 | 233,503 | 177,435 | ||||||||||
Total Clinical | $ | 359,921 | $ | 286,308 | $ | 236,069 | |||||||
Non-Clinical | 41,371 | 44,904 | 41,506 | ||||||||||
Total sales | $ | 401,292 | $ | 331,212 | $ | 277,575 | |||||||
Segment Sales by Geography Region | ' | ||||||||||||
The following table summarizes sales by geographic region (in thousands): | |||||||||||||
Years Ended December 31, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Geographic sales information: | |||||||||||||
North America | |||||||||||||
Clinical | $ | 212,362 | $ | 190,021 | $ | 167,966 | |||||||
Non-Clinical | 36,998 | 38,632 | 37,038 | ||||||||||
Total North America | 249,360 | 228,653 | 205,004 | ||||||||||
International | |||||||||||||
Clinical | $ | 147,559 | $ | 96,286 | $ | 68,103 | |||||||
Non-Clinical | 4,373 | 6,273 | 4,468 | ||||||||||
Total International | 151,932 | 102,559 | 72,571 | ||||||||||
Total sales | $ | 401,292 | $ | 331,212 | $ | 277,575 |
Quarterly_Financial_Informatio1
Quarterly Financial Information (Tables) | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Quarterly Financial Information Disclosure [Abstract] | ' | ||||||||||||||||
Summary of Quarterly Financial Information | ' | ||||||||||||||||
31-Mar | June 30 | 30-Sep | 31-Dec | ||||||||||||||
(Unaudited) | |||||||||||||||||
(In thousands, except per share data) | |||||||||||||||||
2013 | |||||||||||||||||
Total sales | $ | 91,938 | $ | 96,012 | $ | 100,081 | $ | 113,261 | |||||||||
Costs and operating expenses: | |||||||||||||||||
Cost of sales | 42,892 | 52,889 | 51,669 | $ | 60,483 | ||||||||||||
Collaboration profit sharing | 2,110 | 1,425 | 1,410 | 2,567 | |||||||||||||
Research and development | 17,727 | 18,572 | 18,558 | 25,340 | |||||||||||||
Sales and marketing | 19,126 | 19,105 | 19,788 | 21,922 | |||||||||||||
General and administrative | 9,763 | 9,612 | 9,490 | 12,854 | |||||||||||||
Total cost and operating expenses | 91,618 | 101,603 | 100,915 | 123,166 | |||||||||||||
Income (loss) from operations | 320 | (5,591 | ) | (834 | ) | (9,905 | ) | ||||||||||
Other income (expense), net | 374 | (717 | ) | (200 | ) | (264 | ) | ||||||||||
Income (loss) before income tax expense | 694 | (6,308 | ) | (1,034 | ) | (10,169 | ) | ||||||||||
Provision for income tax expense | (381 | ) | (272 | ) | (347 | ) | (148 | ) | |||||||||
Net income (loss) | $ | 313 | $ | (6,580 | ) | $ | (1,381 | ) | $ | (10,317 | ) | ||||||
Basic net income (loss) per share | 0 | (0.10 | ) | (0.02 | ) | (0.15 | ) | ||||||||||
Diluted net income (loss) per share | $ | 0 | $ | (0.10 | ) | $ | (0.02 | ) | $ | (0.15 | ) | ||||||
Weighted average shares used in computing basic net income (loss) per share | 66,824 | 67,295 | 67,573 | 68,230 | |||||||||||||
Weighted average shares used in computing diluted net income (loss) per share | 69,406 | 67,295 | 67,573 | 68,230 | |||||||||||||
Gross profit on sales: | |||||||||||||||||
Sales | $ | 91,938 | $ | 96,012 | $ | 100,081 | $ | 113,261 | |||||||||
Cost of sales | (42,892 | ) | (52,889 | ) | (51,669 | ) | (60,483 | ) | |||||||||
$ | 49,046 | $ | 43,123 | $ | 48,412 | $ | 52,778 | ||||||||||
Quarters Ended | |||||||||||||||||
31-Mar | June 30 | 30-Sep | 31-Dec | ||||||||||||||
(Unaudited) | |||||||||||||||||
(In thousands, except per share data) | |||||||||||||||||
2012 | |||||||||||||||||
Total sales | $ | 77,292 | $ | 81,015 | $ | 80,472 | $ | 92,433 | |||||||||
Costs and operating expenses: | |||||||||||||||||
Cost of sales | 35,608 | 35,072 | 39,789 | 42,896 | |||||||||||||
Collaboration profit sharing | 1,684 | 1,645 | 2,438 | 1,416 | |||||||||||||
Research and development | 22,102 | 16,118 | 16,154 | 17,299 | |||||||||||||
Sales and marketing | 14,512 | 15,108 | 15,993 | 16,294 | |||||||||||||
General and administrative | 11,051 | 11,011 | 11,766 | 9,470 | |||||||||||||
Litigation settlement | — | — | 15,110 | — | |||||||||||||
Total cost and operating expenses | 84,957 | 78,954 | 101,250 | 87,375 | |||||||||||||
Income (loss) from operations | (7,665 | ) | 2,061 | (20,778 | ) | 5,058 | |||||||||||
Other income (expense), net | 238 | (572 | ) | 89 | 241 | ||||||||||||
Income (loss) before income tax expense | (7,427 | ) | 1,489 | (20,689 | ) | 5,299 | |||||||||||
Benefit from (provision for) income taxes | 1,901 | (354 | ) | (607 | ) | 345 | |||||||||||
Net income (loss) | $ | (5,526 | ) | $ | 1,135 | $ | (21,296 | ) | $ | 5,644 | |||||||
Basic net income (loss) per share | $ | (0.08 | ) | $ | 0.02 | $ | (0.32 | ) | $ | 0.09 | |||||||
Diluted net income (loss) per share | $ | (0.08 | ) | $ | 0.02 | $ | (0.32 | ) | $ | 0.08 | |||||||
Weighted average shares used in computing basic net income (loss) per share | 65,027 | 65,695 | 66,145 | 66,370 | |||||||||||||
Weighted average shares used in computing diluted net income (loss) per share | 65,207 | 68,869 | 66,145 | 68,787 | |||||||||||||
Gross profit on sales: | |||||||||||||||||
Sales | $ | 77,292 | $ | 81,015 | $ | 80,472 | $ | 92,433 | |||||||||
Cost of sales | (35,608 | ) | (35,072 | ) | (39,789 | ) | (42,896 | ) | |||||||||
$ | 41,684 | $ | 45,943 | $ | 40,683 | $ | 49,537 |
Organization_and_Summary_of_Si3
Organization and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $) | 12 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | |
MTB/RIF Buy Down Program for the HBDC Market [Member] | MTB/RIF Buy Down Program for the HBDC Market [Member] | Cost of sales [Member] | Cost of sales [Member] | Cost of sales [Member] | The Bill and Melinda Gates Foundation [Member] | United States Agency for International Development [Member] | UNITAID [Member] | Manufacturing capital assets [Member] | Minimum [Member] | Maximum [Member] | ||||
MTB/RIF Buy Down Program for the HBDC Market [Member] | MTB/RIF Buy Down Program for the HBDC Market [Member] | MTB/RIF Buy Down Program for the HBDC Market [Member] | ||||||||||||
Organization And Summary Of Significant Accounting Policies [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Short-term marketable debt securities | 'Maturities of 12 months or less | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long-term marketable debt securities | 'Maturities greater than 12 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of cash and cash equivalents held by the Company's | 55.00% | 71.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Maximum percentage of accounts receivable by any one customer | 14.00% | 7.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of one direct customer to total sales | 10.00% | 10.00% | 10.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation cost | $2,100,000 | $1,100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Estimated useful lives of assets | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '3 years | '7 years |
Impairment charges of tangible assets | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,300,000 | ' | ' |
Depreciation and amortization of property and equipment | 17,769,000 | 13,446,000 | 10,298,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Estimated useful lives of intangible assets | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '3 years | '15 years |
Impairment charge | ' | ' | ' | ' | ' | 1,300,000 | 1,400,000 | ' | ' | ' | ' | ' | ' | ' |
Amortization of remaining up-front license fee | ' | ' | ' | ' | ' | ' | ' | 5,400,000 | ' | ' | ' | ' | ' | ' |
Product warranty, defects free period (in months) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '12 months | '24 months |
Reduced price of Company's Multi-Drug Resistant Tuberculosis test | ' | ' | ' | 9.98 | 9.98 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
One-time payment received | ' | ' | ' | 3,200,000 | ' | ' | ' | ' | 3,500,000 | 3,500,000 | 3,200,000 | ' | ' | ' |
Milestone revenue | 3,200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Agreement period on straight line basis | '10 years | ' | ' | '10 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Milestone revenue related to agreements | $2,700,000 | $4,800,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Requisite service period (years) | '4 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Foreign exchange contracts maturity period | '12 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total anti-dilutive common stock equivalent shares | 5,267,000 | 4,145,000 | 1,011,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Organization_and_Summary_of_Si4
Organization and Summary of Significant Accounting Policies - Components of Inventories (Detail) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Inventory Disclosure [Abstract] | ' | ' |
Raw Materials | $35,760 | $26,041 |
Work in Process | 36,580 | 30,113 |
Finished Goods | 31,526 | 13,960 |
Inventory | $103,866 | $70,114 |
Organization_and_Summary_of_Si5
Organization and Summary of Significant Accounting Policies - Schedule of Property and Equipment (Detail) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Statement Of Financial Position [Abstract] | ' | ' |
Land | $21 | $21 |
Building | 3,970 | 3,044 |
Scientific equipment | 42,845 | 35,248 |
Manufacturing equipment | 45,339 | 26,226 |
Office furniture, computers and equipment | 21,810 | 17,994 |
Leasehold improvements | 48,879 | 31,166 |
Property and equipment, gross | 162,864 | 113,699 |
Less accumulated depreciation and amortization | -77,978 | -58,869 |
Property and equipment, net | $84,886 | $54,830 |
Organization_and_Summary_of_Si6
Organization and Summary of Significant Accounting Policies - Activities in Warranty Provision (Detail) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Commitments And Contingencies Disclosure [Abstract] | ' | ' | ' |
Balance at beginning of year | $1,953 | $1,981 | $969 |
Costs incurred and charged against reserve | -783 | -690 | -571 |
Accrual related to current year product sales | 2,156 | 662 | 1,583 |
Balance at end of year | $3,326 | $1,953 | $1,981 |
Organization_and_Summary_of_Si7
Organization and Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Share (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Basic | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net income (loss) | ($10,317) | ($1,381) | ($6,580) | $313 | $5,644 | ($21,296) | $1,135 | ($5,526) | ($17,965) | ($20,043) | $2,627 |
Basic weighted shares outstanding | 68,230 | 67,573 | 67,295 | 66,824 | 66,370 | 66,145 | 65,695 | 65,027 | 67,485 | 65,812 | 62,735 |
Net income (loss) per share | ($0.15) | ($0.02) | ($0.10) | $0 | $0.09 | ($0.32) | $0.02 | ($0.08) | ($0.27) | ($0.30) | $0.04 |
Diluted | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net income (loss) | ($10,317) | ($1,381) | ($6,580) | $313 | $5,644 | ($21,296) | $1,135 | ($5,526) | ($17,965) | ($20,043) | $2,627 |
Basic weighted shares outstanding | 68,230 | 67,573 | 67,295 | 66,824 | 66,370 | 66,145 | 65,695 | 65,027 | 67,485 | 65,812 | 62,735 |
Effect of dilutive securities: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options, ESPP, restricted stock units and restricted stock awards | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,015 |
Diluted weighted shares outstanding | 68,230 | 67,573 | 67,295 | 69,406 | 68,787 | 66,145 | 68,869 | 65,207 | 67,485 | 65,812 | 66,750 |
Net income (loss) per share | ($0.15) | ($0.02) | ($0.10) | $0 | $0.08 | ($0.32) | $0.02 | ($0.08) | ($0.27) | ($0.30) | $0.04 |
Fair_Value_Assets_and_Liabilit
Fair Value - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total short-term investments | $8,837 | ' |
Foreign currency derivatives | 873 | 1,458 |
Assets, Total | 85,602 | 97,237 |
Foreign currency derivatives | 1,555 | 1,572 |
Contingent consideration | 310 | 550 |
Liabilities, Total | 1,865 | 2,122 |
Total investments | 9,820 | ' |
Amounts classified as cash equivalents [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Cash and cash equivalents | 66,072 | ' |
Corporate debt securities [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total short-term investments | 1,881 | ' |
Total investments | 1,975 | ' |
Commercial paper [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total short-term investments | 5,448 | ' |
Government agency securities [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total short-term investments | 1,508 | ' |
Total investments | 3,405 | ' |
United States government securities [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total investments | 2,149 | ' |
Other [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total investments | 2,291 | ' |
Cash [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Cash and cash equivalents | ' | 84,906 |
Cash equivalents - money market funds [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Cash and cash equivalents | ' | 10,873 |
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total short-term investments | ' | ' |
Foreign currency derivatives | ' | ' |
Assets, Total | 64,772 | 95,779 |
Foreign currency derivatives | ' | ' |
Contingent consideration | ' | ' |
Liabilities, Total | ' | ' |
Total investments | ' | ' |
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total short-term investments | 8,837 | ' |
Foreign currency derivatives | 873 | 1,458 |
Assets, Total | 20,830 | 1,458 |
Foreign currency derivatives | 1,555 | 1,572 |
Contingent consideration | ' | ' |
Liabilities, Total | 1,555 | 1,572 |
Total investments | 9,820 | ' |
Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total short-term investments | ' | ' |
Foreign currency derivatives | ' | ' |
Assets, Total | ' | ' |
Foreign currency derivatives | ' | ' |
Contingent consideration | 310 | 550 |
Liabilities, Total | 310 | 550 |
Total investments | ' | ' |
Fair Value, Measurements, Recurring [Member] | Amounts classified as cash equivalents [Member] | Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Cash and cash equivalents | 64,772 | ' |
Fair Value, Measurements, Recurring [Member] | Amounts classified as cash equivalents [Member] | Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Cash and cash equivalents | 1,300 | ' |
Fair Value, Measurements, Recurring [Member] | Amounts classified as cash equivalents [Member] | Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Cash and cash equivalents | ' | ' |
Fair Value, Measurements, Recurring [Member] | Corporate debt securities [Member] | Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total short-term investments | ' | ' |
Total investments | ' | ' |
Fair Value, Measurements, Recurring [Member] | Corporate debt securities [Member] | Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total short-term investments | 1,881 | ' |
Total investments | 1,975 | ' |
Fair Value, Measurements, Recurring [Member] | Corporate debt securities [Member] | Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total short-term investments | ' | ' |
Total investments | ' | ' |
Fair Value, Measurements, Recurring [Member] | Commercial paper [Member] | Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total short-term investments | ' | ' |
Fair Value, Measurements, Recurring [Member] | Commercial paper [Member] | Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total short-term investments | 5,448 | ' |
Fair Value, Measurements, Recurring [Member] | Commercial paper [Member] | Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total short-term investments | ' | ' |
Fair Value, Measurements, Recurring [Member] | Government agency securities [Member] | Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total short-term investments | ' | ' |
Total investments | ' | ' |
Fair Value, Measurements, Recurring [Member] | Government agency securities [Member] | Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total short-term investments | 1,508 | ' |
Total investments | 3,405 | ' |
Fair Value, Measurements, Recurring [Member] | Government agency securities [Member] | Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total short-term investments | ' | ' |
Total investments | ' | ' |
Fair Value, Measurements, Recurring [Member] | United States government securities [Member] | Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total investments | ' | ' |
Fair Value, Measurements, Recurring [Member] | United States government securities [Member] | Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total investments | 2,149 | ' |
Fair Value, Measurements, Recurring [Member] | United States government securities [Member] | Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total investments | ' | ' |
Fair Value, Measurements, Recurring [Member] | Other [Member] | Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total investments | ' | ' |
Fair Value, Measurements, Recurring [Member] | Other [Member] | Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total investments | 2,291 | ' |
Fair Value, Measurements, Recurring [Member] | Other [Member] | Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Total investments | ' | ' |
Fair Value, Measurements, Recurring [Member] | Cash [Member] | Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Cash and cash equivalents | ' | 84,906 |
Fair Value, Measurements, Recurring [Member] | Cash [Member] | Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Cash and cash equivalents | ' | ' |
Fair Value, Measurements, Recurring [Member] | Cash [Member] | Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Cash and cash equivalents | ' | ' |
Fair Value, Measurements, Recurring [Member] | Cash equivalents - money market funds [Member] | Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Cash and cash equivalents | ' | 10,873 |
Fair Value, Measurements, Recurring [Member] | Cash equivalents - money market funds [Member] | Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Cash and cash equivalents | ' | ' |
Fair Value, Measurements, Recurring [Member] | Cash equivalents - money market funds [Member] | Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Cash and cash equivalents | ' | ' |
Investments_Additional_Informa
Investments - Additional Information (Detail) (USD $) | 12 Months Ended | |
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 |
Investments Debt And Equity Securities [Abstract] | ' | ' |
Available for sale of marketable securities | ' | $0 |
Proceeds from sales of marketable securities | $2.50 | $0 |
Investments_Schedule_of_Availa
Investments - Schedule of Available-for-Sale Marketable Securities (Detail) (USD $) | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | Short-term investments [Member] | Short-term investments [Member] | Short-term investments [Member] | Short-term investments [Member] | Short-term investments [Member] | Investments [Member] | Investments [Member] | Investments [Member] | Investments [Member] | Investments [Member] | |
Commercial paper [Member] | Corporate debt securities [Member] | Government agency securities [Member] | Amounts classified as cash equivalents [Member] | Corporate debt securities [Member] | Government agency securities [Member] | United States government securities [Member] | Other [Member] | ||||
Schedule of Available-for-sale Securities [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Available-for-sale marketable securities, Cost | ' | $8,834 | $6,747 | $1,881 | $1,506 | ($1,300) | $9,810 | $1,970 | $3,405 | $2,145 | $2,290 |
Available-for-sale marketable securities, Gross Unrealized Gain | ' | 3 | 1 | ' | 2 | ' | 11 | 5 | 1 | 4 | 1 |
Available-for-sale marketable securities, Gross Unrealized Loss | ' | ' | ' | ' | ' | ' | -1 | ' | -1 | ' | ' |
Available-for-sale marketable securities, Estimated Fair Value | $0 | $8,837 | $6,748 | $1,881 | $1,508 | ($1,300) | $9,820 | $1,975 | $3,405 | $2,149 | $2,291 |
Investments_Schedule_of_Gross_
Investments - Schedule of Gross Realized Gains and Losses of Marketable Securities (Detail) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 |
Investments Debt And Equity Securities [Abstract] | ' | ' |
Gross realized gains | $2 | ' |
Gross realized losses | ' | ' |
Realized gains, net | $2 | ' |
Investments_Schedule_of_Market
Investments - Schedule of Marketable Securities with Unrealized Losses (Detail) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Schedule of Available-for-sale Securities [Line Items] | ' | ' |
Less than 12 months, Fair Value | $3,084 | ' |
Less Than 12 months, Unrealized Loss | 1 | ' |
More than 12 months, Fair Value | ' | ' |
More than 12 months, Unrealized Loss | ' | ' |
Total, Fair Value | 3,084 | ' |
Total, Unrealized Loss | 1 | ' |
Corporate debt securities [Member] | ' | ' |
Schedule of Available-for-sale Securities [Line Items] | ' | ' |
Less than 12 months, Fair Value | 1,180 | ' |
Less Than 12 months, Unrealized Loss | ' | ' |
More than 12 months, Fair Value | ' | ' |
More than 12 months, Unrealized Loss | ' | ' |
Total, Fair Value | 1,180 | ' |
Total, Unrealized Loss | ' | ' |
Government agency securities [Member] | ' | ' |
Schedule of Available-for-sale Securities [Line Items] | ' | ' |
Less than 12 months, Fair Value | 1,104 | ' |
Less Than 12 months, Unrealized Loss | 1 | ' |
More than 12 months, Fair Value | ' | ' |
More than 12 months, Unrealized Loss | ' | ' |
Total, Fair Value | 1,104 | ' |
Total, Unrealized Loss | 1 | ' |
Other [Member] | ' | ' |
Schedule of Available-for-sale Securities [Line Items] | ' | ' |
Less than 12 months, Fair Value | 800 | ' |
Less Than 12 months, Unrealized Loss | ' | ' |
More than 12 months, Fair Value | ' | ' |
More than 12 months, Unrealized Loss | ' | ' |
Total, Fair Value | 800 | ' |
Total, Unrealized Loss | ' | ' |
Investments_Schedule_of_Amorti
Investments - Schedule of Amortized Cost and Estimated Fair Value of Available-for-Sale Debt Securities by Contractual Maturity (Detail) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Investments Debt And Equity Securities [Abstract] | ' | ' |
Mature in one year or less, Amortized Cost | $10,134 | ' |
Mature after one year through three years, Amortized Cost | 9,810 | ' |
Mature in more than three years, Amortized Cost | ' | ' |
Total debt securities, Amortized Cost | 19,944 | ' |
Securities with no contractual maturity, Amortized Cost | 55 | ' |
Total, Amortized Cost | 19,999 | ' |
Mature in one year or less, Estimated Fair Value | 10,137 | ' |
Mature after one year through three years, Estimated Fair Value | 9,820 | ' |
Mature in more than three years, Estimated Fair Value | ' | ' |
Total debt securities, Estimated Fair Value | 19,957 | ' |
Securities with no contractual maturity, Estimated Fair Value | 55 | ' |
Total, Estimated Fair Value | $20,012 | ' |
Derivative_Financial_Instrumen2
Derivative Financial Instruments - Additional Information (Detail) (USD $) | 12 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Derivatives, Fair Value [Line Items] | ' | ' | ' |
Net deferred loss associated with cash flow hedges | $0.60 | $0.10 | ' |
Gain recognized for foreign currency forward contracts | 0.1 | 0.4 | 0.3 |
Cash flow hedges [Member] | Fair Value of Derivatives Designated as Hedge Instruments [Member] | ' | ' | ' |
Derivatives, Fair Value [Line Items] | ' | ' | ' |
Notional principle amounts of Company's derivative instruments | 96.6 | 79.3 | ' |
Cash flow hedges [Member] | Fair Value of Derivatives Not Designated as Hedge Instruments [Member] | ' | ' | ' |
Derivatives, Fair Value [Line Items] | ' | ' | ' |
Notional principle amounts of Company's derivative instruments | $24.20 | $9.20 | ' |
Derivative_Financial_Instrumen3
Derivative Financial Instruments - Derivative Instruments at Gross Fair Value Reflected in Consolidated Balance Sheets (Detail) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Derivatives, Fair Value [Line Items] | ' | ' |
Foreign exchange contracts, Assets | $873 | $1,458 |
Foreign exchange contracts, Liabilities | -1,555 | -1,572 |
Fair Value of Derivatives Designated as Hedge Instruments [Member] | ' | ' |
Derivatives, Fair Value [Line Items] | ' | ' |
Foreign exchange contracts, Assets | 782 | 1,457 |
Foreign exchange contracts, Liabilities | -1,446 | -1,561 |
Fair Value of Derivatives Not Designated as Hedge Instruments [Member] | ' | ' |
Derivatives, Fair Value [Line Items] | ' | ' |
Foreign exchange contracts, Assets | 91 | 1 |
Foreign exchange contracts, Liabilities | ($109) | ($11) |
Derivative_Financial_Instrumen4
Derivative Financial Instruments - Pre-tax Effect of Derivative Instruments Designated as Cash Flow Hedges in Condensed Consolidated Statements of Operations (Detail) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 |
Derivative Instruments, Gain (Loss) [Line Items] | ' | ' |
Gain/(loss) Recognized in OCI-Effective Portion | ($118) | ($401) |
Gain/(Loss) Reclassified from AOCI into Income-Effective Portion | 427 | -285 |
Gain/(Loss) Recognized-Ineffective Portion and Amount Excluded from Effectiveness Testing | -10 | 38 |
Foreign exchange contracts [Member] | Cash flow hedges [Member] | ' | ' |
Derivative Instruments, Gain (Loss) [Line Items] | ' | ' |
Gain/(loss) Recognized in OCI-Effective Portion | -118 | -401 |
Gain/(Loss) Reclassified from AOCI into Income-Effective Portion | 427 | -285 |
Foreign exchange contracts [Member] | Cash flow hedges [Member] | Other income and expense [Member] | ' | ' |
Derivative Instruments, Gain (Loss) [Line Items] | ' | ' |
Gain/(Loss) Recognized-Ineffective Portion and Amount Excluded from Effectiveness Testing | ($10) | $38 |
Derivative_Financial_Instrumen5
Derivative Financial Instruments - Pre-tax Effect of Derivative Instruments Designated as Cash Flow Hedges in Condensed Consolidated Statements of Operations (Parenthetical) (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Derivative Instruments, Gain (Loss) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net sales | $113,261 | $100,081 | $96,012 | $91,938 | $92,433 | $80,472 | $81,015 | $77,292 | $401,292 | $331,212 | $277,575 |
Cost of sales | 60,483 | 51,669 | 52,889 | 42,892 | 42,896 | 39,789 | 35,072 | 35,608 | 207,933 | 153,365 | 122,840 |
Reclassified from AOCI [Member] | Foreign exchange contracts [Member] | Cash flow hedges [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Derivative Instruments, Gain (Loss) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net sales | ' | ' | ' | ' | ' | ' | ' | ' | 1,300 | 600 | ' |
Cost of sales | ' | ' | ' | ' | ' | ' | ' | ' | $900 | $900 | ' |
Intangible_Assets_Additional_I
Intangible Assets - Additional Information (Detail) (USD $) | 12 Months Ended | 0 Months Ended | 12 Months Ended | ||||||||||||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Sep. 30, 2012 | Feb. 08, 2012 | Dec. 20, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | |
Minimum [Member] | Maximum [Member] | Italy and Australia distributors [Member] | Abaxis [Member] | South Africa [Member] | California [Member] | Italy [Member] | Australia [Member] | Customer relationships [Member] | Customer relationships [Member] | Other intangibles [Member] | Other intangibles [Member] | ||||
Italy and Australia distributors [Member] | Italy and Australia distributors [Member] | ||||||||||||||
Goodwill And Intangible Assets Net [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Estimated useful lives of intangible assets | ' | ' | ' | '3 years | '15 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of ownership interest acquired | ' | ' | ' | ' | ' | ' | ' | 100.00% | 100.00% | 100.00% | 100.00% | ' | ' | ' | ' |
Acquisition date | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1-Apr-13 | 31-Aug-13 | ' | ' | ' | ' |
Total purchase price of transactions | ' | $30,700,000 | ' | ' | ' | $4,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net of cash paid | ' | 24,000,000 | ' | ' | ' | 3,700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Acquired intangible assets | ' | 9,200,000 | ' | ' | ' | 2,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Property and equipment, inventory and other assets, net of liabilities | ' | 4,000,000 | ' | ' | ' | 200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Goodwill | 39,681,000 | 37,694,000 | ' | ' | ' | 1,500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Weighted-average useful life | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '7 years | '5 years 6 months | '15 years | '1 month 6 days |
Cash to be paid | ' | 1,300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Purchase price paid in common stock | ' | 4,600,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Intangible assets | ' | ' | ' | ' | ' | ' | 2,100,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Impairment of acquired intangible assets | 1,300,000 | 1,400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amortization expense of intangible assets | $5,418,000 | $4,965,000 | $6,523,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Intangible_Assets_Net_Carrying
Intangible Assets - Net Carrying Value and Accumulated Amortization of Major Classes of Intangible Assets (Detail) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Gross Carrying Amount | $52,938 | $49,765 |
Accumulated Amortization | -37,693 | -30,998 |
Net Carrying Amount | 15,245 | 18,767 |
Licenses [Member] | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Gross Carrying Amount | 28,577 | 27,452 |
Accumulated Amortization | -21,597 | -19,464 |
Net Carrying Amount | 6,980 | 7,988 |
Technology acquired in acquisitions [Member] | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Gross Carrying Amount | 8,613 | 8,613 |
Accumulated Amortization | -8,613 | -6,843 |
Net Carrying Amount | ' | 1,770 |
Customer relationships and other intangible assets acquired in acquisitions [Member] | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Gross Carrying Amount | 15,748 | 13,700 |
Accumulated Amortization | -7,483 | -4,691 |
Net Carrying Amount | $8,265 | $9,009 |
Intangible_Assets_Expected_Fut
Intangible Assets - Expected Future Annual Amortization Expense of Intangible Assets (Detail) (USD $) | Dec. 31, 2013 |
In Thousands, unless otherwise specified | |
Goodwill And Intangible Assets Disclosure [Abstract] | ' |
2014 | $3,638 |
2015 | 3,030 |
2016 | 2,418 |
2017 | 2,046 |
2018 | 1,964 |
Thereafter | 2,149 |
Total expected future annual amortization | $15,245 |
Income_Taxes_Components_of_Inc
Income Taxes - Components of Income Before Income Taxes (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Income Tax Disclosure [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
United States | ' | ' | ' | ' | ' | ' | ' | ' | ($19,802) | ($26,307) | $3,746 |
Foreign | ' | ' | ' | ' | ' | ' | ' | ' | 2,985 | 4,979 | -1,074 |
Income (loss) before income taxes | ($10,169) | ($1,034) | ($6,308) | $694 | $5,299 | ($20,689) | $1,489 | ($7,427) | ($16,817) | ($21,328) | $2,672 |
Income_Taxes_Schedule_of_Expen
Income Taxes - Schedule of Expense (Benefit) for Income Taxes (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Current | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Federal | ' | ' | ' | ' | ' | ' | ' | ' | ($56) | ' | $3 |
State | ' | ' | ' | ' | ' | ' | ' | ' | -9 | 150 | 189 |
Foreign | ' | ' | ' | ' | ' | ' | ' | ' | 1,770 | 207 | 326 |
Current, Total | ' | ' | ' | ' | ' | ' | ' | ' | 1,705 | 357 | 518 |
Deferred | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Federal | ' | ' | ' | ' | ' | ' | ' | ' | ' | -312 | ' |
State | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Foreign | ' | ' | ' | ' | ' | ' | ' | ' | -557 | -1,330 | -473 |
Deferred, Total | ' | ' | ' | ' | ' | ' | ' | ' | -557 | -1,642 | -473 |
Expense (benefit) | $148 | $347 | $272 | $381 | ($345) | $607 | $354 | ($1,901) | $1,148 | ($1,285) | $45 |
Income_Taxes_Schedule_of_Recon
Income Taxes - Schedule of Reconciliation of Effective Tax Rate on Income from Continuing Operations and Statutory Tax Rate (Detail) | 12 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Income Tax Disclosure [Abstract] | ' | ' | ' |
US Federal statutory income tax rate | 34.00% | 34.00% | 34.00% |
State taxes, net of federal benefit | 0.10% | -0.70% | 7.40% |
Foreign income taxed at other than U.S. rates | 4.40% | 2.00% | -27.50% |
Change in liabilities for uncertain positions | -5.60% | -1.90% | 0.10% |
Change in valuation allowance | -40.00% | -28.70% | -12.10% |
Other | 0.30% | 1.30% | -0.20% |
Effective tax rate | -6.80% | 6.00% | 1.70% |
Income_Taxes_Schedule_of_Defer
Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Income Tax Disclosure [Abstract] | ' | ' |
Net operating loss carryforwards | $36,314 | $34,354 |
Capitalized research and development costs | 64 | 68 |
Research and other credit carryforwards | 13,792 | 12,089 |
Stock option compensation | 15,341 | 13,191 |
Other | 24,955 | 18,516 |
Total deferred tax assets | 90,466 | 78,218 |
Valuation allowance for deferred tax assets | -90,466 | -77,621 |
Total deferred tax liability | -927 | -1,819 |
Net deferred tax liability | ($927) | ($1,222) |
Income_Taxes_Additional_Inform
Income Taxes - Additional Information (Detail) (USD $) | 12 Months Ended | |||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | |
Operating Loss Carryforwards [Line Items] | ' | ' | ' | ' |
Increase (decrease) in valuation allowance | $12,800,000 | $8,400,000 | ($7,700,000) | ' |
Undistributed earnings of foreign subsidiaries | 5,200,000 | 2,900,000 | ' | ' |
Provision for income taxes, federal | 0 | ' | ' | ' |
Provision for income taxes, state | 0 | ' | ' | ' |
Unrecognized tax benefits | 9,241,000 | 7,397,000 | 6,979,000 | 5,186,000 |
Uncertain tax positions, Interest and penalties | 0 | 0 | 0 | ' |
Accrued interest or penalties | 0 | 0 | 0 | ' |
Federal [Member] | ' | ' | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' | ' |
Net operating loss carryforwards | 258,400,000 | ' | ' | ' |
State net [Member] | ' | ' | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' | ' |
Net operating loss carryforwards | 298,600,000 | ' | ' | ' |
State research and development tax credits | 12,600,000 | ' | ' | ' |
Federal and state [Member] | ' | ' | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' | ' |
Net operating loss carryforwards expiration date | '2014 through 2033 | ' | ' | ' |
Research and development [Member] | ' | ' | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' | ' |
Tax credits | 10,700,000 | ' | ' | ' |
Tax credit expiration dates | '2018 through 2033 | ' | ' | ' |
Foreign country [Member] | ' | ' | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' | ' |
Tax credits | $100,000 | ' | ' | ' |
Tax credit expiration year | '2019 | ' | ' | ' |
Income_Taxes_Summary_of_Activi
Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Detail) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Income Tax Disclosure [Abstract] | ' | ' | ' |
Balance at beginning of year | $7,397 | $6,979 | $5,186 |
Increase related to current year tax positions | 1,844 | 829 | ' |
Increase (decrease) for tax positions of prior years | ' | -276 | 1,793 |
Decrease due to lapse of statute | ' | -64 | ' |
Decrease due to settlements | ' | -71 | ' |
Balance at end of year | $9,241 | $7,397 | $6,979 |
Notes_Payable_Additional_Infor
Notes Payable - Additional Information (Detail) (USD $) | 12 Months Ended |
In Millions, unless otherwise specified | Dec. 31, 2013 |
Debt Disclosure [Abstract] | ' |
Outstanding notes payable | $1.70 |
Notes payable, interest rate | 4.00% |
Notes payable repayment year | '2016 |
Commitments_Contingencies_and_2
Commitments, Contingencies and Legal Matters - Summary of Lease, Purchase and Minimum Royalty Commitments (Detail) (USD $) | Dec. 31, 2013 |
In Thousands, unless otherwise specified | |
Commitments And Contingencies Disclosure [Abstract] | ' |
Operating leases, Total | $84,138 |
Operating leases, Less Than 1 Year | 10,450 |
Operating leases, 1-3 Years | 21,917 |
Operating leases, 3-5 Years | 21,728 |
Operating leases, More Than 5 Years | 30,043 |
Purchase obligations, Total | 42,494 |
Purchase obligations, Less Than 1 Year | 37,118 |
Purchase obligations, 1-3 Years | 3,660 |
Purchase obligations, 3-5 Years | 1,716 |
Purchase obligations, More Than 5 Years | ' |
Minimum royalties, Total | 2,583 |
Minimum royalties, Less Than 1 Year | 543 |
Minimum royalties, 1-3 Years | 1,134 |
Minimum royalties, 3-5 Years | 646 |
Minimum royalties, More Than 5 Years | 260 |
Lease, purchase, and minimum royalty commitments, Total | 129,215 |
Lease, purchase, and minimum royalty commitments, Less Than 1 Year | 48,111 |
Lease, purchase, and minimum royalty commitments, 1-3 Years | 26,711 |
Lease, purchase, and minimum royalty commitments, 3-5 Years | 24,090 |
Lease, purchase and minimum royalty commitments, More Than 5 Years | $30,303 |
Commitments_Contingencies_and_3
Commitments, Contingencies and Legal Matters - Additional Information (Detail) (USD $) | 3 Months Ended | 12 Months Ended | ||
Sep. 30, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
sqft | ||||
Commitments And Contingencies Disclosure [Abstract] | ' | ' | ' | ' |
Number of square feet, leased | ' | 640,000 | ' | ' |
Lease expiration date | ' | '2029 | ' | ' |
Asset retirement obligations for buildings under lease | ' | $1,000,000 | $1,000,000 | ' |
Net rent expense for operating leases | ' | 10,200,000 | 8,400,000 | 6,300,000 |
Litigation in exchange for a one-time payment | ' | ' | 17,300,000 | ' |
Allocation for revenue streams | 17,300,000 | ' | ' | ' |
Royalty due on past revenue | 8,700,000 | ' | ' | ' |
Royalty due on future revenue | 2,100,000 | ' | ' | ' |
Amount of litigation | 6,400,000 | ' | ' | ' |
Litigation settlement | -15,110,000 | ' | -15,110,000 | ' |
Fair value of future royalty - Intangible asset | $2,100,000 | ' | ' | ' |
Alternate_Calculation_Structur
Alternate Calculation Structures Remove from Presentation Linkbase (Detail) (USD $) | Dec. 31, 2013 |
In Thousands, unless otherwise specified | |
Commitments And Contingencies Disclosure [Abstract] | ' |
Lease, purchase, and minimum royalty commitments, Total | $129,215 |
Operating leases, Total | 84,138 |
Purchase obligations, Total | 42,494 |
Minimum royalties, Total | 2,583 |
Lease, purchase, and minimum royalty commitments, Less Than 1 Year | 48,111 |
Operating leases, Less Than 1 Year | 10,450 |
Purchase obligations, Less Than 1 Year | 37,118 |
Minimum royalties, Less Than 1 Year | 543 |
Lease, purchase, and minimum royalty commitments, 1-3 Years | 26,711 |
Operating leases, 1-3 Years | 21,917 |
Purchase obligations, 1-3 Years | 3,660 |
Minimum royalties, 1-3 Years | 1,134 |
Lease, purchase, and minimum royalty commitments, 3-5 Years | 24,090 |
Operating leases, 3-5 Years | 21,728 |
Purchase obligations, 3-5 YearsYears | 1,716 |
Minimum royalties, 3-5 Years | 646 |
Lease, purchase and minimum royalty commitments, More Than 5 Years | 30,303 |
Operating leases, More Than 5 Years | 30,043 |
Purchase obligations, More Than 5 Years | ' |
Minimum royalties, More Than 5 Years | $260 |
Shareholders_Equity_Additional
Shareholders' Equity - Additional Information (Detail) (USD $) | 0 Months Ended | 12 Months Ended | |||||
Apr. 24, 2012 | Apr. 29, 2010 | Apr. 24, 2008 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Apr. 27, 2006 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Shares of common stock authorized for stock option plans | ' | ' | ' | ' | ' | ' | 3,800,000 |
Increase in number of common shares reserved for issuance | 5,000,000 | 3,800,000 | 1,800,000 | ' | ' | ' | ' |
Share-based payment award, vesting period, minimum | ' | ' | ' | '3 years | ' | ' | ' |
Common stock reserved for future issuance | ' | ' | ' | 2,090,798 | ' | ' | ' |
Closing stock price | ' | ' | ' | $46.67 | $33.86 | ' | ' |
Aggregate intrinsic value, exercised | ' | ' | ' | $37,000,000 | $54,500,000 | $69,800,000 | ' |
Total pre-tax intrinsic value of all outstanding stock awards | ' | ' | ' | 34,500,000 | 21,700,000 | ' | ' |
Total fair value of stock awards vested | ' | ' | ' | 10,000,000 | 7,400,000 | 4,800,000 | ' |
Total compensation cost not yet recognized, period for recognition | ' | ' | ' | '2 years 8 months 12 days | ' | ' | ' |
Total compensation cost not yet recognized | ' | ' | ' | 29,300,000 | ' | ' | ' |
Estimated forfeiture amount of total compensation cost not yet recognized | ' | ' | ' | 7,000,000 | ' | ' | ' |
2000 Employee Stock Purchase Plan [Member] | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Employee stock purchase plan expiration date | ' | ' | ' | 1-Aug-12 | ' | ' | ' |
Maximum employee subscription rate | ' | ' | ' | 15.00% | ' | ' | ' |
Total compensation cost not yet recognized, period for recognition | ' | ' | ' | '2 years | ' | ' | ' |
Share-based payment award, discount from market Price | ' | ' | ' | 85.00% | ' | ' | ' |
Stock-based compensation expense | ' | ' | ' | ' | ' | 2,600,000 | ' |
2012 Employee Stock Purchase Plan [Member] | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Increase in number of common shares reserved for issuance | ' | ' | ' | 500,000 | ' | ' | ' |
Maximum employee subscription rate | ' | ' | ' | 15.00% | ' | ' | ' |
Total compensation cost not yet recognized, period for recognition | ' | ' | ' | '2 years | ' | ' | ' |
Share-based payment award, discount from market Price | ' | ' | ' | 85.00% | ' | ' | ' |
Total compensation cost not yet recognized | ' | ' | ' | 2,100,000 | ' | ' | ' |
2000 and 2012 Employee Stock Purchase Plan [Member] | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation expense | ' | ' | ' | 3,600,000 | 2,400,000 | ' | ' |
Option Shares [Member] | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Rate of issuance of common stock to the fair market value on grant date | ' | ' | ' | 110.00% | ' | ' | ' |
Percentage of employees entitled for share based awards | ' | ' | ' | 10.00% | ' | ' | ' |
Share based awards, expiration period | ' | ' | ' | '7 years | ' | ' | ' |
Percentage of stock options vested after one year from date of grant | ' | ' | ' | 25.00% | ' | ' | ' |
Incentive Stock Options [Member] | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Percentage of employees entitled for share based awards | ' | ' | ' | 10.00% | ' | ' | ' |
Share based awards, expiration period | ' | ' | ' | '5 years | ' | ' | ' |
Restricted stock awards and restricted stock units [Member] | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Reduction in number of shares available for issuance | ' | ' | ' | 1.75 | 1.75 | 1.75 | ' |
Estimated forfeiture amount of total compensation cost not yet recognized | ' | ' | ' | 4,700,000 | ' | ' | ' |
Total compensation cost not yet recognized, net of estimated forfeitures | ' | ' | ' | $19,200,000 | ' | ' | ' |
Restricted Stock [Member] | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Total compensation cost not yet recognized, period for recognition | ' | ' | ' | '2 years 6 months | ' | ' | ' |
Other than stock option or SAR [Member] | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Reduction in number of shares available for issuance | ' | ' | ' | 1.75 | ' | ' | ' |
Stock option or SAR [Member] | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Reduction in number of shares available for issuance | ' | ' | ' | 1 | ' | ' | ' |
Full Value Equity Awards [Member] | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Share-based payment award, vesting period, minimum | ' | ' | ' | '1 year | ' | ' | ' |
Percentage of aggregate shares of common stock reserved and available for grant, granted | ' | ' | ' | 10.00% | ' | ' | ' |
Shareholders_Equity_Summary_of
Shareholders' Equity - Summary of Stock Option Activity (Detail) (USD $) | 12 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ' | ' | ' |
Shares, Outstanding, Beginning Balance | 6,810 | 7,699 | 9,514 |
Weighted Average Exercise Price, Outstanding, Beginning Balance | $21.81 | $17.54 | $13.03 |
Shares, Granted | 1,553 | 1,141 | 1,501 |
Shares, Exercised | -1,579 | -1,920 | -3,083 |
Shares, Forfeited | -308 | -110 | -233 |
Shares, Outstanding, Ending Balance | 6,476 | 6,810 | 7,699 |
Shares, Exercisable, December 31, 2013 | 3,935 | ' | ' |
Shares, Vested and expected to vest, December 31, 2013 | 6,241 | ' | ' |
Weighted Average Exercise Price, Granted | $38.55 | $36.68 | $32.12 |
Weighted Average Exercise Price, Exercised | $16.19 | $12.93 | $10.73 |
Weighted Average Exercise Price, Forfeited | $32.19 | $32.23 | $18.63 |
Weighted Average Exercise Price, Outstanding, Ending Balance | $26.70 | $21.81 | $17.54 |
Weighted Average Exercise Price, Exercisable, Ending Balance | $20.45 | ' | ' |
Weighted Average Exercise Price, Vested and expected to vest, Ending Balance | $26.28 | ' | ' |
Weighted Average Remaining Contractual Term (in years), Outstanding, December 31, 2013 | '3 years 9 months 29 days | ' | ' |
Weighted Average Remaining Contractual Term (in years), Exercisable, December 31, 2013 | '2 years 7 months 13 days | ' | ' |
Weighted Average Remaining Contractual Term (in years), Vested and expected to vest, December 31, 2013 | '3 years 9 months | ' | ' |
Intrinsic Value, Outstanding, December 31, 2013 | $129,358 | ' | ' |
Intrinsic Value, Exercisable, December 31, 2013 | 103,182 | ' | ' |
Intrinsic Value, Vested and expected to vest, December 31, 2013 | $127,241 | ' | ' |
Shareholders_Equity_Summary_of1
Shareholders' Equity - Summary of Restricted Stock Plan Activity (Detail) (Restricted stock awards and restricted stock units [Member], USD $) | 12 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Restricted stock awards and restricted stock units [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Outstanding, Beginning Balance, Shares | 642 | 596 | 403 |
Granted, Shares | 412 | 271 | 374 |
Vested, Shares | -262 | -209 | -143 |
Cancelled, Shares | -50 | -16 | -38 |
Outstanding, Ending Balance , Shares | 742 | 642 | 596 |
Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance | $29.74 | $25.87 | $17.92 |
Weighted Average Grant Date Fair Value, Granted | $38.23 | $36.90 | $32.30 |
Weighted Average Grant Date Fair Value, Vested | $29.81 | $27.62 | $19.89 |
Weighted Average Grant Date Fair Value, Cancelled | $34.17 | $34.29 | $27.42 |
Weighted Average Grant Date Fair Value, Outstanding, Ending Balance | $34.13 | $29.74 | $25.87 |
Shareholders_Equity_Common_Sto
Shareholders' Equity - Common Stock Reserved for Future Issuance (Detail) | Dec. 31, 2013 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Common stock reserved for future issuance | 2,090,798 |
Options, RSUs and awards outstanding [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Common stock reserved for future issuance | 7,218,000 |
Reserved for future grants [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Common stock reserved for future issuance | 2,091,000 |
2012 Employee Stock Purchase Plan [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Common stock reserved for future issuance | 1,914,000 |
Reserved shares [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Common stock reserved for future issuance | 11,223,000 |
Shareholders_Equity_Summary_of2
Shareholders' Equity - Summary of Assumptions to Estimate Fair Value (Detail) (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Option Shares [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Expected Term (in years) | '4 years 4 months 28 days | '4 years 4 months 17 days | '4 years 6 months 29 days |
Volatility | 0.44% | 0.53% | 0.54% |
Expected Dividends | 0.00% | 0.00% | 0.00% |
Risk Free Interest Rates | 0.90% | 0.80% | 1.64% |
Estimated Forfeitures | 7.61% | 7.63% | 7.74% |
Weighted Average Fair Value | $14.17 | $15.70 | $14.76 |
Employee Stock Purchase Plan [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Expected Term (in years) | '1 year 3 months | '1 year 3 months | '1 year 3 months |
Volatility | 0.42% | 0.54% | 0.51% |
Expected Dividends | 0.00% | 0.00% | 0.00% |
Risk Free Interest Rates | 0.19% | 0.18% | 0.34% |
Weighted Average Fair Value | $12.10 | $13.13 | $9.84 |
Shareholders_Equity_Summary_of3
Shareholders' Equity - Summary of Stock-Based Compensation Expense (Detail) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
Total stock-based compensation expense | $27,635 | $24,496 | $19,768 |
Cost of sales [Member] | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
Stock-based compensation expense | 2,930 | 3,087 | 1,679 |
Research and development [Member] | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
Stock-based compensation expense | 8,540 | 7,563 | 6,551 |
Sales and marketing [Member] | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
Stock-based compensation expense | 5,636 | 5,032 | 4,311 |
General and administrative [Member] | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
Stock-based compensation expense | $10,529 | $8,814 | $7,227 |
Employee_Benefit_Plan_Addition
Employee Benefit Plan - Additional Information (Detail) (USD $) | 12 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Employee Benefit Plans [Line Items] | ' | ' | ' |
Contributions | $1.50 | $1.20 | $0.70 |
Minimum [Member] | ' | ' | ' |
Employee Benefit Plans [Line Items] | ' | ' | ' |
Defer payment percentage, base salary | 5.00% | ' | ' |
Defer payment percentage, cash-based incentive awards | 5.00% | ' | ' |
Maximum [Member] | ' | ' | ' |
Employee Benefit Plans [Line Items] | ' | ' | ' |
Defer payment percentage, base salary | 75.00% | ' | ' |
Defer payment percentage, cash-based incentive awards | 100.00% | ' | ' |
Segment_and_Significant_Concen2
Segment and Significant Concentrations - Additional Information (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Segment | |||||||||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of operating business segments | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' |
Sales to customers | $113,261,000 | $100,081,000 | $96,012,000 | $91,938,000 | $92,433,000 | $80,472,000 | $81,015,000 | $77,292,000 | $401,292,000 | $331,212,000 | $277,575,000 |
United States [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sales to customers | ' | ' | ' | ' | ' | ' | ' | ' | 237,800,000 | 216,600,000 | 189,000,000 |
Long lived-assets excluding intangible assets | 63,900,000 | ' | ' | ' | 36,600,000 | ' | ' | ' | 63,900,000 | 36,600,000 | ' |
Sweden and Countries in the European Union [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long lived-assets excluding intangible assets | 21,000,000 | ' | ' | ' | 18,200,000 | ' | ' | ' | 21,000,000 | 18,200,000 | ' |
South Africa [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sales to customers | ' | ' | ' | ' | ' | ' | ' | ' | $41,600,000 | $22,800,000 | $12,900,000 |
Segment_and_Significant_Concen3
Segment and Significant Concentrations - Summary of Total Sales (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Segment Reporting, Revenue Reconciling Item [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | $113,261 | $100,081 | $96,012 | $91,938 | $92,433 | $80,472 | $81,015 | $77,292 | $401,292 | $331,212 | $277,575 |
System and other sales [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting, Revenue Reconciling Item [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | ' | ' | ' | ' | ' | ' | ' | ' | 76,763 | 65,111 | 73,999 |
Reagent and disposable sales [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting, Revenue Reconciling Item [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | ' | ' | ' | ' | ' | ' | ' | ' | $324,529 | $266,101 | $203,576 |
Segment_and_Significant_Concen4
Segment and Significant Concentrations - Sales Information by Segments (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Revenue from External Customer [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | $113,261 | $100,081 | $96,012 | $91,938 | $92,433 | $80,472 | $81,015 | $77,292 | $401,292 | $331,212 | $277,575 |
Clinical Systems [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenue from External Customer [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | ' | ' | ' | ' | ' | ' | ' | ' | 66,980 | 52,805 | 58,634 |
Clinical Reagents [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenue from External Customer [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | ' | ' | ' | ' | ' | ' | ' | ' | 292,941 | 233,503 | 177,435 |
Clinical [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenue from External Customer [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | ' | ' | ' | ' | ' | ' | ' | ' | 359,921 | 286,308 | 236,069 |
Non-Clinical [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenue from External Customer [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | ' | ' | ' | ' | ' | ' | ' | ' | $41,371 | $44,904 | $41,506 |
Segment_and_Significant_Concen5
Segment and Significant Concentrations - Segment Sales by Geography Region (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | $113,261 | $100,081 | $96,012 | $91,938 | $92,433 | $80,472 | $81,015 | $77,292 | $401,292 | $331,212 | $277,575 |
Clinical [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | ' | ' | ' | ' | ' | ' | ' | ' | 359,921 | 286,308 | 236,069 |
Non-Clinical [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | ' | ' | ' | ' | ' | ' | ' | ' | 41,371 | 44,904 | 41,506 |
North America [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | ' | ' | ' | ' | ' | ' | ' | ' | 249,360 | 228,653 | 205,004 |
North America [Member] | Clinical [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | ' | ' | ' | ' | ' | ' | ' | ' | 212,362 | 190,021 | 167,966 |
North America [Member] | Non-Clinical [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | ' | ' | ' | ' | ' | ' | ' | ' | 36,998 | 38,632 | 37,038 |
International [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | ' | ' | ' | ' | ' | ' | ' | ' | 151,932 | 102,559 | 72,571 |
International [Member] | Clinical [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | ' | ' | ' | ' | ' | ' | ' | ' | 147,559 | 96,286 | 68,103 |
International [Member] | Non-Clinical [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | ' | ' | ' | ' | ' | ' | ' | ' | $4,373 | $6,273 | $4,468 |
Collaboration_Profit_Sharing_A
Collaboration Profit Sharing - Additional Information (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Other Income And Expenses [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Collaboration profit sharing expense | $2,567 | $1,410 | $1,425 | $2,110 | $1,416 | $2,438 | $1,645 | $1,684 | $7,512 | $7,183 | $4,863 |
Collaborative_Agreements_and_C1
Collaborative Agreements and Contracts - Additional Information (Detail) (USD $) | 12 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||
Dec. 31, 2013 | Dec. 31, 2012 | Jan. 31, 2011 | 31-May-06 | Mar. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Aug. 31, 2007 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2012 | |
FIND [Member] | FIND [Member] | FIND [Member] | FIND [Member] | FIND [Member] | FIND [Member] | LIFE and Northrop Grumman Corporation [Member] | LIFE and Northrop Grumman Corporation [Member] | MTB/RIF Buy Down Program for the HBDC Market [Member] | MTB/RIF Buy Down Program for the HBDC Market [Member] | MTB/RIF Buy Down Program for the HBDC Market [Member] | MTB/RIF Buy Down Program for the HBDC Market [Member] | |||
The Bill and Melinda Gates Foundation [Member] | United States Agency for International Development [Member] | |||||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Term of development portion of agreement | ' | ' | ' | '30 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Additional development portion of agreement term | ' | ' | ' | '5 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Supply term of agreement | ' | ' | ' | '12 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Research development costs | ' | ' | $5,100,000 | ' | $1,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenue recognized from agreement | ' | ' | ' | ' | ' | 800,000 | 2,200,000 | 1,800,000 | ' | ' | ' | ' | ' | ' |
Reduced price of Company's Multi-Drug Resistant Tuberculosis test | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9.98 | 9.98 | ' | ' |
One-time payment received | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,200,000 | ' | 3,500,000 | 3,500,000 |
Milestone revenue | 3,200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Agreement period on straight line basis | '10 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | '10 years | ' | ' | ' |
Milestone revenue related to agreements | 2,700,000 | 4,800,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Master purchase agreement | ' | ' | ' | ' | ' | ' | ' | ' | $200,000,000 | $112,000,000 | ' | ' | ' | ' |
Subsequent_Event_Additional_In
Subsequent Event - Additional Information (Detail) (Subsequent Event [Member], 1.25% convertible senior notes [Member], USD $) | 1 Months Ended |
Feb. 28, 2014 | |
Debt Instrument, Redemption [Line Items] | ' |
Convertible notes issued | $345,000,000 |
Convertible notes fixed rate | 1.25% |
Convertible note, maturity date | 1-Feb-21 |
Net proceeds from offering after deducting expenses | 336,400,000 |
Convertible debt, conversion rate, shares per $1000 in principal amount | 15.3616 |
Convertible debt, conversion rate, principal amount | 1,000 |
Price per share of common stock | $65.10 |
Repurchase price notes percentage plus accrued and unpaid interest | 100.00% |
Convertible notes maturity date | 1-Aug-20 |
Cap price of convertible senior notes | $78.61 |
Scenario two [Member] | ' |
Debt Instrument, Redemption [Line Items] | ' |
Consecutive trading days | '5 days |
Percentage of conversion price | 98.00% |
Scenario one [Member] | ' |
Debt Instrument, Redemption [Line Items] | ' |
Trading days | 20 |
Consecutive trading days | '30 days |
Percentage of conversion price | 130.00% |
Capped call options [Member] | ' |
Debt Instrument, Redemption [Line Items] | ' |
Amount of options purchased related to Company's common stock shares | $25,000,000 |
Quarterly_Financial_Informatio2
Quarterly Financial Information - Summary of Quarterly Financial Information (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Income Statement [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total sales | $113,261 | $100,081 | $96,012 | $91,938 | $92,433 | $80,472 | $81,015 | $77,292 | $401,292 | $331,212 | $277,575 |
Costs and operating expenses: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cost of sales | 60,483 | 51,669 | 52,889 | 42,892 | 42,896 | 39,789 | 35,072 | 35,608 | 207,933 | 153,365 | 122,840 |
Collaboration profit sharing | 2,567 | 1,410 | 1,425 | 2,110 | 1,416 | 2,438 | 1,645 | 1,684 | 7,512 | 7,183 | 4,863 |
Research and development | 25,340 | 18,558 | 18,572 | 17,727 | 17,299 | 16,154 | 16,118 | 22,102 | 80,197 | 71,673 | 59,362 |
Sales and marketing | 21,922 | 19,788 | 19,105 | 19,126 | 16,294 | 15,993 | 15,108 | 14,512 | 79,941 | 61,907 | 50,691 |
General and administrative | 12,854 | 9,490 | 9,612 | 9,763 | 9,470 | 11,766 | 11,011 | 11,051 | 41,719 | 43,298 | 36,004 |
Litigation settlement | ' | ' | ' | ' | ' | 15,110 | ' | ' | ' | 15,110 | ' |
Total cost and operating expenses | 123,166 | 100,915 | 101,603 | 91,618 | 87,375 | 101,250 | 78,954 | 84,957 | 417,302 | 352,536 | 273,760 |
Income (loss) from operations | -9,905 | -834 | -5,591 | 320 | 5,058 | -20,778 | 2,061 | -7,665 | -16,010 | -21,324 | 3,815 |
Other income (expense), net | -264 | -200 | -717 | 374 | 241 | 89 | -572 | 238 | -807 | -4 | -1,143 |
Income (loss) before income tax expense | -10,169 | -1,034 | -6,308 | 694 | 5,299 | -20,689 | 1,489 | -7,427 | -16,817 | -21,328 | 2,672 |
Benefit from (provision for) income taxes | -148 | -347 | -272 | -381 | 345 | -607 | -354 | 1,901 | -1,148 | 1,285 | -45 |
Net income (loss) | -10,317 | -1,381 | -6,580 | 313 | 5,644 | -21,296 | 1,135 | -5,526 | -17,965 | -20,043 | 2,627 |
Basic net income (loss) per share | ($0.15) | ($0.02) | ($0.10) | $0 | $0.09 | ($0.32) | $0.02 | ($0.08) | ($0.27) | ($0.30) | $0.04 |
Diluted net income (loss) per share | ($0.15) | ($0.02) | ($0.10) | $0 | $0.08 | ($0.32) | $0.02 | ($0.08) | ($0.27) | ($0.30) | $0.04 |
Weighted average shares used in computing basic net income (loss) per share | 68,230 | 67,573 | 67,295 | 66,824 | 66,370 | 66,145 | 65,695 | 65,027 | 67,485 | 65,812 | 62,735 |
Weighted average shares used in computing diluted net income (loss) per share | 68,230 | 67,573 | 67,295 | 69,406 | 68,787 | 66,145 | 68,869 | 65,207 | 67,485 | 65,812 | 66,750 |
Gross profit on sales: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sales | 113,261 | 100,081 | 96,012 | 91,938 | 92,433 | 80,472 | 81,015 | 77,292 | ' | ' | ' |
Cost of sales | -60,483 | -51,669 | -52,889 | -42,892 | -42,896 | -39,789 | -35,072 | -35,608 | -207,933 | -153,365 | -122,840 |
Gross profit on product sales | $52,778 | $48,412 | $43,123 | $49,046 | $49,537 | $40,683 | $45,943 | $41,684 | ' | ' | ' |
Schedule_II_Valuation_and_Qual1
Schedule II - Valuation and Qualifying Accounts - Summary of Valuation and Qualifying Accounts (Detail) (Allowance for Doubtful Accounts [Member], USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Allowance for Doubtful Accounts [Member] | ' | ' | ' |
Valuation and Qualifying Accounts Disclosure [Line Items] | ' | ' | ' |
Balance at Beginning of Year | $176 | $61 | $61 |
Costs and Expenses | 63 | 135 | 81 |
Deductions | -41 | -20 | -81 |
Balance at End of Year | $198 | $176 | $61 |